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Cardiovascular disease (CVD) is the leading cause of mortality in developed countries.1 
The 2010 Global Burden of Disease study estimated that CVD caused 15.6 million deaths 
worldwide, which is 29.6% of all deaths. As longevity increases, mortality rates due 
to cardiovascular disease are expected to rise even further. Heart failure (HF) plays a 
particularly important part in these developments. From 1994 to 2004, deaths from HF 
increased by 28%, while the overall death rate decreased by 2%.2 In the western world, 
approximately 1-2% of the adult population and >10% of patients of 70 years of age or 
older suffers from HF.3 Thus, HF has become one of the key contributors to the burden of 
chronic disease in the elderly in terms of mortality, morbidity, and cost.
The form of HF whose pathophysiology is best understood is HF with reduced ejection 
fraction (HFREF; sometimes also referred to as ‘systolic HF’), which is also the main focus 
of the European Society of Cardiology (ESC) guidelines.4 In >60% of all cases, HFREF is 
caused by coronary artery disease (CAD), even though hypertension and diabetes are 
often contributing factors (ref ). After myocardial injury (e.g. myocardial infarction), sys-
tolic dysfunction may occur, which is characterized by progressive worsening over time 
due to maladaptive changes that cause increased enlargement of the left ventricle and 
decline in ejection fraction, called ‘remodeling’. Reduction of the cardiac function due 
to remodeling causes systemic responses, including systemic neurohormonal activa-
tion. This subsequently causes further myocardial injury, creating a pathophysiological 
‘vicious cycle’, eventually leading to the syndrome of HF. The syndrome of HF includes 
pump-failure, that may cause decompensation and may eventually lead to cardiac death, 
as well as myocardial electrical instability that may lead to life-threatening arrhythmias.
Installing appropriate secondary prevention measures in HF patients, e.g. interven-
tional, medicinal or artificial in the form of electrical devices, requires adequate iden-
tification of individuals at highest risk. Nowadays, prognosis of HF patients is usually 
assessed by means of physical examination and a limited number of standard imaging 
and laboratory tests. For individual patients, this approach falls short; although we know 
that overall, 50% of patients will die in 5 years, we still cannot foresee to which individual 
patients this pertains. Thus, improved methods for risk stratification are urgently needed.
The main purpose of this thesis was to provide knowledge on patient and procedural 
characteristics associated with adverse clinical outcome and to present novel prediction 
models that may aid in risk stratification of patients at different stages of CVD. First we 
focused on patients with CAD, with or without left ventricular dysfunction. Specifi-
cally, we examined patients undergoing percutaneous coronary intervention (PCI), and 
studied outcome after initial intervention. Then we focused on the disease course of 
patients with HF. Finally, we examined HF patients carrying implantable cardioverter-
defibrillators (ICDs) to protect them from potentially life-threatening arrhythmias due to 
myocardial electrical instability
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The research questions investigated in this thesis were as follows:
1. First part of this thesis: patients with CAD, with or without left ventricular dysfunction:
 a.  What are the limitations of current mortality risk scores and prediction tools after 
PCI and can we provide a better tool?
 b.  Different generations of drug-eluting stents (DES) carry different prognosis, but 
do these results apply to all patient-categories, in particular, to both patients 
with and without established cardiac failure?
 c.  What (angiographic) factors are related to presentation with an out of hospital 
cardiac arrest (OHCA) in ST-elevation myocardial infarction (STEMI) patients?
2.  Second part of this thesis: patients with established HF. Specifically, we investigated 
methods that may aid in individual risk assessment of patients with acute or chronic HF 
(CHF):
 a.  What is the incremental value of serially measuring blood biomarkers, to clinical 
assessment in terms of serial NYHA class measurements, for monitoring stable 
CHF outpatients?
 b.  Which biomarkers or combinations of biomarkers are best suited for prognosti-
cation in (C)HF patients?
3. Third part of this thesis: patients with a poor cardiac function, which mandates ICD im-
plantation with or without cardiac resynchronization therapy (CRT) for protection from 
potentially life-threatening arrhythmias:
 a.  Which patient characteristics favor or disfavor defibrillation therapy, with or 
without cardiac resynchronization therapy CRT?
 b.  Which patient characteristics are associated with response to CRT and with clini-
cal outcome after installment of CRT?
 c.  What are the limitations of current CRT risk scores and are we able to provide a 
better tool for predicting mortality?
The outline of this thesis is as follows.
Part i : the influence of patient baseline and procedural characteristics on 
outcome after percutaneous coronary interventions.
Multiple mortality risk scores and prediction tools for patients that have undergone PCI 
have been developed, but nearly all of them focus on short term outcome, i.e. 30-day 
mortality.5-17. Risk prediction instruments with a prolonged time horizon are becoming 
increasingly important, as decisions during PCI have long-term consequences for pa-
tient management, and impact long-term outcome. In chapter 2 we aimed to develop a 
model to predict long-term, e.g. 5-year, mortality after PCI, which may also aid in select-
ing patients suitable for bioresorbable scaffolds, specifically designed to eliminate the 
late complications of permanent metallic implants, and to improve vessel physiology.
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Furthermore, it is known that newer generation DES are superior to early generation 
DES,18-20; on the other hand, it is known that patients with a reduced left ventricular ejec-
tion fraction (LVEF) are more prone to stent thrombosis (ST) than those with a normal 
LVEF.21-23 In chapter 3 we aimed to investigate the difference in clinical outcome of pa-
tients with or without LV dysfunction using newer generation DES vs. early generation 
DES.
chapter 4 describes factors related to the occurrence of out-of-hospital cardiac ar-
rest (OHCA) in ST-elevation myocardial infarction (STEMI), especially the differences in 
angiographic factors of STEMI patients presenting with and without OHCA.
Part ii : novel methods and markers for risk assessment of patients with heart 
failure.
Blood biomarkers are capable of monitoring subtle (patho)physiological processes that 
reflect and possibly predict adverse changes before they become clinically apparent.24,25 
B-type natriuretic peptides (BNP) and N-terminal proBNP (NT-proBNP), cardiac troponin 
T and I and C- reactive protein (CRP) have been related to adverse clinical outcomes in 
HF patients in several large studies.24,26-35 The majority of these studies have examined 
single, baseline measurements. However, temporal biomarker patterns may improve 
risk assessment. So far, studies that have examined changing biomarker patterns over 
time have mostly focused on natriuretic peptides, generally used only few repeated 
biomarker measurements, and have utilized simplified representations of temporal bio-
marker evolution. In chapters 5 and 6 we present the first results of the Bio-SHiFT study. 
In this study, we performed frequent, longitudinal blood sampling and assessed mul-
tiple biomarkers simultaneously,36 and thereby aimed to provide a basis for improved, 
personalized risk assessment in patients with CHF. First we examined the associations 
between serially measured biomarkers (i.e. NT-proBNP, high-sensitive cardiac troponin 
T (HsTnT) and CRP), serially scored New York Heart Association (NYHA) functional class, 
as well as the associations of their temporal patterns with adverse clinical outcome 
(chapter 3.1). Based on this, we evaluated the incremental value of serially measuring 
blood biomarkers to clinical assessment for monitoring stable CHF outpatients. Second 
we applied joint modelling to examine whether individual, temporal trajectories of NT-
proBNP, HsTnT and CRP are associated with longer-term prognosis (chapter 3.2).
MicroRNAs (miRs) are promising, upcoming novel biomarkers. MiRs are non-coding, 
~22 nucleotide long RNA sequences, which target mRNAs for cleavage or translational 
repression and thereby influence a great variety of biological processes.37 The stability of 
miRs in plasma, and consequently their reliable assessment in easily accessible samples, 
potentially makes them attractive biomarkers for a wide range of diseases.38 Several 
studies have shown associations between miRs and myocardial infarction (MI)39-42 and 
HF,43-48, as well as associations with diabetes mellitus,49 However, most studies pertain-
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ing to HF were performed in case-control settings and used limited study sample size. 
Furthermore, these studies usually assessed miRs only once. In chapter 7 we have per-
formed frequent repeated measurements of multiple miRs (miR-1254a, miR-22-3p, miR-
345-5p, miR-378, miR-423-5p, miR-486-5p and miR320) in patients with CHF from the 
Bio-SHiFT study, and have investigated the associations of the thus obtained temporal 
patterns with adverse clinical outcome. Finally, in chapter 8 we performed an analysis 
similar to the analysis presented in chapter 7. We used RNA sequencing to identify novel 
candidate miRs and compared this to previously identified miRs (miR-1254, miR-22-3p, 
miR-345-5p, miR-378a-3p, miR-423-5p, miR-320a, miR-133a-3p, miR-133b, miR-499a-5p, 
miR-622, and miR-208a-3p) in patients with acute HF that were included in the TRIUMPH 
study.
Part iii: Novel insights in characteristics associated with favorable outcome in 
defibrillation therapy and response to cardiac resynchronization therapy.
Patients are eligible for ICD therapy if they have a LVEF ≤35%.50 Patients who have a 
LVEF ≤35% and cardiac dyssynchrony, are eligible for CRT-D.51 Data from randomized 
and observational studies have shown beneficial effect of CRT in selected patients with 
drug refractory HF, reduced left ventricular ejection fraction (LVEF), and electrical dys-
synchrony: it improves clinical symptoms, reduces hospitalizations and lowers mortality 
in a considerable proportion of patients.52-55 Theoretically, all patients who meet the 
indication criteria for CRT also qualify to have an ICD for primary prevention of sudden 
cardiac death. Consequently, ICDs combined with CRT (CRT-D) are part of the standard 
management of HF patients with reduced LVEF.4,56 Some patients respond well to CRT 
and reach a LVEF of >35%. In chapter 9 we referred to these patients as ‘functional 
responders’ and we assessed characteristics associated with functional response and 
the necessity of defibrillation therapy in these patients. In chapter 10 we investigated 
the influence of atrial fibrillation on outcome of CRT-D patients. chapter 11 describes 
the difference in outcome of patients with ICD and CRT-D that have ischemic versus 
non-ischemic heart disease. Finally, since mortality risk among HF patients is highly 
heterogeneous and only a minority of patients will experience ventricular arrhythmias, 
appropriate risk prediction in CHF patients carrying a CRT-D device is of paramount im-
portance. However, adequate risk estimation models to predict mortality in this specific 
patient population are lacking. In chapter 12 we constructed a risk model for predicting 
mortality in CHF patients with a CRT-D device.
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ABstrAct
Background: Clinical trials are currently designed to demonstrate superiority of bio-
absorbable scaffolds over metal devices up to 5 years after implantation. We aimed to 
develop a model to predict long-term mortality after percutaneous coronary interven-
tion (PCI), to aid in selecting patients with sufficient life expectancy to benefit from 
bioabsorbable scaffolds.
methods: From 2000-2011, 19.532 consecutive patients underwent PCI in a tertiary 
referral hospital. Patients were randomly (2:1) divided into a training (N=13,090) and 
validation (N=6,442) set. Cox regression was used to identify determinants of long-term 
mortality in the training set and used to develop a risk model. Model performance was 
studied in the training and validation dataset.
results: Median age was 63 years (IQR 54 - 72) and 72% were men. Median follow-up 
was 3.6 years (interquartile range [IQR] 2.4-6.8). The ratio elective vs. non-elective PCIs 
was 42/58. During 88620 patient-years of follow-up 3156 deaths occurred, implying an 
incidence rate of 35.6 per 1000. Estimated 5-year mortality was 12.9%.Regression analy-
sis revealed age, body mass index, diabetes mellitus, renal insufficiency, prior myocardial 
infarction, PCI indication, lesion location, number of diseased vessels and cardiogenic 
shock at presentation as determinants of mortality. The long-term risk model showed 
good discrimination in the training and validation sets (c-indices 0.76 and 0.74), whereas 
calibration was appropriate.
conclusions: A simple risk model, containing 9 baseline clinical and angiographic 
variables effectively predicts long-term mortality after PCI and may possibly be used to 
select suitable patients for bioabsorbable scaffolds.
Five-year mortality after PCI risk model 21
iNtroductioN
Percutaneous coronary intervention (PCI) has become one of the most important and 
widely used treatments in patients suffering from coronary artery disease (CAD).1 In gen-
eral, clinical outcome after PCI is good, but baseline risk factors as diabetes mellitus, renal 
impairment and cardiogenic shock at presentation proved to significantly impact both 
short and long-term outcomes. In the past decade, several mortality risk models have 
been developed in order to quantify clinical prognosis after PCI.2-14 The prediction horizon 
of the existing models, however, is limited and usually only covers the 30 day post-PCI 
period. Risk prediction instruments with a prolonged time horizon are becoming increas-
ingly important, as decisions during PCI have long-term consequences for patient man-
agement, and impact long-term outcome. For example, the benefit of second generation 
drug eluting stent (DES) over first generation DES on the incidence of stent thrombosis, 
myocardial infarction (MI) and mortality appears beyond 3 years.15 The potential benefits 
of bioresorbable scaffolds potential benefit is anticipated at even later time points.16 Few 
tools are available to predict longer-term outcome.17,18 Syntax score was created using a 
dataset consisting of study patients with three-vessel or left main CAD and was mainly 
designed to aid in decision making between coronary artery bypass grafting (CABG) and 
PCI.17 The other score was based on a dataset with follow-up up to 2008 and consequently 
consisted of less up-to-date characteristics, such as a lower number of DES.18
Bioresorbable scaffolds are specifically designed to eliminate the late complications 
of permanent metallic implants, and improve vessel physiology. Based on the excellent 
early outcome of recent studies on bioresorbable scaffolds,19,20 large-scale clinical tri-
als are currently designed to demonstrate the superiority of these scaffolds over metal 
devices up to 5 years after implantation. Then, obviously, instruments are needed to 
help select patients with sufficient life expectancy, who will potentially benefit most 
from these more expensive stents.
The main objective of the Improved Drug Eluting Artificial BIOcompatable Coronary 
Implants: IDEA-BIO study was to create a risk model to predict long-term mortality after 
PCI, using simple baseline clinical and procedural variables. We explored the dataset of 
the 19,532 patients who underwent PCI during 2000-2011 in our institution, with up to 
12 years follow-up.
methods
Patients and treatment
The IDEA-BIO study contains information of a total of 19,996 consecutive patients, who 
underwent PCI with stent placement at the Erasmus MC, Rotterdam, The Netherlands 
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from January 2000 to December 2011.The preferred stent type changed during the study 
period: bare metal stents (BMS) were used until April 2002, sirolimus-eluting stents (SES) 
between April 2002 and March 2003, paclitaxel-eluting stents (PES) between March 
2003 and March 2007, and everolimus-eluting stents (EES) between March 2007 and 
December 2011. The preferred stent was almost exclusively used in all patients within 
these subsequent periods, except for (the small number of ) patients who participated in 
trials comparing different stents.
Patient management was in accordance with the applicable guidelines of the Euro-
pean Society of Cardiology, which changed over time.21-29 In summary, patients received 
antiplatelet therapy by aspirin and clopidogrel (until 2008) or prasugrel (since 2008) 
around the PCI procedure. Patients presenting with ST-elevation MI (STEMI) received 
both drugs preferably in the ambulance during transportation to the cathlab. Glyco-
protein IIb/IIIa antagonists were used at the discretion of the clinician. All patients were 
advised to remain on a lifetime dose of aspirin, whereas clopidogrel or prasugrel was 
advised to be continued for at least 1, 3 or 6 months in patients with BMS, SES, PES and 
EES, respectively.
Baseline data collection
At baseline, data were collected on age, gender, CAD risk factors, the broad history of 
CAD, renal function, indication for the index PCI (emergent, urgent or elective) and 
hemodynamic status at presentation. Furthermore, angiographic and procedural char-
acteristics were collected, including the location of the culprit lesion, the number of dis-
eased vessels, and the type, number, length en diameter of the implanted stents. Renal 
failure was defined as an estimated glomerular filtration rate (eGFR) <60ml/min/1.73m2 
(eGFR was calculated using the modification of diet in renal disease (MDRD) formula).
study endpoint
The primary endpoint of this study was 5-year all-cause mortality. Patients were actively 
followed up on this endpoint by reviewing hospital medical records and municipal civil 
registries. The latest follow-up was performed in December 2012. A total of 464 (2.3%) 
patients were lost-to-follow-up. We report on the 19,532 patients with complete data 
on the primary endpoint, with a median follow-up of 3.6 years (interquartile range [IQR] 
2.4 - 6.8; maximum 12 years).
statistical analysis
Most clinical and angiographical variables that we considered had complete information 
in 95% of all patients. However, for body mass index (BMI), information was missing in 
a larger portion of research subjects (24% missing). We considered variables with up to 
25% missing values and applied multiple imputation to evaluate the relation between 
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patient characteristics and the primary endpoint. Since the efficiency of an estimate 
based on m imputations is approximately (1+y/m)-1 where y is the rate of missing infor-
mation.30 Five imputed datasets sufficed, since (1+0.25/5)-1 provided 95.2% efficiency.
The associations between continuous variables and the primary endpoint were tested 
for linearity using splines and cut-off values were based on the shape of the curve. In 
case of linearity, cut-off values were based on clinical grounds or practical use. In case of 
non-linearity or u-shaped curves, multiple cut-off values were tested in the multivariate 
Cox model.
We randomly (2:1 ratio) divided the available patients in a training (N=13090) and 
validation (N=6442) dataset.31 Multivariate Cox proportional hazard regression analyses 
were applied on the training set to develop a model for the prediction of long-term mor-
tality. We used the broad range of characteristics that are listed in table 1 as potential 
determinants. Initially, all variables entered the model, whereas backward elimination 
of the least significant variables was applied, until all variables had a significance level 
of p<0.05. Based on the results of these analyses, a risk score was developed to predict 
long-term (i.e. 5-year) mortality post-PCI, which included the variables that comprised 
the final regression model, weighed according to the corresponding regression coef-
ficient. The performance of the risk score was studied with respect to discrimination 
(c-index) in the training and validation data sets. For this purpose we calculated the area 
under the receiver characteristic curve using SPSS. However, routine tests for assessing 
c-indices are not designed for survival analysis. Therefore, we performed a sensitivity 
analysis of the calculated c-indices, by determining Harrell’s c-index, which is more suit-
able for survival analysis,32 using R statistical software (package “dynpred”). Performance 
was also analysed with respect to calibration (difference between predicted and ob-
served mortality).
Information on left ventricular function (LVF) was lacking in 56% of patients, and 
therefore we decided to not consider this variable in our main analyses. Still, LVF is an 
important prognostic factor in PCI patients. Consequently, we decided to perform a 
sensitivity analysis on the subgroup of patients with complete data on LVF. We also per-
formed a sensitivity analysis in the 4.7% of patients presenting with cardiogenic shock.
All analyses were performed by using SPSS 22.0 (SPSS Inc., Chicago, IL).
ethics
This is an observational study. For the purpose of this study patients were not subject to 
acts, neither was any mode of behaviour imposed, otherwise than as part of their regular 
treatment. Therefore, according to Dutch law, written informed consent for a patient to 
be enrolled in this study was not required. This study was conducted according to the 
Privacy Policy of the Erasmus MC, and according to the Erasmus MC regulations for the 
appropriate use of data in patient oriented research.
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table 1 - Baseline characteristics
training cohort
N=13090
Validation cohort
N=6442
P
Age 63 (54-71) 63 (54-72) 0.76
male gender 72 72 0.80
Body mass index 27 (24-30) 27 (24-30) 0.54
hypertension 48 48 0.98
hypercholesterolemia 55 56 0.26
insulin dependent diabetes mellitus 5.4 5.4 0.93
familial history of cardiovascular disease 33 34 0.23
diabetes mellitus 19 19 0.64
current smoker 26 26 0.66
ever smoker 41 40 0.36
Prior myocardial infarction 29 31 0.09
Prior Pci 74 73 0.40
Prior cABG 9.3 9.8 0.30
renal insufficiency 5.9 5.8 0.70
indication
Emergent PCI 32 32 0.07
Urgent PCI 28 28 0.41
Elective PCI 42 42 0.27
Number of diseased vessels
1 50 49 0.38
2 31 32 0.28
3 19 19 0.97
culprit vessel
Left main 3.2 3.4 0.43
Proximal Left anterior descending 21 21 0.40
Left anterior descending 41 41 0.79
Right coronary artery 36 35 0.33
Left circumflex 23 23 0.89
cardiogenic shock 4.6 4.8 0.52
Left ventricular function*
Normal 77 76 0.66
Moderate 18 18 0.41
Poor 5.9 5.6 0.58
Bare metal stent 18 19 0.41
drug eluting stent
Paclitaxel eluting stent 36 36 0.88
Sirolimus eluting stent 7.7 7.3 0.28
Everolimus eluting stent 38 38 0.83
Continuous data are presented as median values (25th–75th percentile); nominal data are presented as 
percentages. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
*Available for 44% of all patients
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resuLts
Patient characteristics
Median age of the study cohort was 63 years (interquartile range 54-72) and 72% were 
men. The majority of patients underwent an elective procedure (42%) in hemodynami-
cally stable condition (4.7% of patients had cardiogenic shock). Most patients received a 
drug eluting stent (82%). Baseline clinical and procedural characteristics were similar in 
the patients who composed the training and validation datasets (table 1).
mortality risk score
A total of 3156 deaths occurred during 88620 patient-years of follow-up, implying an 
incidence rate of 35.6 per 1000. Overall mortality at 5 year was 12.9% and the estimated 
survival time of the total study population was 9.6 (CI 9.6-9.7) years. Mortality in the 
training and validation sets was similar. Estimated survival times assorted by age are 
presented in figure 1.
Variables associated with the primary endpoint in the training dataset were age, BMI 
<25, diabetes mellitus, renal insufficiency (glomerular filtration rate <60 mL/min) , prior 
myocardial infarction, indication for PCI, culprit left main, number of diseased vessels 
and cardiogenic shock (table 2). An analysis on the patients presenting without cardio-
genic shock revealed the same factors.
The association between age and the primary endpoint was linear and the association 
between BMI and the primary endpoint was U-shaped, but only a BMI <25 was signifi-
cantly associated with the primary endpoint when using multiple cut-off values.
figure 1 – Kaplan-meier curves of survival assorted by age
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figure 2 – the long-term mortality after percutaneous coronary intervention prediction model with 
scores assigned in training cohort
table 2 – risk scores for long term mortality after Pci
risk factor score hazard ratio
(95% confidence interval)
Age
<50 years 0 -
≥50 - 60 years 2 1.66 (1.28-2.15)
≥60 - 70 years 4 2.98 (2.33-3.81)
≥70 - 80 years 6 5.14 (4.04-6.55)
≥80 years 9 9.11 (7.05-11.77)
Body mass index <25 1 1.25 (1.12-1.39)
diabetes mellitus 2 1.64 (1.47-1.83)
renal insufficiency 3 2.08 (1.77-2.45)
Prior myocardial infarction 1 1.25 (1.13-1.39)
indication of Pci
Elective 0 -
Urgent 1 1.37 (1.19-1.57)
Emergent 3 2.07 (1.77-2.41)
culprit left main 2 1.55 (1.23-1.97)
Number of diseased vessels
1 0 -
2 1 1.23 (1.09-1.39)
3 3 1.91 (1.69-2.16)
cardiogenic shock 4 2.89 (2.12-3.94)
PCI, percutaneous coronary intervention.
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Figure 2 shows the prediction model for long-term mortality after PCI based on the 
training set. Theoretically, the risk score ranges between 0 and 25 points. Actually, the 
majority of patients had a low or intermediate mortality risk score: the 5th and 95th per-
centiles were 2 and 14, respectively (table 3).
table 3 - total risk scores
total risk score Patients (%) Predicted risk (%)
0 1.01 1.7
4.2
1 2.23 2.2
2 4.28 2.9
3 8.28 3.7
4 9.02 4.7
5 11.07 6.0
6 10.89 7.6
12.1
7 11.45 9.6
8 9.60 12.1
9 8.01 15.1
10 6.86 18.6
11 4.91 22.8
30.4
12 3.48 27.7
13 3.24 33.1
14 2.11 39.0
15 1.38 45.2
16 0.88 51.6
58.1
17 0.60 57.9
18 0.34 64.0
19 0.15 69.6
20 0.12 74.8
21 0.04 79.3
81.5
22 0.04 83.2
23 0.01 86.5
24 0.00 89.2
25 0.00 91.4
model performance
The performance of the long-term mortality risk prediction model in terms of discrimi-
nation was fair in the training cohort, with a median c-index 0.76 (range 0.75-0.76 in the 
5 times multiple imputed datasets), as well as in the validation cohort (c-index 0.74 in 
all of the 5 times multiple imputed datasets) using routine tests. The performance of the 
model in terms of discrimination using Harrell’s C-index displayed the same c-indices in 
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the training cohort (Harrell’s c-index 0.76 in all of the 5 times multiple imputed datasets), 
as well as in the validation cohort (Harrell’s c-index 0.74 in all of the 5 times multiple 
imputed datasets). Furthermore, as shown in figure 3, the model has a fair calibration in 
both the training and validation cohort. H-L-value of the complete risk score was signifi-
figure 3 – observed and predicted mortality risk by total risk score for all patients in the a) training 
(n=13090) and b) validation (n=6442) cohort
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cant in the training cohort (p-value 0.025 (range 0.016 to 0.061)), but it has to be noted 
that our power was very low for patients with risk scores >15 (±2%, as shown in table 
3). If the patients with scores >15 were pooled, as shown in figures 2 and 3, H-L-value 
of the training cohort was 0.086 (range 0.085-0.27). H-L-value of the complete risk score 
was 0.065 (range 0.041-0.37) in the validation cohort and 0.12 (range 0.057-0.45) if the 
patients with scores >15 were pooled, as described before.
Table 4 shows the model performance in clinically relevant subgroups.
table 4 - subgroup validation in validation cohort
subgroup sample
(mortality percentage)
c-index [range] hosmer Lemeshow
p-value [range]
Age
<50 years 967 (7.0) 0.69 [0.68-0.70] 0.13 [0.07-0.33]
≥50 - 60 years 1666 (5.8) 0.65 [0.64-0.65] 0.05 [0.05-0.06]
≥60 - 70 years 1882 (11) 0.67 [0.67-0.68] 0.09 [0.08-0.09]
≥70 - 80 years 1490 (20) 0.69 [0.69-0.69] 0.92 [0.62-0.97]
≥80 years 438 (30) 0.64 [0.64-0.65] 0.88 [0.73-0.93]
Body mass index <25 2090 (16) 0.74 [0.72-0.74] 0.34 [0.19-0.51]
diabetes mellitus 1207 (18) 0.74 [0.74-0.75] 0.47 [0.20-0.62]
renal insufficiency 371 (29) 0.70 [0.69-0.71] 0.64 [0.26-0.95]
Prior myocardial infarction 1968 (15) 0.76 [0.76-0.76] 0.35 [0.28-0.75]
indication of Pci
Elective 2795 (9.1) 0.70 [0.69-0.70] 0.48 [0.38-0.80]
Urgent 1858 (15) 0.72 [0.71-0.72] 0.44 [0.34-0.82]
Emergent 1953 (16.1) 0.76 [0.76-0.76] 0.07 [0.01-0.31]
culprit left main 221 (29) 0.74 [0.71-0.76] 0.61 [0.36-0.99]
Number of diseased vessels
1 3094 (8.3) 0.70 [0.70-0.70] 0.63 [0.56-0.93]
2 1919 (12) 0.72 [0.72-0.73] 0.12 [0.03-0.20]
3 1168 (23) 0.69 [0.69-0.70] 0.92 [0.58-0.95]
cardiogenic shock 311 (31) 0.70 [0.69-0.71] 0.15 [0.12-0.16]
C-index and Hosmer Lemeshow p-value are displayed as median [range] of the 5 times multiple imputated 
datasets. PCI, percutaneous coronary intervention.
subgroup analyses on patients with available data on LVf
In the patients with complete data on LVF, 77% had a normal LVF, whereas 18% and 6% 
had a moderate or poor LVF, respectively. After adjustment for all variables that com-
pose the main risk model, LVF appeared a significant determinant of long-term mortality 
(moderate LVF HR 1.80, CI 1.49-2.16; poor LVF HR 4.25, CI 3.44-4.25). Except for culprit left 
main and prior myocardial infarction, all other variables remained significant. Adding 
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LVF to the main model did not result in an improvement of performance measures: the 
c-index in the training and validation sets was 0.74 and 0.78, respectively.
discussioN
We succeeded in the objective of the IDEA-BIO study to create an easy to use long-term 
mortality risk score based on nine simple clinical and angiographic baseline variables 
(Table 2). A score of >10 resulted in a 20% mortality risk at 5 years, while a score of 
>15 resulted in 50% mortality. The score included age, BMI, diabetes mellitus, renal 
insufficiency, prior myocardial infarction, indication for PCI, culprit left main, number of 
diseased vessels and cardiogenic shock as key predictors. The risk score showed good 
performance in terms of discrimination and calibration. The strengths of our risk-model 
are the large sample size and the long follow-up, which could make it a useful tool to 
predict long-term mortality in PCI patients. The risk model may possibly aid in selecting 
patients who might benefit from more expensive treatment options, such as biodegrad-
able scaffolds, in PCI if long-term benefit will be demonstrated by current studies.
Wilson et al described “long-term” predictors of patients undergoing PCI and revealed 
associations between long-term mortality after PCI and age, diabetes, cardiogenic 
shock, renal failure, multivessel disease and indication for PCI, but they did not create a 
risk score, nor did they use a specific time frame.33 Wu et al also created a risk score for 
prediction of long-term mortality.18 However, their model was based on a smaller data 
set with fewer DES used. Our objective was to create an easy to use risk score based on 
simple baseline and angiographic variables, which could be used as an aid for patients 
and clinicians to predict long-term survival. Our model containing only 9 variables, 
achieved a predictive value comparable to the 11 variable based model of Wu et al.
The original anatomical Syntax Score was developed for optimal selection of patients 
for multivessel disease or left main PCI or which should be referred for CABG and is 
based on 12 parameters assigned for all 15 major coronary artery segments.34 Although 
a web based algorithm is available the score is considered cumbersome and has a poor 
correlation coefficient of r=0.49 and wide limits of agreement when scores of interven-
tional cardiologist are compared to technicians of a trained corelab.35 More important 
it did not include any patient or clinical parameters. The logistic clinical Syntax score 
based on 7 randomized trials introduced these parameters but as for most clinical trial 
included mostly a relative low-risk patient group (3-year mortality of pooled analysis 
6.3%). Iqbal et al build a prediction model adding 4 clinical parameters to the original 
Syntax Score for predicting 3-year mortality.36 The final predictive value of this model 
showed a c-index of 0.71, which does not reflect a potential beneficial effect of includ-
ing a more extensive coronary anatomy model (Syntax Score) vs. our model with only 
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2 coronary artery anatomy related parameters. Their most extensive model showed 
comparable predictive value. The addition of an extensive anatomical model did not 
provide improvement of predictive value beyond our model. Finally, Farooq et al created 
the Syntax score 2, which may be used to predict long-term (4-year) mortality after PCI, 
but this score was designed for decision making for PCI versus CABG, in a study popula-
tion of patients with three-vessel or left main CAD.17 Our model was specifically created 
to identify PCI patients with a longer life expectancy. These patients with a longer life 
expectancy might benefit from new developments in PCI like more expensive stents 
with bioresorbable coatings or fully bioresorbable scaffolds. These stents have shown 
similar outcomes at one year in the selected patients,20,37,38 and (ABSORB IV; ClinicalTrials.
gov number, NCT02173379) but are designed to demonstrate superiority at 5 years. The 
COMPARE-ABSORB (NCT02486068) trial will include more real-world patients at higher 
risk of target vessel failure but with an expected life expectancy of >5 years.
LVF was a significant predictor of long-term mortality, but adding LVF to the main 
model did not improve its performance. This could be due to the fact that adding LVF to 
the model was at the expense of removing culprit left main disease and prior myocar-
dial infarction as significant predictors. Also, the presence of cardiogenic shock, which 
is included in our model, often identifies patients with a poor LVF. Furthermore, the 
relatively great number of missing information on LVF directly reflects clinical practise 
since LVF is not frequently measured during or before emergent or urgent PCIs. This is 
also shown by the fact data on LVF is often missing in PCI risk models, created by real 
world registries of PCI patients.
Limitations
Several issues concerning this study warrant further consideration. First of all, PCI strate-
gies have improved over time, which could lead to better outcomes in patients who 
underwent PCI more recently than patients receiving a PCI over 10 years ago. Despite 
all developments in PCIs over time, we did not find significant differences in 30-day 
mortality rates between patients who underwent a PCI between 2000-2002, 2003-2005, 
2006-2008 and 2009-2011, but we cannot compare long-term differences in mortality 
rates, due to the differences in follow-up time inherent to the time-period of inclusion.
Moreover, some patients have very long-term follow-up data (i.e. 12 years), but the 
data is not robust at this range of follow-up. Since median follow-up was 3.6 years, the 
model should be useful for PCI patients with a longer life expectancy in general, but 
future studies should study its usefulness in bioabsorbable scaffolds recipients.
Additionally, despite the fact that our registry includes multiple important character-
istics, it is possible that several potentially important factors were not recorded, such 
as atrial fibrillation, haemoglobin level (which is a known risk factor for PCI patients, 
as described by Nikolsy et al),39 or other co morbidity burden or biomarkers, could be 
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prognostically important. Addition of biomarkers associated with adverse outcomes 
after PCI, may further enhance long-term mortality risk prediction after PCI. Medicinal 
treatment such as the use of beta-blockers, diuretics, angiotensin-converting enzyme, 
platelet inhibitors, etc., was deliberately not entered into the models, because their 
estimates could lead to confounding by indication. Furthermore, renal failure was 
calculated using the MDRD formula, but recent data suggests using the chronic kidney 
disease epidemiology collaboration (CKD-EPI) equation for risk stratification among 
patients undergoing PCI.40
Finally, our results are based on a single centre experience, which could limit external 
validity. Yet, the Thoraxcentre in Rotterdam can be considered representative for larger 
tertiary referring and teaching or academic hospitals.
conclusion
We developed and validated a risk score to predict long-term mortality after PCI, based 
on a large sample of heterogeneous patients with long-term follow-up, up to 12 years. 
The tool is easy to use, contains solely simple baseline clinical and angiographic vari-
ables and adequately predicts long-term mortality after PCI. The model may be a useful 
tool to select patients who might benefit from more expensive PCI treatment options, 
such as biodegradable scaffolds, if long-term benefit will be demonstrated by current 
studies. A score of 10 or more selects patients with a predicted 5 year mortality of more 
than 20 percent.
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ABstrAct
Background: Everolimus drug-eluting stents (EES) are superior to early generation 
drug-eluting stents (DES), releasing sirolimus (SES) or paclitaxel (PES) in preventing 
stent thrombosis (ST). Since an impaired left ventricular ejection fraction (LVEF) seems 
to increase the risk of ST, we aimed to investigate the difference in outcome of patients 
with varying LVEF using EES versus early generation DES.
methods: In a prospective cohort study we compared the risk of ST in patients in 3 LVEF 
subgroups: normal (LVEF >50%), mildly impaired (LVEF >40%&≤50%) and moderate-
severely impaired (LVEF ≤40%). Within these various LVEF groups we compared EES to 
SES and PES after adjustment for baseline differences.
results: We assessed a cohort of 5363 patients, with follow-up of up to 4 years and 
available LVEF. Overall definite ST occurred in 123 (2.3%) patients. ST rates were higher 
in the LVEF moderate-severely impaired group as compared to the normal LVEF group 
(2.8% vs. 2.1%; Hazard radio (HR) 1.82; confidence interval (CI) 1.10-3.00). Especially early 
ST (EST) was more frequent in the moderate-severely impaired LVEF group (HR 2.20; CI 
1.06-4.53). Overall rates of definite ST were lower in patients using EES, as compared to 
patients using SES or PES in all LVEF groups. Interaction terms were not statistically sig-
nificant. ST rates were higher in the moderate-severely impaired LVEF group compared 
to the normal LVEF group when using SES or PES, but not significantly different when 
using EES.
conclusions: EES was associated with a lower risk of definite ST compared to early gen-
eration DES. This lower risk was independent of LVEF, even though ST rates were higher 
in patients with a moderate-severely impaired LVEF.
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iNtroductioN
Early-generation drug-eluting stents (DES), sirolimus eluting stents (SES) and paclitaxel 
eluting stents (PES) appeared to be very effective at reducing the rates of restenosis 
and target lesion revascularization compared to bare metal stents.1-4 However, stent 
thrombosis (ST), which causes acute coronary obstruction and could lead to myocardial 
infarction (MI) or sudden cardiac death, was found to be an infrequent, but devastating 
complication of DES. Multiple randomized trials showed a comparable incidence of ST 
in DES compared to bare metal stents up to 1 year after the percutaneous coronary 
intervention (PCI).5-7 However, ST occurring more than 1 year after the index PCI, which 
is mainly caused by delayed healing in combination with other clinical and procedural 
risk factors of the stented coronary segment,8-11 appeared as a serious complication of 
DES stents. More recently, several randomized controlled trials have shown a reduction 
in the incidence of ST occurring more than 1 year after the index PCI with newer gen-
eration DES, releasing everolimus (i.e. everolimus-eluting stents - EES),12-14 which may 
have a favourable effect on cardiac death and incident MI. In these stents, everolimus, a 
sirolimus analogue, is released from a thin coating with more biocompatible polymers 
and reduced drug dose.
Several studies have identified impaired left ventricular function as a risk factor for 
mortality,15-19 MI,15,17, ST.17,20,21 and target lesion revascularization,22 in patients under-
going PCI. It has been suggested that these patients may benefit from drug-eluting 
stents,22 especially since patients with impaired left ventricular ejection fraction (LVEF) 
more frequently present with an acute coronary syndrome in case of in-stent resteno-
sis.23 Since newer generation EES stents seem to be superior to early generation DES 
in an overall population of patients undergoing PCI,12-14 it would be useful to provide 
knowledge about the long-term safety and benefits of newer generation EES in patients 
with a reduced cardiac function.
Against this background, we evaluated the long-term incidence of ST and clinical 
outcomes after PCI with DES in relation to LVEF in the Bern part of the Bern-Rotterdam 
registry. Secondly, we studied the performance of the newer generation DES (EES) 
compared with the early-generation SES and PES in relation to left ventricular function.
methods
study design, Patient Population and Procedures
For the purpose of this study, we used the Bern (Bern University Hospital, Bern) part 
of the Bern-Rotterdam registry, which has been described before.12 We only used the 
Bern part of the registry, since systematic data on the LVEF was not available in the Rot-
40 Chapter 3
terdam part of the study population. The study population we used, consisted of 5761 
consecutive patients, who underwent PCI with PES, SES or EES, between April 2002 and 
March 2009. Between April 16, 2002, and December 31, 2005, a total of 2774 consecu-
tive patients underwent coronary intervention with SES (Cypher, Cordis Corp, Johnson 
& Johnson, Warren, NJ) and 1365 were treated with PES (TAXUS, Express, or Liberte´, 
Boston Scientific) in the Swiss centre. The individual use of both stent types has been 
described in detail elsewhere.24 A total of 1622 patients were treated with EES (XIENCE 
V, Abbott Vascular, Santa Clara, CA; or PROMUS, Boston Scientific, Natick, MA), which 
has been part of the usual care since November 1, 2006 and implanted on a daily basis 
alternating with biolimus-eluting stents and zotarolimus-eluting stents. Patients with 
EES were included until March 31, 2009. Patients were excluded from the registry if more 
that one stent type was implanted during PCI. The nature of this study was observational 
and the procedure, periprocedural and postprocedural medication regimen, were per-
formed according to current practice guidelines. The diameter of EES and PES was 2.25 
to 4.0mm and the diameter of SES was 2.25 to 3.5mm. The length of all stents started at 
8 mm, with a maximum length of 28mm of EES, 33mm of SES and PES had a maximum 
length of 32mm. All patients received a loading dose of clopidogrel 300 to 600mg dur-
ing or immediately after PCI and a lifelong prescription of daily aspirin. Clopidogrel was 
prescribed for duration of at least 12 months. Glycoprotein IIb/IIIa antagonists were 
used at the discretion of the clinician.
The registry was approved by the local ethics committees, and was conducted in ac-
cordance with the Declaration of Helsinki. Written informed consent was obtained from 
all patients.
Left ventricular function
Baseline LVEF was routinely assessed by left ventricular angiography at the time of 
coronary angiography and determined by visual estimate. The visual estimate was per-
formed by 2 experienced cardiologists. First by a fellow interventional cardiology and 
this was subsequently verified or overruled by an attending senior invasive cardiologist. 
The estimate was based on the average of the right anterior oblique and left anterior 
oblique projection. Cineangiography was usually performed at 15 frames per second 
during injection of at least 30 ml contrast agent at a rate of 10 ml per second. Attention 
was paid to left ventricular size, overall contractility, any wall motion abnormalities and 
presence of mitral regurgitation. All senior invasive cardiologists perform yearly more 
than 500 coronary angiographies and the experience of a fellow interventional cardiol-
ogy evolves over time. On average, a fellow interventional cardiology performs more 
than 800 cases in one year.
We divided patients in 3 different categories: 1) normal LVEF (>50%), 2) mildly impaired 
LVEF (>40-≤50%) or 3) moderate-severely impaired LVEF (≤40%), which corresponds 
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with generally accepted thresholds.15,19,25 LVEF was available in 5446 (94.5%) patients in 
the Swiss centre. Further analysis was performed only on patients with available LVEF.
study endpoints
In Bern, follow-up lasted until February 1, 2007 in patients with SES or PES implanta-
tion and patients who received EES were followed-up until February 1, 2010. Thus, the 
follow-up observation was up to 4 years in these subjects. Survival status was obtained 
from hospital records and municipal civil registries. Patients were actively followed up on 
adverse cardiac events by questionnaires that were sent to patients including questions 
on rehospitalization and major adverse cardiac events. Medical records, discharge let-
ters and coronary angiography documentation were collected and reviewed in patients 
with suspected events.
Primary endpoint: definite stent thrombosis
Definite ST was the primary endpoint of our study, which was defined in agreement 
with the definitions of the Academic Research Consortium (ARC).26 We further classified 
the endpoint according to its timing (again in agreement with ARC): early ST (EST) (0-
30 days after stent implantation) and late ST (LST) (>30 days). An independent clinical 
event committee adjudicated all suspect ST events. The committee members were not 
informed on the type of stent implanted.
Secondary endpoints
Secondary endpoints comprised adverse clinical events, including death from any cause, 
cardiac death, MI, as well as definite or probable ST.
Cardiac death was defined as any death from an immediate cardiac cause, procedure-
related death, unwitnessed death, and death with an unknown cause. Myocardial 
infarction (MI) was defined as increased creatine kinase >2 times the upper limit of the 
normal value and >3 times the upper limit of the normal value of creatine kinase-MB in 
combination with ischemic changes on ECG. All suspect clinical events were adjudicated 
by the cardiologists who were affiliated with the institutions in which the patients were 
treated.
statistical Analysis
Categorical baseline and procedural variables are presented as counts and percentages, 
whereas differences between the three LVEF groups are evaluated by Pearson’s χ2 test, 
or Fisher’s exact test, as appropriate. Continuous variables are presented as mean ± 
one standard deviation (SD), in case of a normal distribution, or as median, 1st and 3rd 
quartiles, in case of a non-normal distribution. Differences between the LVEF groups 
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were evaluated by applying analysis of variance (ANOVA), Student t tests, Kruskall-Wallis 
tests and Mann-Whitney U tests, as appropriate.
The incidence of the primary and secondary endpoints during follow-up in relation 
to left ventricular function was evaluated according to the method of Kaplan-Meier in 
combination with log-rank tests, and by Cox proportional hazard regression analysis. 
Multivariable Cox models were developed to adjust the relation between LVEF and out-
come for potential confounders. Baseline (clinical and procedural) characteristics that 
had a statistically significant (p<0.05) relation with the endpoint were entered into the 
model. No model-reduction strategies were applied. We report adjusted hazard ratios 
(aHR) and their 95% confidence intervals (CI). All events were only counted once.
Subsequently, we studied the relation between DES types and the study endpoints in 
relation to left ventricular function. For this purpose we used a method that our research 
group applied previously.12 We estimated propensity scores for receiving EES using a 
logit model that included age, sex, and pre-treatment variables associated with stent 
selection at p<0.10: family history of coronary artery disease, acute coronary syndrome, 
cardiogenic shock and body mass index. Propensity scores were used to derive the 
inverse probability of treatment weights, with the inverse of the propensity score as 
analytic weights in EES patients and the inverse of 1 minus the propensity score in early-
generation DES patients. Comparisons between DES types were performed with the Cox 
model. Adjusted HRs were calculated with the inverse probability of treatment weights 
as analytical weighing factors. All Cox proportional hazard assumptions were visualized 
using the graph of the log(-log(survival)) versus log of survival time graph and tested 
with Schoenfeld residuals. Interaction terms between LVEF and DES type were added 
to evaluate homogeneity of the effect of DES type on the study endpoints in relation to 
left ventricular function.
resuLts
A total of 5761 consecutive patients underwent PCI with PES (1365), SES (2774) or EES 
(1622) between April 16, 2002, and March 31 2009. All analyses were performed on 
5363 patients with PES (1298), SES (2599) or EES (1466), because LVEF was unavailable 
in 315 patients and 83 patients were lost to follow-up. Median follow-up was 2.4 years 
(interquartile range (IQR) 1.9-3.0 years) in patients treated with EES, 3.6 years (IQR 2.8-4.0 
years) in patients treated with SES and 4.0 (IQR 3.4-4.0 years) in patients treated with PES.
Baseline and procedural characteristics
We observed several differences in clinical baseline and procedural characteristics 
between the three LVEF groups (table 1). Most notable were the differences in age, hy-
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pertension, body mass index, family history of coronary artery disease, smoking status, 
dyslipidemia and renal failure. Patients with a moderate-severely impaired or mildly im-
paired LVEF presented more often with an acute coronary syndrome (74.7% and 74.0% 
table 1 – Baseline and Procedural characteristics
Variable LVef
>50%
(n=3106)
LVef
>40%-≤50%
(n=1244)
LVef
≤40%
(n=1013)
P
Age (years) 63.4±11.2 62.5±12.2 65.6±12.0 <0.0001
male sex 2343 (75.4) 982 (78.9) 759 (74.9) 0.03
Bmi 27.4±4.2 27.3±4.3 26.6±4.2 <0.0001
hypertension 1897 (61.2) 640 (51.6) 490 (49.0) <0.0001
family history of cAd 960 (30.9) 323 (26.0) 219 (21.9) <0.0001
current smoking 1646 (53.1) 666 (53.7) 466 (46.6) 0.0007
dyslipidemia 1827 (58.9) 609 (49.1) 444 (44.4) <0.0001
diabetes mellitus 529 (17.1) 203 (16.4) 195 (19.5) 0.12
renal failure (Gfr<60mL/min) 291 (12.1) 107 (12.0) 180 (21.8) <0.0001
Acute coronary syndrome 1276 (41.1) 921 (74.0) 757 (74.7) <0.0001
Unstable angina 222 (17.4) 55 (6.0) 27 (3.6) 
Non-ST-segment-elevation MI 686 (53.8) 343 (37.2) 267 (35.3) 
ST-segment-elevation MI 368 (28.8) 523 (56.8) 463 (61.1) 
cardiogenic shock 0 11 (0.9) 59 (5.8) <0.0001
Paclitaxel eluting stent 804 (25.9) 300 (24.1) 194 (19.2) <0.0001
sirolimus eluting stent 1566(50.4) 584 (46.9) 449 (44.3) 0.002
everolimus eluting stent 736 (23.7) 360 (28.9) 370 (36.5) <0.0001
multivessel treatment 609 (19.7) 177 (14.3) 181 (17.9) 0.0001
Lesions treated per patient 1.6±0.8 1.5±0.8 1.6±0.9 0.23
culprit left main coronary artery 59 (1.8) 22 (1.8) 62 (6.1) <0.0001
Arterial bypass graft 8 (0.3)  2 (0.2) 3 (0.3) 0.78
saphenous vein graft 80 (2.6) 33 (2.7) 44 (4.3) 0.01
multistent treatment 1492 (48.0) 632 (50.8) 549 (54.2) 0.03
Average stent diameter 2.9±0.6 2.9±0.4 3.0±0.4 0.004
total stent length per patient 28.6±18.0 30.8±18.1 32.2±18.8 <0.0001
Glycoprotein iib/iiia antagonist 441 (14.2) 390 (31.4) 353 (34.8) <0.0001
Aspirin at discharge 3176 (99.1) 1225 (98.5) 963 (95.1) <0.0001
clopidogrel at discharge 3098 (99.7) 1227 (98.6) 963 (95.1) <0.0001
oral anticoagulation at discharge 37 (1.2) 18 (1.5) 38 (3.8) <0.0001
Categorical variables are expressed as count (percentage). Valid percentages may vary for some counts, be-
cause of missing values. Continuous variables are expressed as mean ±SD when appropriate. BMI indicates 
body mass index; CAD, coronary artery disease; GFR, glomerular filtration rate; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction.
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respectively) than patients with a normal LVEF (41.1%). Only patients with an impaired 
left ventricular function presented with cardiogenic shock (0.9% in the mildly impaired 
LVEF group and 5.8% in the moderate-severely impaired LVEF group).
Remarkable were the differences in number of patients undergoing multivessel treat-
ment, stent diameter and length, number of stents implanted, use of glycoprotein IIb/
IIIa and discharge medication. Normal LVEF patients more frequently had PES or SES 
implanted, compared to more EES use in moderate-severely impaired LVEF patients. 
In the moderate-severely impaired LVEF group, the culprit vessel was more frequently 
the left main or left anterior descending artery, whereas relatively more normal LVEF 
patients culprit lesions in the left circumflex or right coronary artery.
study endpoints in relation to left ventricular function
The study endpoints are presented in table 2. Definite ST occurred in 123 (2.3%) patients 
and definite/probable ST occurred in 331 (6.2%) subjects. No patients had multiple ST’s. 
In general, patients with impaired left ventricular function had a higher incidence of ST. 
In particular, patients with a moderate-severely impaired LVEF had a higher incidence 
of definite ST (aHR 1.82; 95% CI 1.10-3.00; p-value 0.02) and definite/probable ST (aHR 
1.86; 95% CI 1.30-2.66; p-value 0.001) than patients with a normal LVEF. This difference 
was based on higher EST rates in moderate-severely impaired LVEF patients (aHR 2.20; CI 
1.06-4.53), whereas LST rates did not significantly differ (aHR 1.34; CI 0.72-2.50).
table 2 - clinical outcomes
Variable
Adjusted hazard ratio
LVef
>50%
(n=3106)
LVef
>40%-
≤50%
(n=1244)
LVef
≤40%
(n=1013)
LVef >40%-
≤50%
vs
LVef >50%
P LVef ≤40%
vs
LVef >50%
P
definite st 64 (2.1) 31 (2.5) 28 (2.8) 1.22 (0.75-1.99) 0.42 1.82 (1.10-3.00) 0.02
Early 18 (0.6) 10 (0.8) 14 (1.4) 1.24 (0.56-2.73) 0.60 2.20 (1.06-4.53) 0.03
Late 46 (1.5) 21 (1.7) 14 (1.4) 1.09 (0.63-1.86) 0.77 1.34 (0.72-2.50) 0.35
definite/
probable st
143 (4.6) 75 (6.0) 113 (11.2)
1.28 (0.88-1.86) 0.20 1.86 (1.30-2.66) 0.001
Early 50 (1.6) 38 (3.1) 82 (8.1) 1.39 (0.80-2.41) 0.24 2.09 (1.27-3.41) 0.004
Late 93 (3.0) 37 (3.0) 31 (3.1) 1.17 (0.69-1.97) 0.56 1.75 (1.03-2.98) 0.04
death 177 (5.7) 109 (8.8) 194 (19.2) 1.46 (1.09-1.95) 0.01 2.09 (1.60-2.73) <0.0001
cardiac death 104 (3.4) 82 (6.6) 150 (14.8) 1.88 (1.32-2.66) <0.0001 2.58 (1.86-3.58) <0.0001
mi 138 (4.4) 53 (4.2) 49 (4.8) 1.05 (0.76-1.45) 0.77 1.37 (0.98-1.92) 0.07
LVEF indicates left ventricular ejection fraction; ST, stent thrombosis; MI, myocardial infarction. Clinical out-
come numbers are expressed as counts (percentage). Adjusted HR’s were calculated using multivariate 
analysis. All baseline and procedural characteristics with P<0.05 in univariate analysis were entered into the 
multivariate analysis to calculate adjusted HR’s.
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The incidence of clinical endpoints was also clearly associated with left ventricular 
function. Specifically, more patients in the moderate-severely impaired LVEF group 
died (aHR 2.09; CI1.60-2.73). A Similar difference in clinical outcome was found in the 
incidence of cardiac death (aHR 2.58; CI 1.85-3.58). The occurrence of MI between was 
equal in the various LVEF groups.
Left ventricular function, stent type and study endpoints
Table 3 and figure 1 show the relationship between DES type and study endpoints. In 
general, patients who received EES had a lower incidence of ST than patients receiving 
PES or SES, although statistical significance could not be demonstrated for all endpoints. 
Differences between EES and PES were most pronounced. These observations were con-
sistent in the three groups of patients according to LVEF. In particular, patients treated 
with EES had a lower incidence of definite ST than those treated with PES (aHRs 0.15, 0.13 
table 3 – clinical outcomes, sorted by drug-eluting stent type
Adjusted hazard ratio
Variable
LVef ees ses Pes
ees
vs
ses
P
ees
vs
Pes
P
overall definite st ≤40%
3 (0.03)
14 
(0.10)
11 
(0.16)
0.28 (0.08-
0.98)
0.04 0.15 (0.04-
0.55)
0.004
>40%-
≤50%
1(0.01)
22 
(0.10)
8 (0.07)
0.11 (0.02-
0.78)
0.03 0.13 (0.02-
0.99)
0.049
>50%
3 (0.01)
35 
(0.06)
26 
(0.08)
0.20 (0.06-
0.71)
0.01 0.12 (0.03-
0.44)
0.001
early definite st ≤40%
1 (0.29) 7 (1.68) 6 (3.31)
0.21 (0.03-
1.71)
0.14 0.11 (0.01-
0.89)
0.04
>40%-
≤50%
1(0.28) 5 (0.88) 4 (1.37)
0.44 (0.05-
3.75)
0.45 0.30 (0.02-
2.83)
0.15
>50%
2 (0.27)
11 
(0.71)
5 (0.63)
0.42 (0.09-
1.91)
0.26 0. (0.09-
2.34)
0.35
Late definite st ≤40%
2 (0.02) 7 (0.05) 5 (0.08)
0.37 (0.08-
1.69)
0.20 0.21 (0.04-
1.07)
0.06
>40%-
≤50%
0
17 
(0.08)
4 (0.03)
N.A.
N.A.
N.A. N.A.
>50%
1 (0.00)
24 
(0.04)
21 
(0.06)
0.05 (0.01-
0.36)
0.03 0.02 (0.00-
0.18)
<0.0001
overall definite/
probable st
≤40% 31 
(0.31)
53 
(0.37)
29 
(0.44)
0.70 (0.45-
1.09)
0.12 0.52 (0.31-
0.88)
0.02
>40%-
≤50%
15 
(0.15)
38 
(0.18)
22 
(0.18)
0.67 (0.36-
1.25)
0.21 0.65 (0.33-
1.30)
0.22
>50% 19 
(0.09)
77 
(0.13)
47 
(0.14)
0.73 (0.44-
1.20)
0.21 0.47 (0.27-
0.81)
 
0.01
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and 0.12 for those with a normal, mildly impaired and moderate-severely impaired LVEF 
respectively) and a lower incidence of definite/probable ST (aHRs 0.47, 0.65 and 0.52). 
Moderate-severely impaired LVEF patients had significantly higher rates of definite ST 
when using PES (P=0.04) and a trend towards a higher incidence of ST when using SES 
table 3 – clinical outcomes, sorted by drug-eluting stent type (continued)
Adjusted hazard ratio
Variable
LVef ees ses Pes
ees
vs
ses
P
ees
vs
Pes
P
early definite/
probable st
≤40% 26 
(7.49)
38 
(9.14)
18 
(9.94)
0.77 (0.47-
1.28)
0.32 0.73 (0.40-
1.33)
0.30
>40%-
≤50%
11 
(3.14)
16 
(2.81)
11 
(3.79)
1.00 (0.45-
2.21)
0.99 0.71 (0.29-
1.72)
0.44
>50% 12 
(1.65)
23 
(1.49)
15 
(1.90)
1.18 (0.58-
2.38)
0.65 0.89 (0.41-
1.90)
0.75
Late definite/
probable st
≤40%
5 (0.05)
15 
(0.11)
11 
(0.17)
0.48 (0.17-
1.33)
0.16 0.22 (0.07-
0.71)
0.01
>40%-
≤50%
4 (0.04)
22 
(0.11)
11 
(0.09)
0.41 (0.13-
1.23)
0.11 0.58 (0.19-
1.78)
0.34
>50%
7 (0.03)
54 
(0.09)
32 
(0.10)
0.45 (0.20-
.0.98)
0.045 0.26 (0.11-
0.61)
0.002
death ≤40% 59 
(0.59)
92 
(0.61)
43 
(0.61)
0.81 (0.58-
1.13)
0.22 0.78 (0.52-
1.18)
0.24
>40%-
≤50%
27 
(0.26)
50 
(0.23)
32 
(0.26)
1.01 (0.61-
1.67)
0.96 0.93 (0.53-
1.62)
0.80
>50% 28 
(0.13)
91 
(0.15)
58 
(0.17)
0.84 (0.55-
1.28)
0.42 0.71 (0.45-
1.11)
0.13
cardiac death ≤40% 47 
(0.47)
68 
(0.45)
35 
(0.49)
0.85 (0.58-
1.25)
0.42 0.75 (0.48-
1.18)
0.21
>40%-
≤50%
21 
(0.20)
35 
(0.16)
26 
(0.21)
1.12 (0.64-
1.98)
0.69 0.83 (0.45-
4.53)
0.55
>50% 16 
(0.07)
50 
(0.08)
38 
(0.11)
0.85 (0.49-
1.49)
0.57 0.62 (0.35-
1.11)
0.11
mi ≤40% 6 (0.06) 27 
(0.19)
16 
(0.24)
0.29 (0.12-
0.70)
0.01 0.19 (0.07-
0.54)
0.002
>40%-
≤50%
11 
(0.11)
25 
(0.12)
17 
(0.14)
0.65 (0.35-
1.57)
0.44 0.65 (0.29-
1.43)
0.28
>50% 19 
(0.09)
74 
(0.12)
45 
(0.14)
0.77 (0.47-
1.29)
0.32 0.50 (0.29-
0.87)
0.01
EES indicates everolimus-eluting stent; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PES, 
paclitaxel-eluting stent; SES, sirolimus-eluting stent; ST, stent thrombosis. Clinical outcome numbers are 
expressed as counts (number of events/ month/ 100 patients). Adjusted risk ratios were calculated with 
the inverse probability of treatment weights as analytical weighting in Cox proportional hazards models.
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figure 1 - Kaplan-meier hazard curve of overall definite stent thrombosis
Overall definite stent thrombosis in patients using different drug-eluting stents of patients with a a) mod-
erate-severely impaired left ventricular ejection fraction, b) mildly impaired left ventricular ejection fraction 
and c) normal left ventricular ejection fraction.
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figure 2 - Kaplan-meier hazard curve of overall definite stent thrombosis
Overall definite stent thrombosis in patients with a moderate-severely impaired vs. normal left ventricular 
ejection fraction of patients with a) paclitaxel-eluting stents (PES), b) sirolimus-eluting stents (SES) and c) 
everolimus-eluting stents (EES).
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(P=0.07), whereas ST rates were similar in both LVEF groups when using EES (P=0.34) 
(figure 2).
Most noteworthy, concerning the differences in incidence of clinical endpoints be-
tween the DES types, is the difference in the incidence of MI between patients treated 
with EES and those treated with PES (aHR 0.50, 0.65 and 0.19). The graph of the log(-
log(survival)) versus log of survival time graph resulted in parallel curves and Schoenfeld 
residuals indicated Cox proportional hazard assumptions were not violated.
None of the LVEF * DES type interaction terms were significant in the multivariate 
analyses that we applied. Thus, we did not reveal any indication of heterogeneity in the 
relation between DES type and the study endpoints according to left ventricular func-
tion.
discussioN
This large observational cohort study with long-term follow-up of patients undergo-
ing PCI with early generation DES or newer generation EES shows us that: 1) impaired 
left ventricular function was associated with increased risk of ST; 2) newer generation 
EES was associated with a reduced risk of ST compared to early generation DES; 3) the 
association between relative reduction of ST and EES was independent of LVEF. 4) EES 
seemed especially associated with reduced LST rates in patients with a normal LVEF, 
while the lower ST rates in the mildly impaired and moderate-severely impaired LVEF 
groups seemed unrelated to the timing of ST.
Our findings, concerning the association between increased risk of ST and patients 
with impaired left ventricular function are consistent with earlier findings.17,20,21 Al-
though the exact cause of the higher rate of ST in patients with reduced left ventricular 
function remains unclear, it has been suggested that a decrease in LVEF is associated 
with impaired blood flow through the stented coronary artery, increasing the risk of 
ST.27 In this study, the overall risk of ST in patients with impaired LVEF was increased 
by 61% compared with patients with a normal LVEF and by 13% compared to patients 
with a mildly impaired LVEF. Interestingly, a moderate-severely impaired LVEF did not 
seem to be associated with LST, but the difference in overall ST rates seems to be due 
to the strong association between the increased risk of having EST and a a moderate-
severely impaired LVEF, compared to patients with a normal LVEF (a moderate-severely 
impaired LVEF was associated with a 120% increased risk of having EST). Sardi et al 
found an increase in the risk of ST with a HR of 2.56 (CI 1.44-4.55) when comparing 
patients with a LVEF of 25-40% to patients with a normal LVEF during 1 year follow-up, 
which is somewhat higher than the increase in the risk of ST we found in patients with 
a moderate-severely impaired LVEF of ≤40% at 1 year (HR 1.84; CI 1.01-3.34), but CI’s are 
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overlapping.17 Van Werkum et al also found considerably higher ST rates in patients with 
impaired systolic LV function (HR 2.27; CI 1.43-3.60), but they defined impaired cardiac 
function as LVEF<30%.21 A LVEF <30% is substantially lower than a LVEF ≤40%. Since 
a poorer LVEF seems to increase the risk of ST, a higher HR in this study is in line with 
expectations.
Patients with a moderate-severely impaired LVEF, treated with different kinds of DES 
also had higher all-cause mortality and cardiac mortality risk compared to normal LVEF 
patients. A trend towards a higher risk of MI was found in patients with a moderate-
severely impaired LVEF. Our findings regarding the relationship between a reduced LVEF 
and the increased mortality,15-18 and risk of MI,15,17 are also consistent with earlier findings. 
Mortality and cardiac mortality seem to increase as LVEF drops. In the moderate-severely 
impaired LVEF group, overall one year mortality was 11.8% and 11.3% in patients who 
had EES implanted. The one year mortality rates in this group are comparable to earlier 
findings.15,17 Patients with a mildly impaired LVEF and normal LVEF showed one year 
mortality rates of 4.4% and 1.8% respectively.
The present study is the first study that specifically compared the outcome of early 
generation DES stents, SES and PES, compared to newer generation EES in patients with 
a varying systolic cardiac function, in a registry with long-term follow-up observation 
to 4 years. This registry has the advantage that it consists of consecutive patients, has 
long-term follow-up and is not a post hoc analysis of a large randomized controlled trial, 
which apply specific inclusion criteria that complicates extrapolation of their results to 
the more diverse, real-life population of patients.
The study shows that EES is associated with lower ST rates compared to early genera-
tion DES, irrespective of left ventricular function. Interestingly, when comparing the dif-
ference in definite overall ST rates between patients with a moderate-severely impaired 
LVEF versus normal LVEF per stent, we found statistically higher ST rates in patients 
using PES and a trend towards higher ST rates when using SES, but no differences in the 
incidence of ST when found when using EES. On the other hand, we found no interac-
tion when comparing EES to early generation DES in various LVEF groups. It could be 
possible that the event rate in our study population of patients using EES was to low 
to show interaction. Another explanation could be the fact that a moderate-severely 
impaired LVEF seemed to be especially associated with increased risk of EST, whereas 
EES, a sirolimus derivate, with more biocompatible polymers and reduced drug dose, 
seemed predominantly associated with lower LST and very late ST rates compared to 
early generation DES.12-14 Although EES also seems superior in preventing EST compared 
to early generation DES.12,13
The findings of this study can be used in clinical practice when performing a PCI in 
patients with systolic dysfunction. The study emphasizes the known fact that EES is su-
perior to early generation DES, but also shows that whether systolic dysfunction is pres-
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ent or not, EES remains superior. Even after 4 years. When performing PCI on patients 
with a reduced LVEF, the executive physician should keep in mind that these patients 
have higher ST rates, in particular EST, higher incidence of MI and higher mortality rates. 
Despite these improved lower ST rates achieved by using EES, more efforts and research 
to improve ST and mortality rates is mandated to improve the outcome of patients with 
a reduced systolic cardiac function, undergoing PCI.
Limitations
Several issues concerning this study warrant further consideration. First of all, the ST 
event-rate was quite low, especially in EES patients. This low event-rate may have caused 
a lack of power to show significant differences.
The use of LVEF, which was performed angiographically, using biplane assessment 
by visual estimate, is inherently an issue, since reproducibility of this method may be 
questioned. To accommodate this limitation, we divided all study patients in 3 different 
LVEF categories, to reduce the effect of measurement discrepancies in LVEF assessment.
Furthermore, there were differences in baseline characteristics between patients who 
had been stented with EES, SES and PES after PCI and no randomization was performed. 
These differences in baseline characteristics had to be adjusted for using the inverse 
probability of treatment weighting, as we did before,12 to minimize a potential bias. Also, 
follow-up at 4 years was not complete in patients treated with EES and PES.
Another issue that should be taken into account, is the fact that a primary arrhythmia 
causing death within 30 days would full the ARC criteria for probable ST,26 which with-
holds us from distinguishing between sudden death due to ST and a primary arrhythmia. 
This may consequently have influenced our results.
PCI strategies have improved over time, which may have contributed to an improved 
outcome among patients with EES, compared to patients with early generation DES.
Other limitations of this study are related to the database and these limitations have 
been reported before.12
conclusion
Newer generation EES was associated with a reduced risk of ST compared to early 
generation DES, even after long-term follow-up of up to 4 years, regardless of LVEF. The 
relative reduction found, was independent of LVEF, even though ST rates were higher in 
patients with a moderate-severely impaired LVEF. This association between reduced ST 
rates and a normal LVEF using EES was predominantly based on lower LST rates, whereas 
the lower occurrence of ST achieved by EES in patients with a reduced LVEF seemed 
unrelated to the timing of ST. Finally, all-cause mortality and cardiac mortality rates 
seems inversely related to left ventricular function.
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supplemental table – Baseline and Procedural characteristics of all Patients, sorted by stent type
Variable Paclitaxel
eluting stent
(n=1298)
sirolimus
eluting stent
(n=2599)
everolimus
eluting stent
(n=1466)
P
Age (years) 63.9±11.6 62.7±11.5 64.9±11.7 <0.0001
male sex 990 (76.3) 1976 (76.0) 1118 (76.3) 0.98
Bmi 27.0±4.1 27.2±4.3 27.2±4.4 0.12
hypertension 748 (57.6) 1422 (54.7) 857 (59.3) 0.01
family history of cAd 334 (26.5) 738 (28.4) 420 (29) 0.30
current smoking 671 (51.7) 1371 (52.8) 736 (50.9) 0.51
dyslipidemia 683 (52.6) 1403 (54.0) 794 (54.9) 0.48
diabetes mellitus 210 (16.2) 471 (18.1) 246 (17.0) 0.30
renal failure (Gfr<60mL/min) 138 (14.2) 294 (15.6) 146 (11.6) 0.005
Acute coronary syndrome 714 (55.1) 1385 (53.3) 855 (58.3) 0.009
Unstable angina 67 (9.4) 129 (9.3) 108 (12.6) 
Non-ST-segment-elevation MI 292 (40.9) 622 (44.9) 382 (44.7) 
ST-segment-elevation MI 355 (49.7) 634 (45.8) 365 (42.7) 
cardiogenic shock 9 (0.7) 28 (1.1) 33 (2.3) 0.001
LVef 55.3±11.5 54.3±11.9 51.5±12.7 <0.0001
Moderate-severely impaired LVEF 194 (14.9) 449 (17.3) 370 (25.2) <0.0001
Mildly impaired LVEF 300 (23.0) 584 (22.4) 360 (24.6)
Normal LVEF 804 (61.9) 1566 (60.3) 736 (50.2)
multivessel treatment 218 (16.8) 407 (15.7) 342 (23.3) <0.0001
Lesions treated per patient 1.5±0.7 1.5±0.7 1.8±1.0 <0.0001
culprit left main coronary artery 30 (2.3) 46 (1.8) 67 (4.6) <0.0001
Arterial bypass graft 5 (0.4) 5 (0.2) 3 (0.2) 0.49
saphenous vein graft 33 (2.5) 77 (3.0) 47 (3.2) 0.58
multistent treatment 614 (47.3) 1215 (46.7) 844 (57.6) <0.0001
Average stent diameter 2.9±0.4 2.9±0.6 2.9±0.4 0.21
total stent length per patient 29.1±16.9 31.9±18.3 32.8±18.9 <0.0001
Glycoprotein iib/iiia antagonist 245 (18.9) 501 (19.3) 438 (29.9) <0.0001
Aspirin at discharge 1282 (98.8) 2549 (98.1) 1433 (97.7) 0.13
clopidogrel at discharge 1290 (99.4) 2566 (98.7) 1432 (97.7) 0.001
oral anticoagulation at discharge 15 (1.2) 51 (2.0) 27 (1.8) 0.17
Categorical variables are expressed as count (percentage). Valid percentages may vary for some counts, be-
cause of missing values. Continuous variables are expressed as mean ±SD when appropriate. BMI indicates 
body mass index; CAD, coronary artery disease; GFR, glomerular filtration rate; LVEF, left ventricular ejection 
fraction; MI, myocardial infarction.
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ABstrAct
Background: Factors related to the occurrence of out-of-hospital cardiac arrest (OHCA) 
in ST-elevation myocardial infarction (STEMI) are still poorly understood. The current 
study sought to compare STEMI patients presenting with and without OHCA to identify 
angiographic factors related to OHCA.
methods: This multicenter registry consisted of consecutive STEMI patients, includ-
ing OHCA patients with return-of-spontaneous circulation. Patients were treated with 
primary percutaneous coronary intervention (PCI) and therapeutic hypothermia when 
indicated. Outcome consisted of in-hospital neurological recovery, scored using the Ce-
rebral Performance Categories (CPC) scale, and 1-year survival. Logistic regression was 
used to identify factors associated with OHCA and survival was displayed with Kaplan 
Meier curves and compared using log rank tests.
results: In total, 224 patients presented with OHCA and 3259 without OHCA. Average 
age was 63.3 years and 75% of patients were male. OHCA occurred prior to ambulance 
arrival in 68% of patients and 48% required intubation. Culprit lesion was associated with 
OHCA: risk was highest for proximal left coronary lesions and lowest for right coronary 
lesions. Also, culprit lesion determined the risk of cardiogenic shock and sub-optimal 
reperfusion after PCI, which were strongly related to survival after OHCA. Neurological 
recovery was acceptable (CPC≤2) in 77.1% of OHCA patients and did not differ between 
culprit lesions.
conclusions: In the present STEMI population, coronary culprit lesion was associated 
with the occurrence of OHCA. Moreover, culprit lesion influenced the risk of cardiogenic 
shock and success of reperfusion, both of which were related to prognosis of OHCA 
patients.
Angiographic lesions associated with OHCA 57
iNtroductioN
Out-of-hospital cardiac arrest (OHCA) is a common and life threatening condition fre-
quently caused by coronary artery disease.1 Historically, prognosis of OHCA has been 
poor.2 Revascularization techniques in OHCA have been under investigation for some 
time in an attempt to improve the prognosis of these patients. While thrombolysis 
during resuscitation failed to proof beneficial, coronary angiography with angioplasty 
showed promising results.3,4 Early or primary percutaneous coronary intervention 
(PPCI) has been shown to improve survival after OHCA due to ST-elevation myocardial 
infarction (STEMI) and at present, PPCI is readily available in the Netherlands for STEMI 
patients suffering an OHCA due to extensive nationwide networks of care designed to 
minimize ischemic times.5-7
Although PPCI for OHCA due to STEMI is commonly performed, factors associated 
with the occurrence of OHCA in setting of STEMI are still poorly understood. The current 
study sought to compare STEMI patients presenting with and without OHCA to identify 
angiographic factors related to the occurrence and prognosis of OHCA treated with PPCI 
and therapeutic hypothermia (TH).
methods
design and patients
The current Dutch registry prospectively included STEMI patients treated in 3 high-vol-
ume tertiary centers in the Netherlands. The design of this registry has been described 
previously.8 In short, all consecutive STEMI patients undergoing PPCI between January 
2006 and December 2009 were included. STEMI was defined as symptoms of angina 
lasting longer than 30 minutes along with typical electrocardiographical changes (ST-
segment elevation ≥0.2 mV in ≥2 contiguous leads in V1 through V3 or ≥0.1 mV in other 
leads or presumed new left bundle branch block) or presumed new regional wall motion 
abnormalities on echocardiogram when these criteria were unavailable or inconclusive. 
In case of OHCA, only patients with return-of-spontaneous-circulation (ROSC) on arrival 
at the catheterization laboratory were included. Patients permanently living outside the 
Netherlands were excluded to make follow-up through municipality records possible.
Emergency medical services (EMS) were staffed with nurses trained in advanced car-
diac life support. Patients were triaged in the field by 12-lead electrocardiogram faxed 
to the operator on call. In-ambulance medication included aspirin, intravenous heparin 
bolus and loading dose of clopidogrel. Glycoprotein IIb/IIIa inhibitors were administered 
up-front in the Leiden University Medical Center and periprocedurally in the other hos-
pitals. Upon arrival at the hospital, unresponsive patients were admitted to the emer-
58 Chapter 4
gency department and following stabilization transferred directly to the catheterization 
laboratory. Stable patients were transferred directly to the catheterization laboratory. 
Procedures were performed according to current clinical guidelines. Patients remain-
ing unresponsive (Glasgow Coma Scale <8) after resuscitation were transferred to the 
intensive care unit, where TH (32-34°C) was induced for 24 hours using ice packs, cooling 
blankets and intravenous NaCl 0.9% of 4°C, if necessary. After this period, TH was ceased 
and as body temperature returned to normal values sedation was weaned. Patients re-
maining unresponsive (Glasgow Coma Scale motor response <5) 24 hours after reaching 
normothermia and weaning of sedation underwent sensory evoked potentials testing. 
Severe and permanent neurologic dysfunction was diagnosed if the N20 response was 
bilaterally absent. Patients with a positive N20 response remaining comatose after 72 
hours underwent neurological clinical examination and electro-encephalography after 
which further treatment strategy was decided.
Patients treated in the Leiden University Medical Center were treated according to the 
institutional MISSION! protocol, a standardized pre-hospital, in-hospital and outpatient 
clinical framework for STEMI care.9 These patients were intensively monitored at the 
outpatient clinic for 1 year, after which they were referred to the general practitioner 
or regional cardiology clinic. In the other centers, local residents were managed at the 
outpatient clinics and patients referred from regional hospitals were referred back for 
further management by regional cardiologists.
data collection
All hospitals prospectively registered patients. Close collaboration with regional EMS 
supplied pre-hospital times and resuscitation characteristics. Vital status was obtained 
using municipality records. In-hospital outcome was a composite of all-cause mortality 
and neurological outcome. Neurological outcome was scored retrospectively using the 
Cerebral Performance Categories (CPC) scale consisting of 5 categories: 1. Conscious, 
good cerebral performance, able to work; 2. Conscious, moderate cerebral disability, able 
to work in a sheltered environment; 3. Conscious, severe cerebral disability, dependent 
on others; 4. Coma or vegetative state; 5. Brain death.10 Long term outcome consisted 
of 1-year all-cause mortality. Deaths were considered cardiac unless a clear non-cardiac 
cause could be identified.
statistical analyses
Continuous variables are presented as mean ± standard deviation or median (25th to 75th 
percentile) and were compared using Student’s t-test in case of mean and Mann-Whitney 
U test in case of median. Categorical variables are expressed as counts and percentages 
and were compared by means of Pearson’s χ2 test. All statistical tests were 2-tailed and a 
p-value <0.05 was considered statistically significant. Univariable logistic regression was 
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performed to investigate the association of angiographic factors with OHCA and other 
prognostic factors. Cumulative incidences of endpoints were displayed visually using 
Kaplan-Meier plots and compared with log rank tests. Analyses were performed using 
IBM SPSS Statistics version 20.
resuLts
Of the 3483 consecutive STEMI patients treated during the inclusion period, 224 (6.4%) 
presented with OHCA and 3259 (93.6%) without cardiac arrest. Baseline characteristics 
(Table 1) showed that symptom-to-balloon time was shorter in patients presenting with 
OHCA. In contrast, door-to-balloon time was longer in OHCA patients compared to non-
arrest patients. During angiography, patients presenting with OHCA more frequently 
table 1 - Baseline and procedural characteristics
ohcA
(N=224)
No ohcA
(N=3259)
p-Value
Age, years, mean ± standard deviation 62.5 ± 12.1 63.3 ± 12.5 0.365
Male sex 78.6 (176/224) 74.8 (2439/3259) 0.212
Diabetes mellitus 9.1 (20/219) 11.3 (366/3230) 0.318
Previous myocardial infarction 10.9 (24/221) 10.8 (351/3241) 0.989
Previous percutaneous coronary intervention 6.8 (15/221) 8.5 (275/3241) 0.378
Previous coronary artery bypass grafting 3.2 (7/221) 2.4 (78/3246) 0.477
Symptoms-to-balloon time, median minutes 150 (116-192) 181 (131-285) <0.001
Door-to-balloon time, median minutes 53 (36-79) 46 (33-66) 0.014
Culprit artery <0.001
Left main 3.1 (7/224) 1.2 (40/3257) 0.017
Left anterior descending 55.8 (125/224) 39.4 (1282/3257) <0.001
Left circumflex 21.9 (49/224) 15.5 (504/3257) 0.011
Right coronary artery 18.3 (41/224) 42.8 (1393/3257) <0.001
Bypass graft 0.9 (2/224) 1.2 (38/3257) 0.710
Multivessel disease 50.9 (114/224) 53.1 (1729/3256) 0.522
Stenting 96.9 (217/224) 95.6 (3114/3257) 0.367
Cardiogenic shock during PCI 30.8 (69/224) 4.8 (158/3259) <0.001
Intra-aortic balloon pump implantation 25.4 (57/224) 2.8 (92/3259) <0.001
TIMI flow ≤1 pre-procedure 79.9 (179/224) 79.3 (2582/3254) 0.841
TIMI flow 3 post-procedure 91.1 (204/224) 91.5 (2976/3254) 0.842
Values are percentage (n) or median (25th to 75th percentile). TIMI = Thrombolysis in myocardial infarction.
*defined as systolic blood pressure lower than 90 mmHg with signs of tissue hypoperfusion requiring treat-
ment in form of inotropic agents or assistant devices.
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showed left coronary artery culprit lesions compared to patients without arrest. Also, 
OHCA patients were more often in cardiogenic shock and were treated more commonly 
with intra-aortic balloon pumps. Thrombolysis-in-myocardial infarction flow pre- and 
post-procedure was comparable between the groups.
Table 2 shows the characteristics of the OHCA patients according to moment of arrest. 
Approximately two thirds of patients suffered a cardiac arrest before arrival of EMS. Most 
OHCAs were witnessed and delay in basic life support occurred in a quarter of patients 
with OHCA before EMS arrival. In most cases, the first observed rhythm was ventricular 
fibrillation or tachycardia. Intubation was performed in 108 patients. Of these patients, 
95.4% (103/108) survived PCI and 88.0% (95/108) underwent TH. The rest had no indica-
tion for TH due to return of consciousness.
factors associated with ohcA
Angiographic culprit lesion was associated with risk of OHCA (Figure 1, Table 3). Lesions 
located in the left coronary artery (with the exception of diagonal branch lesions) were 
found to result in the highest risk of OHCA. In addition, proximally located left coronary 
artery lesions displayed a higher risk of OHCA compared to non-proximally located left 
coronary artery lesions: OR 1.43 (95% CI 1.05-1.95, p=0.025). Separately, proximal vs. 
non-proximal left anterior descending or left circumflex culprit lesions were not signifi-
cantly associated with higher risk.
table 2 - characteristics and treatment of out-of-hospital cardiac arrest
ohcA witnessed by ems 
(N=71)
ohcA not witnessed by 
ems (N=153)
Delay in basic life support >5 minutes* 0.0 (0/71) 24.2 (37/153)
Bystander witnessed arrest 100 (71/71) 90.8 (139/153)
First observed rhythm
Ventricular fibrillation / tachycardia 95.8 (68/71) 93.4 (142/152)
Bradycardia 2.8 (2/71) 2.0 (3/152)
Asystole / Pulseless electrical activity 1.4 (1/71) 4.6 (7/152)
Treatment performed
Automatic external defibrillator 0.0 (0/71) 17.6 (27/153)
Defibrillation 95.7 (3/70) 94.1 (143/152)
Average number of shocks 1 (1-2) 2 (1-4)
Chest compressions 51.4 (36/70) 88.2 (135/153)
Intubation 10.0 (7/70) 66.0 (101/153)
Therapeutic hypothermia† 100 (7/7) 87.1 (88/101)
Values are percentage (n) or median (25th to 75th percentile).
*Based on history from bystanders; † The denominator is intubated patients.
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figure 1 - culprit location and risk of out-of-hospital cardiac arrest and cardiogenic shock
Right coronary artery 
OHCA:  7.96 
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CarSh: 0.55* 
OHCA: 3.31 
CarSh: 0.88* 
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CarSh: 0.90* 
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OHCA: 4.55 
CarSh: 1.70* 
OHCA: 3.50 
CarSh: 1.03* OHCA: 3.30 
CarSh: 1.21* 
*: non-significant 
CX 
LAD 
Left coronary artery 
Values are odds ratios. CarSh = cardiogenic shock; CX = circumflex artery; LAD = leftanterior descending 
artery; OHCA = out-of-hospital cardiac arrest.
table 3. Association of angiographic culprit location with ohcA, cardiogenic shock and timi flow
OHCA OR
(95% CI)
p-Value CarSh OR
(95% CI)
p-Value TIMI 
<3 
after 
PCI
OR
(95% CI)
p-Value
rcA
Proximal 
(N=530)
2.4 
(12)
Reference - 5.0 
(25)
Reference - 8.7 
(44)
Reference -
Non-proximal 
(N=834)
3.1 
(29)
1.31 (0.66-
2.59)
0.436 4.5 
(42)
0.90 (0.54-
1.50)
0.685 8.8 
(82)
1.00 (0.68-
1.47)
0.984
Left main artery 
(N=43)
16.3 
(7)
7.96 (2.95-
21.45)
<0.001 51.2 
(22)
20.03 
(9.74-
41.18)
<0.001 18.6 
(8)
5.96 (2.37-
14.99)
<0.001
LAd
Proximal 
(N=816)
10.0 
(82)
4.57 (2.47-
8.47)
<0.001 8.9 
(73)
1.88 (1.18-
3.00)
0.008 9.2 
(75)
1.06 (0.72-
1.56)
0.780
Non-proximal 
(N=521)
7.5 
(39)
3.31 (1.71-
6.40)
<0.001 4.4 
(23)
0.88 (0.49-
1.58)
0.674 7.9 
(41)
0.90 (0.57-
1.40)
0.624
Side branch 
(N=72)
5.6 (4) 2.41 (0.76-
7.68)
0.138 2.8 (2) 0.55 (0.13-
2.36)
0.418 4.2 (3) 0.45 (0.14-
1.50)
0.195
cx
Proximal 
(N=220)
10.0 
(22)
4.55 (2.21-
9.36)
<0.001 8.2 
(18)
1.70 (0.91-
3.19)
0.096 6.8 
(15)
0.76 (0.42-
1.40)
0.384
Non-proximal 
(N=216)
7.9 
(17)
3.50 (1.64-
7.45)
0.001 5.1 
(11)
1.03 (0.50-
2.12)
0.945 4.6 
(10)
0.51 (0.25-
1.03)
0.059
Side branch 
(N=134)
7.5 
(10)
3.30 (1.39-
7.81)
0.007 6.0 (8) 1.21 (0.54-
2.76)
0.643 9.8 
(13)
1.13 (0.59-
2.17)
0.712
Bypass graft 
(N=22)
2 (9.1) 4.09 (0.86-
19.52)
0.077 13.6 
(3)
3.02 (0.84-
10.88)
0.091 8 
(36.4)
2.38 (1.04-
5.46)
0.040
CarSh = cardiogenic shock; Cx = Circumflex artery; LAD = Left anterior descending artery; OR = odds ratio; 
RCA = Right coronary artery other abbreviations as in table 1.
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Left main and proximal left anterior descending artery lesions were also associated 
with development of cardiogenic shock (Figure 1, Table 3). Moreover, culprit lesions in 
the left main and bypass grafts were associated with sub-optimal TIMI fl ow after PCI 
(Table 3).
Neurological recovery and outcome during 1-year follow-up
Discharge CPC was known in 218 OHCA patients (97.3%) (Figure 2). The majority of 
patients had acceptable CPC scores (CPC≤2 in 77.1%, n=168). Thirty-fi ve patients were 
in CPC 5/dead, of which 21 patients were brain dead and 14 patients suff ered cardiac 
death. Of the 107 patients with a proximal left coronary culprit lesion, 77 recovered 
(72.0%). This rate was slightly higher for the patients with a non-proximal left culprit le-
sion (84.1%, 58/69 patients recovered) and the patients with a right culprit lesion (80%, 
32/40 patients recovered). Of the 2 patients with a bypass graft culprit lesion, one died 
due to neurological causes. The p-value for trend between the culprit groups was 0.212.
One-year survival status was known in 3479 patients. In-hospital mortality was higher 
in OHCA patients compared to patients without OHCA (16.5% vs. 3.1%, p<0.001). Also, 
1-year mortality (19.2% vs. 6.6%, p<0.001) was higher, which was due to in-hospital 
figure 2 - in-hospital cerebral Performance categories scale according to culprit lesion
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67% (146) 
10% (22) 
5% (10) 
2% (5) 
16% (35) 
All OHCA patients 
66% (71) 
6% (6) 
4% (4) 
3% (3) 
22% (23) 
Proximal left culprit lesions 
CPC 1 CPC 2 CPC 3 CPC 4 CPC 5 
67% (46) 
17% (12) 
4% (3) 
1% (1) 
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Non-proximal left culprit lesions 
CPC = cerebral performance categories scale.
Other abbreviations as in fi gure 1.
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mortality as post-discharge survival was similar between patients with and without 
OHCA (3.2% vs. 3.6%, p=0.774). Figure 3A and 3B show the association between culprit 
location and mortality during follow-up in patients with and without OHCA. Figure 3C 
and 3D shows the association of cardiogenic shock and success of reperfusion with 
survival. OHCA patients with optimal TIMI flow after PCI had a better prognosis than 
OHCA patients with a sub-optimal TIMI flow after procedure, regardless of cardiogenic 
shock during PCI. In contrast, presence of cardiogenic shock was more important than 
success of reperfusion in patients without OHCA.
discussioN
The present multicenter registry identified an association between angiographic culprit 
location and the occurrence of OHCA in STEMI patients: left proximal coronary lesions 
were associated with the highest risk for OHCA and right coronary lesions with the low-
est. Moreover, culprit location was associated with cardiogenic shock and sub-optimal 
reperfusion after PCI, both of which were driving factors of prognosis after OHCA.
Attempts to improve the historically poor prognosis of OHCA led to investigation of 
revascularization techniques for OHCA patients.2 While thrombolysis during resuscita-
tion failed to prove beneficial, coronary angiography with angioplasty showed promise 
from early on.3,4 At present, extensive networks of care make PPCI readily available for 
patients suffering an OHCA due to STEMI. In the current STEMI population, symptom-
figure 3 - survival in patients with and without ohcA according to A) and c) culprit lesion, B) and d) 
cardiogenic shock and timi flow after Pci
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to-balloon times were strongly reduced in OHCA patients, a finding also observed 
by others, possibly reflecting the severity of symptoms leading to early initiation of 
professional care by either patient or bystanders.5,6 In contrast, the prolonged door-to-
balloon times in OHCA patients were likely related to time needed for in-hospital patient 
stabilization. Patients presenting with OHCA were more frequently in cardiogenic shock 
on arrival, due to impaired coronary perfusion during cardiac arrest and culprit lesion 
location. Culprit location varied between OHCA and non-arrest patients and was found 
to be associated with occurrence of OHCA. Left coronary lesions resulted in the high-
est and right coronary artery lesions in the lowest risk for OHCA. Moreover, proximally 
located culprit lesions within the left coronary artery were associated with higher risk of 
OHCA compared to non-proximally located lesions. This is likely explained by the larger 
area of myocardium-at-risk in proximal left lesions, which was supported by the finding 
that left main and proximal left anterior descending artery culprits were also associated 
with cardiogenic shock.11 The lower percentage of right coronary artery culprit lesions is 
possibly explained by the commonly occurring vagal reaction in inferior MI, which may 
have a protective effect against VF.12 However, it cannot be completely ruled out that 
inferior MI may have caused more severe ischemia, preventing ROSC and thus inclusion 
in this registry.
In-hospital and 1-year outcome rates stratified according to culprit lesion were similar 
in OHCA patients. Nevertheless, location of culprit lesions contributed indirectly to mor-
tality due to the association with cardiogenic shock and sub-optimal reperfusion. Left 
main lesions were the highest risk lesions for STEMI patients, due to the strong associa-
tion with OHCA, cardiogenic shock and sub-optimal reperfusion, which is supported by 
other reports.13 Also, bypass graft culprit lesions were associated with reperfusion fail-
ure. The no-reflow phenomenon in setting of STEMI has multiple mechanisms, among 
which distal embolization and ischemic injury.14 The occurrence of distal embolization 
is notorious in PCI of saphenous vein grafts and remains a challenge for operators.15 The 
importance of optimal reperfusion in OHCA patients was stressed by the lower survival 
rates for sub-optimally reperfused OHCA patients without cardiogenic shock during PCI 
compared to optimally reperfused OHCA patients with cardiogenic shock during PCI. 
No-reflow possibly reflects the duration of ischemia prior to PCI in OHCA patients and 
the effect on prognosis may therefore also be explained by a prolonged resuscitation. In 
contrast, presence of cardiogenic shock was a stronger factor than failed reperfusion in 
patients without OHCA. This was likely explained by a smaller area of myocardium at risk 
in these patients due to the different distribution of culprit lesions.
Using a combined treatment strategy of primary PCI and TH, 77% of the OHCA popula-
tion was discharged with acceptable neurological outcome and 1-year survival was 81%. 
The combination of PPCI and TH was previously investigated in the PROCAT registry, 
where the investigators reported an overall in-hospital survival rate of 40%, rising to 54% 
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in STEMI patients after successful PCI which predicted improved prognosis.7 Further-
more, the positive influence of both PCI and TH on long term survival was established in 
a cohort of OHCA patients, which included a large percentage of STEMI patients.16 Also, 
a recent smaller study focusing specifically on use of TH in STEMI complicated by OHCA 
reported a neurological recovery rate comparable to the rate observed in the popula-
tion treated with TH in the current study, supporting the accuracy of our findings.17
Limitations
Our investigation represents one of the largest studies covering outcomes in OHCA 
patients due to STEMI. However, our study was observational and thus shares the limita-
tions of all observational analyses. Because the registry only included STEMI patients 
with ROSC, no data was available on OHCA patients without ROSC or patients not 
referred for PPCI. Data covering these patients may have provided more insight into the 
full community experience.
conclusions
Location of angiographic culprit lesion was associated with the occurrence of OHCA 
in the current STEMI population. Moreover, angiographic culprit location predicted 
cardiogenic shock and success of reperfusion, both of which were associated with the 
prognosis of OHCA patients.
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ABstrAct
Background: Blood biomarkers carry potential for monitoring severity of chronic heart 
failure (CHF). Studies correlating repeated measurements of blood biomarkers with 
repeatedly assessed NYHA class over a prolonged follow-up period, and concomitantly 
investigating their associations with clinical endpoints, have not yet been performed.
methods: In 2011-2013, 263 CHF patients were included. At inclusion and subsequently 
every 3 months, we measured N-terminal pro-B-type natriuretic (NT-proBNP), high-
sensitivity troponin T (Hs-TnT) and C-reactive protein (CRP), and assessed NYHA class. 
The primary endpoint comprised heart failure hospitalization, cardiovascular mortality, 
cardiac transplantation or left ventricular assist device implantation. Time-dependent 
Cox models were used.
results Mean age was 67±13 years, 72% were men and 27% were in NYHA class III–IV. We 
obtained 886 repeated measures (median 3[IQR 2-5] per patient). The primary endpoint 
was reached in 41 patients during a median follow-up of 1.0[0.6-1.4] year. Repeatedly 
measured NT-proBNP and Hs-TnT were significantly associated with repeatedly assessed 
NYHA class, whereas CRP was not (NT-proBNP: β[95%CI]:1.56[1.17–2.06]ln(ng/L) in-
crease per point increase in NYHA class, p=0.002; HsTNT: β[95%CI]:1.58[1.21–2.07]. Seri-
ally measured NT-proBNP (HR[95%CI]: 2.86 [1.73-4.73], CRP (1.69 [1.21-2.34]) and NYHA 
class (2.33 [1.51-3.62]) were positively and independently associated with the primary 
endpoint, whereas Hs-TnT lost statistical significance after multivariable adjustment. A 
model containing serially measured NYHA-class and NT-proBNP displayed a c-index of 
0.84, while serially measured NYHA-class and CRP showed a c-index of 0.82.
conclusions: Temporal NT-proBNP, CRP and NYHA class patterns are independently 
associated with adverse clinical outcome. Serially measured NT-proBNP and NYHA-class 
are best suited for monitoring CHF outpatients.
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iNtroductioN
Adjustment of medicinal treatment for chronic heart failure (CHF) requires considerable 
clinical acumen and may in some cases cause misjudgement in risk assessment and 
consequently suboptimal treatment.1-4 Therefore, several diagnostic tools have been 
developed over the past decades which aim to objectify disease severity, such as the 
New York Heart Association (NYHA) Functional Classification,1,4 which has limited repro-
ducibility and high inter-observer variability.5 Conversely, circulating blood biomarkers 
are less subjective to interpretation, and carry potential to monitor subtle changes in 
the heart that reflect and possibly predict adverse changes before they become clini-
cally apparent.6 The use of biomarkers, such as B-type natriuretic peptides (BNP), cardiac 
troponins and C- reactive protein (CRP), for risk stratification of CHF patients has already 
been demonstrated.7-13 Moreover, although trials on natriuretic peptide-guided therapy 
of HF have provided somewhat inconsistent results,9,14 natriuretic peptide-guided HF 
therapy has recently been given a class IIa recommendation in US HF guidelines to 
achieve guideline-directed medical therapy.15,16
Several studies have previously examined NYHA class in relation to clinical outcome 
in CHF patients. However, these studies either used single, baseline assessments or 2 
repeated assessments taken in a relatively short time interval.17,18 Furthermore, stud-
ies on the association between blood biomarkers and NYHA class in CHF are scarce, 
and studies assessing both these properties repeatedly are non-existent. Finally, the 
predictive value of serially assessed blood biomarkers and NYHA class scores for adverse 
clinical outcome has never yet been compared in stable CHF patients.
Therefore, the aim of the current investigation, performed in 263 patients with CHF, 
was to examine the associations between repeatedly measured NT-proBNP, troponin T 
(Hs-TnT), CRP, and NYHA class, as well as the associations of their temporal patterns with 
adverse clinical outcome. Based on this, we evaluated the incremental value of serially 
measuring blood biomarkers, to clinical assessment in terms of serial NYHA class scor-
ing, for monitoring stable CHF outpatients.
methods
Patients
The Serial biomarker measurements and new echocardiographic techniques in chronic heart 
failure patients result in tailored prediction of prognosis (Bio-SHiFT) study was designed to 
investigate the hypothesis that temporal patterns of biomarkers involved in CHF are 
associated with prognosis. Bio-SHiFT is an ongoing prospective, observational study of 
stable outpatients with CHF, conducted in Erasmus MC, Rotterdam, The Netherlands and 
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Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands. Patients were recruited during 
their regular outpatient visits and were in clinically stable condition. Patients were eligible 
for inclusion if aged 18 years or older, capable of understanding and signing informed 
consent, and if CHF (including HF with preserved ejection fraction) was diagnosed ≥3 
months ago according to the guidelines of the European Society of Cardiology (ESC).1,4,19 
Detailed inclusion and exclusion criteria are shown in figure 1. The study was approved 
by the medical ethics committees of the participating hospitals and was conducted in 
accordance with the Declaration of Helsinki. Written informed consent was obtained 
from all patients.The study is registered in ClinicalTrials.gov, number NCT01851538. 
Follow-up for this analysis lasted from October 2011 until November 2013.
figure 1 - inclusion and exclusion criteria 
 
 
 
 
 
 
 
 
Heart failure with preserved ejection fraction (HFPEF) 
diagnosed ≥ 3 months ago according to the definition of the 
ESC, which includesthe following features: 
 Presence of signs and/or symptoms of HF (as 
described above) 
AND 
 Presence of normal or only mildly abnormal systolic 
function (LVEF ≥ 50%) 
AND 
 Evidence of diastolic left ventricular dysfunction 
according to the criteria of the ESC: 
o E/E’>15 
OR 
o 15> E/E’ > 8 AND 
NT-proBNP > 220pg/ml /  
BNP > 220 pg/ml  
OR  
o E/A < 0.5 and DT > 280 ms  
OR  
o Atrial fibrillation 
Inclusion criteria 
1. Age ≥ 18 years 
2. Diagnosis chronic heart failure ≥ 3 months* 
3. Written informed consent 
Heart failure, diagnosed ≥ 3 months ago according to the 
definition of the European Society of Cardiology (ESC), which 
includes the following features: 
 Symptoms typical of heart failure: breathlessness at 
rest or on exercise, fatigue, tiredness, ankle swelling 
AND 
 Signs typical of heart failure: tachycardia,  
tachypnea, pulmonary rales, pleural effusion,  
raised jugular venous pressure, peripheral oedema, 
hepatomegaly 
AND 
 Objective evidence of a structural or functional 
abnormality of the heart at rest: cardiomegaly, third 
heart sound, cardiac murmurs, abnormality on the 
echocardiogram, raised natriuretic peptide 
concentration 
 
Exclusion criteria 
 
1. Heart failure secondary to circulatory high output conditions 
2. Scheduled for surgery or intervention for both coronary and non-
coronary indication within 6 months of inclusion 
3. Severe renal failure for which dialysis is needed 
4. Known moderate or severe liver disease 
5. COPD Gold stage IV 
6. Coexistent condition with life expectancy ≤ 1 year 
7. Congenital heart disease 
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Baseline assessment
At baseline, patients were evaluated by trained research physicians, who collected infor-
mation on HF-related symptoms, including NYHA class.1,4 History of chronic renal failure 
was defined as glomerular filtration rate less than 60 mL/min/1.73m2. Alcohol consump-
tion was defined as drinking ≥1 alcoholic consumption per day. Electrocardiography 
and echocardiography were performed. Data were entered into electronic case report 
forms. Non-fasting blood and urine samples were collected.
follow-up visits
Study follow-up visits were scheduled every 3 months (a window of ±1 month was 
allowed), for a maximum of 30 months. At each tri-monthly study visit, a short medi-
cal evaluation was performed, NYHA functional class was scored and blood and urine 
samples were collected.
Blood sampling and biomarker measurement
Blood samples were collected at baseline and at each follow-up visit, and were processed 
and stored locally at a temperature of -80°C within 2 hours after blood collection. When 
applicable, samples were transported to the central laboratory (Erasmus MC, Rotterdam, 
The Netherlands) under controlled conditions (at a temperature of -80°C), until batch 
analysis was performed. Thus, the biomarker measurements performed for this study 
did not lead to treatment adjustments.
Batch analysis of NT-proBNP, Hs-TnT, and CRP was performed in the Clinical Chemistry 
Laboratory of the Erasmus MC. Plasma NT–proBNP and Hs-TnT were analysed using elec-
trochemiluminesence immunoassays (Roche Diagnostics, Elecsys 2010, Indianapolis, 
Indiana, USA). For NT-proBNP, concentrations were measured ranging from 5 to 35.000 
pmol/L. Coefficients of variation (CVs) were <5% at mean values ranging from 5.19-274 
pmol/L. For Hs-TnT, concentrations were measured ranging from 3-10000 ng/L. CVs 
were <5% at mean values ranging from 12.7-1819 ng/L. CRP was measured using an 
immunoturbidimetric assay (Roche Hitachi 912 chemistry analyser, Basel, Switzerland). 
This system measures concentrations ranging from 0.3 to 350 mg/L, and CVs were <5% 
at mean values ranging from 0.84-284 mg/L.
clinical study endpoints
During follow-up, endpoints were recorded in the electronic case report forms by 
trained research physicians, and associated hospital records and discharge letters were 
collected. Subsequently, a clinical event committee blinded to the biomarker results 
reviewed all collected information and adjudicated primary and secondary endpoints.
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The primary endpoint comprised the composite of cardiac death, cardiac transplanta-
tion, left ventricular assist device implantation, and hospitalization for the management 
of acute or worsened HF.
Cardiac death was defined as death from myocardial infarction (MI) or other ischemic 
heart disease (ICD-10: I20-I25), death from other heart disease including HF (I30-I45 and 
I47-I52), sudden cardiac death (I46), sudden death undefined (R96) or unwitnessed or 
ill-described death (R98, R99). Hospitalisation for acute or worsened HF was defined as 
exacerbation of symptoms typical of HF, in combination with 2 of the following: BNP 
or NT-proBNP >3x the upper limit of normal, signs of worsening HF, such as pulmonary 
rales, raised jugular venous pressure or peripheral oedema, increased dose or intrave-
nous administration of diuretics, or administration of positive inotropic agents.
statistical analysis
Statistical methods are described in detail in the supplemental text. In brief, we used 
linear mixed models to assess the associations between serial biomarker measurements 
and repeated assessment of NYHA functional class. Associations between serial mea-
surements of biomarkers and NYHA class, and occurrence of the primary endpoint, were 
examined by entering the serial measurements as time-varying covariates into extended 
Cox proportional hazards models. First, the models were adjusted for age, gender, sys-
tolic blood pressure and estimated glomerular filtration rate (eGFR; calculated using the 
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation). Subsequently, 
all variables, i.e. NT-proBNP, Hs-TnT, CRP and NYHA functional class, were entered 
simultaneously into the models to investigate their independence. We calculated time-
dependent C-indices based on the extended Cox models. Analyses were performed with 
R Statistical Software and MedCalc.
resuLts
study population
A total of 263 were included from October 2011 to June 2013. Baseline characteristics 
are displayed in table 1. Mean age was 67 years (SD±13), 72% were men, and 73% were 
in New York heart association (NYHA) class I or II. Median duration of HF at inclusion was 
4.6 years (IQR 1.7–9.9). Median baseline NT-proBNP was 137.3 pmol/L (IQR 51.9–272.9), 
Hs-TnT:18.0 ng/L (IQR 9.6–33.2) and CRP:2.2 mg/L (IQR 0.9–4.8).
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table 1 – Baseline characteristics
NYhA class i
(n=78)
NYhA class ii
(n=116)
NYhA class iii/iV
(n=66)
total
(n=263)
demographics
Age 64 (±11) 68 (±13) 72 (±11) 67 (±13)
Male gender 60 (78) 81 (69) 48 (70) 189 (72)
Caucasian ethnicity 71 (92) 107 (92) 66 (94) 244 (94)
clinical characteristics
Body mass index kg/m2 28 (±5) 27 (±4) 28 (±4) 28 (±5)
Heart rate, bpm 63 (±10) 68 (±11) 69 (±13) 67 (±12)
SBP, mmHg 123 (±19) 124 (±20) 120 (±21) 122 (±20)
DBP, mmHg 75 (±11) 72 (±11) 71 (±10) 72 (±11)
Biomarker level
NT-proBNP (pmol/L) 93 (38-175) 141 (49-583) 225 (120-436) 140 (52-273)
HsTNT (ng/L) 13 (7.8-21) 19 (9.9-37) 24 (16-43) 18 (10 -33)
CRP (mg/L) 1.6 (0.6-3.4) 2.3 (1.0-5.3) 2.7 (1.3-4.9) 2.2 (0.9-4.8)
Creatinine (mg/dL) 1.2 (1.0 – 1.5) 1.1 (1.0 – 1.4) 1.3 (1.0 – 1.6) 1.2 (1.0 – 1.5)
eGFRa (ml/min/1.73 m2) 62 (42 – 83) 58 (46 – 78) 53 (38 – 72) 58 (43 – 76)
medical history
CAD 29 (39) 57 (50) 56 (84) 142 (46)
ICD 42 (55) 67 (57) 42 (61) 151 (59)
CRT 20 (26) 40 (34) 18 (26) 78 (30)
CVA 8 (10) 18 (15) 15 (22) 41 (16)
Chronic renal failure 34 (44) 61 (52) 41 (59) 136 (53)
Diabetes Mellitus 16 (23) 34 (28) 31 (42) 81 (31)
Hypercholesterolemia 26 (34) 41 (35) 26 (38) 93 (36)
Hypertension 33 (43) 56 (48) 31 (45) 120 (46)
intoxications
Alcohol consumption 30 (40) 51 (44) 27 (39) 108 (42)
Ever smoker 58 (75) 79 (68) 48 (70) 185 (71)
medication use
ACE-i or ARB 75 (96) 109 (94) 61 (88) 245 (93)
Aldosteron antagonist 44 (56) 81 (70) 53 (80) 178 (68)
Diuretic 64 (82) 107 (92) 66 (96) 237 (90)
Beta-blocker 68 (87) 106 (91) 58 (88) 232 (88)
Aspirin 14 (18) 16 (14) 15 (22) 45 (17)
Vitamin K antagonist 59 (77) 88 (78) 53 (77) 200 (77)
Normally distributed continuous variables are presented as mean (± standard deviation). Non-normally 
distributed continuous variables are expressed as median (25th – 75th percentile). Categorical variables are 
expressed as count (percentage). Valid percentages may vary for some counts, because of missing values. 
ACE-i = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; CAD = coronary 
artery disease; CRP = C-reactive protein; CRT = cardiac resynchronisation therapy; CVA = cerebro vascular 
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Associations between serial biomarker measurements and serial assessment of 
NYhA class
During follow-up, we collected 921 blood samples and scored NYHA functional class 
1292 times. Of all follow-up visits, 1135 took place before the occurrence of the primary 
endpoint. During these follow-up visits, 886 blood samples were drawn (median 3; IQR 
2-5 per patient), and NYHA functional class was scored 1114 times (median 4; IQR 2-6 
per patient).
Repeatedly measured NT-proBNP and Hs-TnT showed strong associations with repeatedly 
assessed NYHA class, whereas CRP did not (NT-proBNP: β[95%CI]:1.56[1.17–2.06]ln(ng/L) 
increase per point increase in NYHA class, p=0.002; HsTNT: β[95%CI]:1.58[1.21–2.07], 
p=0.001; CRP: β[95%CI]:1.22[0.98–1.53], p=0.076)(supplemental table 1).
clinical endpoints
The composite endpoint was reached by 41 patients (16%), during a median follow-up 
of 1.0 [0.6-1.4] years: 5 patients died from a cardiovascular cause, 35 patients were re-
hospitalized for worsened HF and 1 patient underwent heart transplantation. Of the 35 
patients reaching the primary endpoint because of re-hospitalisation for HF, 16 patients 
died eventually during further follow-up, of whom 12 patients died from a cardiovascu-
lar cause. Overall all-cause mortality was 21 (8.0%).
Baseline biomarker measurements and NYhA class and the primary endpoint
NT-proBNP, Hs-TnT, CRP, and NYHA class all displayed strong and positive associations 
with the primary endpoint (table 2). After multivariable adjustment, NT-proBNP, CRP 
and NYHA class remained independently associated with the primary endpoint, while, 
Hs-TnT lost statistical significance. Of all other baseline characteristics, only age was 
independently associated with the primary endpoint.
serial measurements of biomarkers and NYhA class, and the primary endpoint
Temporal evolutions of serial biomarker measurements and NYHA class are displayed 
in figure 2. Serially measured NT-proBNP, Hs-TnT, CRP, and NYHA class all displayed 
strong and positive associations with the primary endpoint (table 2). After multivariable 
adjustment for all serially measured variables, NT-proBNP, CRP and NYHA class remained 
significantly associated with the primary endpoint.
accident DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; HsTNT = high sensi-
tive cardiac troponin T; ICD = implantable cardioverter defibrillator; NT-proBNP = N-terminal pro-B-type 
natriuretic peptide; NYHA = New York Heart Association; SBP = systolic blood pressure.
aeGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
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model performance
The discriminative abilities of the models containing baseline measurements of NT-
proBNP, Hs-TnT, CRP and NYHA class are shown in supplemental table 2, and those of se-
rial measurements in table 3. All individual serially assessed c-indices, except for Hs-TnT, 
were numerically higher than corresponding baseline c-indices. Adding serial NT-proBNP 
to the model containing age, sex, systolic blood pressure and eGFR and NYHA class, 
provided a substantial increase in C-index from 0.76(CI 0.66–0.86) to 0.84(0.74 – 0.93), 
although this did not reach statistical significance (p=0.26). Adding serial CRP instead 
to this same multivariable model resulted in a C-index of 0.82(0.72 – 0.92), p=0.40. Add-
ing both serial NT-proBNP and CRP to the multivariable model only resulted in a slight 
improvement compared to addition of NT-proBNP only: 0.85(CI 0.75–0.95), p=0.20.
discussioN
In this prospective, observational cohort of CHF patients, repeatedly measured NT-
proBNP and Hs-TnT were positively and significantly associated with repeatedly assessed 
NYHA class. Serial assessments of NT-proBNP, CRP and NYHA class were independently 
table 2 – Associations between blood biomarker measurements, NYhA class, and the primary end-
point
Associations between baseline measurements and the primary endpoint
univariable modelsa multivariable modelb
hr (95% ci) p hr (95% ci) p
Nt-proBNPc 3.10 (1.87 – 5.13) <0.001 2.37 (1.39 – 4.02) 0.003
hs-tntc 1.94 (1.33 – 2.84) <0.001 1.50 (0.96 – 2.33) 0.11
crPc 1.55 (1.12 – 2.16) 0.005 1.53 (1.10 – 2.14) 0.013
NYhA classd 2.22 (1.41 – 3.50) <0.001 2.14 (1.33 – 3.45) 0.003
Associations between serial measurements and the primary endpoint
univariable modelsa multivariable modelb
hr (95% ci) p hr (95% ci) p
Nt-proBNPc 4.02 (2.50 – 6.47) <0.001 2.86 (1.73 – 4.73) <0.001
hs-tntc 1.95 (1.36 – 2.77) <0.001 1.26 (0.86 – 1.84) 0.32
crPc 2.08 (1.50 – 2.87) <0.001 1.69 (1.21 – 2.34) 0.001
NYhA classd 2.80 (1.83 – 4.28) <0.001 2.33 (1.51 – 3.62) <0.001
HR= hazard ratio; CRP = C-reactive protein; Hs-TnT = high-sensitive cardiac troponin T; NT-proBNP = N-
terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association.
a Including age and gender
b Including age, gender, systolic blood pressure and estimated glomerular filtration rate
c HR per standard deviation increase in log transformed level
d HR per 1-step increase
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associated with adverse clinical outcome. Repeatedly measured NT-proBNP and CRP 
both added individually to serial NYHA-class assessments in terms of discriminative 
ability. However, a model combining both of these biomarkers with serially scored 
NYHA-class, seemed to have little incremental value over serial NYHA-class assessment 
combined with only one of these blood biomarkers. In particular, adding NT-proBNP 
only seemed the best suited strategy for monitoring stable CHF outpatients.
Strengths of the current study include simultaneous assessment of multiple biomark-
ers and NYHA class on the one hand, as well as frequent, repeated assessment of these 
properties on the other hand. Combined with clinical follow-up on adverse events, this 
renders insight into temporal evolution and manifestation of CHF. On top of that, using 
biomarker measurements for monitoring patients with CHF has the appealing feature of 
being objective, and thus uniform and reproducible.
Serial NT-proBNP and CRP measurements were both independently associated with 
the endpoint and adding serial NT-proBNP and CRP measurements to a model con-
taining NYHA class assessments greatly increased the c-index, from 0.76 to 0.85. This 
increase did not reach statistical significance, but recently it has been demonstrated that 
testing for improvement in prediction performance is actually redundant if a variable 
figure 2 - temporal evolution of serial biomarker measurements and NYhA class
X-axes display the time that is left until occurrence of the clinical endpoint.
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has already been shown to be an independent risk factor, and that standard testing pro-
cedures such as c-indices are very conservative and thus insensitive to improvements in 
prediction performance.20 Nevertheless, to provide an impression of the magnitude of 
the incremental prognostic value, we presented C-indices. Altogether, our results sup-
port combining blood biomarkers with clinical assessment for prognostication in CHF 
patients.
While the prognostic value of blood biomarkers for clinical events has been widely 
investigated, less is currently known about the association between blood biomarkers 
and NYHA class in CHF patients. Only two studies have previously assessed this as-
sociation. These studies measured natriuretic peptide level both at study baseline and 
at 6±2 weeks of follow-up, and correlated these measurements with, among others, 
clinical change as categorized by clinicians.17,18 Studies performing multiple, repeated 
measurements of biomarkers and NYHA class over a prolonged follow-up period, and 
concomitantly investigating their association with clinical endpoints have not yet been 
performed. Although the NYHA functional classification is a common and globally used 
system,1,4 its biggest disadvantage is the non-uniformity in its application by individual 
clinicians. Raphael et al conducted a study to investigate consistency in NYHA functional 
class assessment and found that inter-observer variability was high, with only 54% con-
cordance between two cardiologists.5 In this respect, adding biomarker information to 
clinical patient assessment could be valuable for obtaining a more objective estimate of 
patient prognosis.
table 3 – discriminative ability of models containing serial blood biomarker- and NYhA assessment
model c-index (ci) P-value
Modela 0.62 (0.52 – 0.71) NA
Modela + NT-proBNP 0.80 (0.70 – 0.90) 0.010b
Modela + Hs-TnT 0.72 (0.62 – 0.82) 0.13b
Modela + CRP 0.76 (0.66 – 0.85) 0.048b
Modela + NYHA class 0.76 (0.66 – 0.86) 0.040b
Modela + NYHA class + NT-proBNP 0.84 (0.74 – 0.93) 0.26c
Modela + NYHA class + Hs-TnT 0.79 (0.69 – 0.89) 0.67c
Modela + NYHA class + CRP 0.82 (0.72 – 0.92) 0.40c
Modela + NT-proBNP + CRP 0.82 (0.73 – 0.92) 0.40c
Modela + NYHA class + NT-proBNP + CRP 0.85 (0.75 – 0.95) 0.20c
CI = Confidence interval; CRP = C-reactive protein; Hs-TnT = High-sensitive cardiac troponin T; NT-proBNP = 
N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association.
a Including age, gender, systolic blood pressure and estimated glomerular filtration rate
b P-value compared to modela
c P-value compared to modela + NYHA class
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Limitations
Extended Cox models with time-dependent covariates were used to analyse the effects 
of changes in NYHA class and temporal biomarker patterns on the primary endpoint, 
because these models are able to accommodate multiple time-varying covariates. 
However, time-dependent Cox models assume that biomarker levels do not change 
between measurements.21 In reality, blood biomarkers are dynamic and continuously 
change over time, parallel to the condition of the patient. Therefore, we performed a 
sensitivity analysis by means of a joint modelling approach. Joint models combine a 
linear mixed-effects model for the serial biomarker measurements with a Cox propor-
tional hazards model for the occurrence of the primary endpoint.21 We estimated the 
individual biomarker trajectories and NYHA trajectories using separate joint models, 
then extracted the fitted trajectories from the joint models, and entered the extracted 
trajectories simultaneously into one extended Cox model. The results of this analysis 
were materially the same as those we described in the paper. Furthermore, the majority 
of the patient population was in NYHA class I or II, and thus at relatively low risk. The 
results and conclusions should be judged accordingly.
conclusion
Serial assessments of NT-proBNP and Hs-TnT are positively associated with NYHA class. 
Temporal patterns of NT-proBNP, CRP and NYHA class are independently associated 
with adverse clinical outcome. A model containing these serially measured variables 
displayed good discriminative ability. However, serially measured CRP had only little 
incremental discriminative value compared to a strategy combining serial assessments 
of NYHA class and NT-proBNP. Altogether, our findings underscore the incremental value 
of biomarkers to NYHA class for monitoring stable CHF outpatients.
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suPPLemeNtAL text
statistical analysis
Variables with normal distributions are presented as mean±standard deviation (SD). 
Variables with non-normal distributions are presented as median and interquartile 
range (IQR). Categorical data are displayed as count and percentage. In case of skewed 
distributions, continuous variables were logarithmically transformed for further analy-
ses.
To assess the associations between serial biomarker measurements and repeated 
assessment of NYHA functional class, we used linear mixed models. Time was used as a 
random effect. NYHA class was used as the independent variable (fixed effect), in order 
to be able to uniformly display the change in each of the biomarkers per point increase 
in NYHA class. Each of the biomarkers was consecutively used as the dependent variable. 
Associations amongst the 3 biomarkers were examined likewise. For these analyses, all 
samples drawn were used.
Associations between baseline values of NT-proBNP, Hs-TnT, CRP, and NYHA functional 
class on the one hand, and the primary endpoint on the other hand, were assessed 
using only the samples drawn before the occurrence of the primary endpoint. Cox 
proportional hazards models were used. Associations between serial measurements of 
the aforementioned variables and occurrence of the primary endpoint were examined 
by entering the serial measurements into extended Cox proportional hazards models as 
time-varying covariates. First, the models were adjusted for age, gender, systolic blood 
pressure and estimated glomerular filtration rate (eGFR; calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation). Subsequently, all vari-
ables, i.e. NT-proBNP, Hs-TnT, CRP and NYHA functional class, were entered simultane-
ously into the models to investigate their independence. For serial measurements, this 
meant that all variables were simultaneously entered as time-varying covariates into 
the extended Cox analysis. The multivariable models also included age, gender, systolic 
blood pressure and eGFR.
It has previously been demonstrated that testing for improvement in prediction per-
formance is actually redundant if a variable has already been shown to be an indepen-
dent risk factor. Independence already proves presence of incremental value [20]. Still, to 
provide an impression of the magnitude of the incremental discriminative ability of the 
individual and combined serial measurements of the biomarkers and NYHA functional 
class, we calculated time-dependent C-indices based on the extended Cox models.
Finally, to investigate the incremental value of serial biomarker measurements to 
baseline assessment only, we simultaneously added the baseline measurements and 
the series of longitudinal measurements of NT-proBNP, CRP, Hs-TnT and NYHA class into 
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the models, in order to obtain separate hazard ratios for the baseline measurements and 
for the series of longitudinal measurements.
Analyses were performed with R Statistical Software using packages ‘Survival’ and 
‘nlme’. C-indices were compared using MedCalc. All tests were two-tailed and p-values 
<0.05 were considered statistically significant.
supplemental table 1 – Associations between serial blood biomarker measurements and NYhA class
Nt-proBNPa
Nt-proBNPa Β
(95%ci)
p-value hs-tnta
hs-tnta 1.66
(1.53 – 1.81)
<0.001 Β
(95%ci)
p-value crPa
crPa 1.11
(1.06 – 1.16)
<0.001 1.03
(0.99 – 1.08)
0.11 Β
(95%ci)
p-value
NYhA classb 1.56
(1.17 – 2.06)
0.002 1.58
(1.21 – 2.07)
0.001 1.22
(0.98 – 1.53)
0.076
CRP = C-reactive protein; Hs-TnT = high sensitive cardiac troponin T; NT-proBNP = N-terminal pro-B-type 
natriuretic peptide; NYHA = New York Heart Association.
a Beta coefficient per standard deviation increase in log transformed level
b Beta coefficient per 1-step increase
supplemental table 2 – discriminative ability of models containing baseline blood biomarker- and 
NYhA assessment
model c-index (ci)
Modela 0.62 (0.52 – 0.71)
Modela + NT-proBNP 0.76 (0.67 – 0.86)
Modela + Hs-TnT 0.72 (0.62 – 0.81)
Modela + CRP 0.68 (0.58 – 0.78)
Modela + NYHA class 0.71 (0.60 – 0.81)
Modela + NT-proBNP + CRP + Hs-TnT + NYHA class 0.80 (0.71 – 0.91)
CI = Confidence interval; CRP = C-reactive protein; Hs-TnT = High-sensitive cardiac troponin T; NT-proBNP = 
N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association.
a Including age, gender, systolic blood pressure and estimated glomerular filtration rate.
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ABstrAct
Background: We examined the prognostic information of detailed temporal patterns 
of N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitive troponin T 
(HsTNT) and C-reactive protein (CRP) in patients with chronic heart failure (CHF).
methods: From 2011-2013, 263 CHF patients were included. NT-proBNP, HsTNT and CRP 
were measured at baseline and every 3 months. The primary endpoint (PE) comprised 
heart failure hospitalization, cardiovascular mortality, cardiac transplantation and 
LVAD-implantation. Associations between temporal biomarker patterns and the PE were 
investigated by joint modelling, which combines mixed models with Cox regression.
results: Mean age was 67±12 years and 72% were men. Median follow-up was 2.2 (IQR 
1.4–2.5) years. We used 2022 blood samples (median 9(IQR 5-10) per patient) and 70 
(27%) patients reached the PE. Temporal patterns of NT-proBNP, HsTNT and CRP level 
were associated with the PE (multivariable adjusted HR per doubling of biomarker: NT-
proBNP 2.28 (95%CI 1.82–2.86), HsTNT 2.05(1.63–2.58), CRP 1.65 (1.30–2.08). A combined 
3 biomarker model demonstrated independent associations for the temporal patterns 
of NT-proBNP and CRP level (HRs 2.06(1.53–2.79) and 1.38(1.01–1.89), respectively). 
Instantaneous change in biomarker level was also independently associated with the 
PE for NT-proBNP and CRP. Long-term biomarker elevation showed an association for 
NT-proBNP.
conclusions: Temporal patterns representing evolution of level and rate of change in 
level of NT-proBNP and CRP, and long-term elevation of NT-proBNP are independently 
associated with adverse prognosis in CHF patients. Individual patterns of change and 
combining multiple biomarkers could carry value for prognostication and for therapy 
guidance.
NT-proBNP, HsTNT and CRP patterns in CHF patients 87
iNtroductioN
The diagnosis of progression of chronic heart failure (CHF) is primarily based on clinical 
signs and symptoms and the decision to adjust therapy is usually made once symptoms 
of progression have become manifest. Blood biomarkers are capable of monitoring 
subtle (patho)physiological processes that reflect and possibly predict adverse changes 
before they become clinically apparent.1,2 B-type natriuretic peptides (BNP) and N-ter-
minal proBNP (NT-proBNP), cardiac troponin T and I and C- reactive protein (CRP) have 
been unequivocally related to adverse clinical outcomes in heart failure (HF) patients in 
several large studies.2-12
The majority of these studies have examined single, baseline measurements of these 
blood biomarkers. However, since patients with CHF display large biological heteroge-
neity, distinguishing patients at different levels of risk of adverse events based on single 
biomarker measurements only is challenging. Measuring biomarkers repeatedly could 
contribute to individualized risk assessment. Studies that have assessed changing bio-
marker patterns over time have mostly focused on natriuretic peptides, generally used 
only few repeated biomarker measurements, and have utilized simplified representa-
tions of temporal biomarker evolution, such as change between two time-points.3-6,12-14 
Results of these studies strongly depend on the statistical approach that was used.1 
Subsequent trials on natriuretic peptide-guided therapy of HF have provided inconsis-
tent results.8-10,15,16 Although such trials are promising for individual risk assessment and 
personalized treatment, most existing trials have applied uniform natriuretic peptide 
cut-off values for all patients, and did not use individualized target levels; nor did they 
take into consideration multiple biomarkers. Moreover, they did not investigate optimal 
frequency of the measurements, nor did they adapt this frequency to the patient’s 
individual situation.
The above illustrates that in order to properly install personalized risk assessment that 
makes use of blood biomarkers, first, more detailed information is needed on temporal 
biomarker patterns in individual patients. Specifically, having measurements available 
that are performed closely in time to the moment that the endpoint of interest occurs, 
would provide further insight into the biomarkers’ behaviour as this endpoint nearly ap-
proaches. This would enable an adequate investigation of whether, and to which degree, 
increasing (or decreasing) biomarker levels contribute to an individual’s risk, regardless 
of whether his or her blood levels exceed classic, absolute cut-points at any random 
point in time (such as ‘study baseline’). However, in practice, biomarker measurements 
performed shortly before the endpoint occurs are difficult to acquire, because they re-
quire a high frequency of blood sampling during prolonged follow-up. Therefore, most 
studies on this topic have performed only two measurements over time and are thus not 
able to properly investigate the biomarker trajectory shortly before the endpoint occurs.
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In the current study, we have performed frequent (up to 11), repeated measurements 
of multiple blood biomarkers (NT-proBNP, HsTNT and CRP) in 263 patients with CHF, and 
have investigated the associations of the thus obtained temporal patterns with adverse 
clinical outcome. These 3 biomarkers were chosen because each of them represents 
different aspects of heart failure pathophysiology (wall stress, myocyte damage and 
inflammation) and because a large body of evidence exists for the prognostic value of 
single measurements of these markers. By performing multiple, longitudinal measure-
ments, assessing multiple biomarkers simultaneously and using appropriate, modern 
statistical methods, we aimed to provide a basis for improved, personalized risk assess-
ment in patients with CHF.
methods
Patients
Bio-SHiFT is a prospective, observational study of stable outpatients with CHF, conducted 
in Erasmus MC, Rotterdam, The Netherlands and Noordwest Ziekenhuisgroep, Alkmaar, 
The Netherlands. Patients were recruited during their regular outpatient visits and 
were in clinically stable condition. Detailed inclusion and exclusion criteria are shown 
in figure 1. Patients were eligible if CHF (including HF with preserved ejection fraction) 
was diagnosed ≥ 3 months ago according to the guidelines of the European Society of 
Cardiology (ESC).17-19 This study was approved by the medical ethics committee of the 
Erasmus MC, Rotterdam, The Netherlands and was conducted in accordance with the 
Declaration of Helsinki. Written informed consent was obtained from all patients. The 
study is registered in ClinicalTrials.gov, number NCT01851538. Estimated enrolment is 
400 patients. In this paper, we have performed an interim analysis on the 263 patients 
who were enrolled during the first inclusion period between October 2011 and June 
2013.
Baseline assessment
At baseline, patients were evaluated by trained research physicians, who collected 
information on HF-related symptoms, including NYHA class,17,18 and performed physical 
examination, including blood pressure, heart rate and body mass index. Information on 
aetiology of heart failure, presence of systolic dysfunction, cardiovascular risk factors, 
medical history and medical treatment was retrieved primarily from hospital records. 
History of chronic renal failure was defined as glomerular filtration rate (GFR) less than 60 
mL/min/1.73 m2. Alcohol consumption was defined as drinking ≥1 alcoholic consump-
tion per day. Data were entered into electronic case report forms. Electrocardiography 
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and echocardiography were performed. Non-fasting blood and urine were collected, as 
described below.
follow-up visits
Routine outpatient follow-up by the treating physician continued for all patients during 
the study. Study follow-up visits were scheduled every 3 months (a window of ±1 month 
was allowed), to a maximum follow-up duration of 30 months. At each follow-up visit, a 
short medical evaluation was performed and blood and urine samples were collected. 
Changes in medication as well as occurrence of adverse cardiovascular events since the 
previous visit were recorded.
figure 1 - inclusion and exclusion criteria 
 
 
 
 
 
 
 
 
Heart failure with preserved ejection fraction (HFPEF) 
diagnosed ≥ 3 months ago according to the definition of the 
ESC, which includesthe following features: 
 Presence of signs and/or symptoms of HF (as 
described above) 
AND 
 Presence of normal or only mildly abnormal systolic 
function (LVEF ≥ 50%) 
AND 
 Evidence of diastolic left ventricular dysfunction 
according to the criteria of the ESC: 
o E/E’>15 
OR 
o 15> E/E’ > 8 AND 
NT-proBNP > 220pg/ml /  
BNP > 220 pg/ml  
OR  
o E/A < 0.5 and DT > 280 ms  
OR  
o Atrial fibrillation 
Inclusion criteria 
1. Age ≥ 18 years 
2. Diagnosis chronic heart failure ≥ 3 months* 
3. Written informed consent 
Heart failure, diagnosed ≥ 3 months ago according to the 
definition of the European Society of Cardiology (ESC), which 
includes the following features: 
 Symptoms typical of heart failure: breathlessness at 
rest or on exercise, fatigue, tiredness, ankle swelling 
AND 
 Signs typical of heart failure: tachycardia,  
tachypnea, pulmonary rales, pleural effusion,  
raised jugular venous pressure, peripheral oedema, 
hepatomegaly 
AND 
 Objective evidence of a structural or functional 
abnormality of the heart at rest: cardiomegaly, third 
heart sound, cardiac murmurs, abnormality on the 
echocardiogram, raised natriuretic peptide 
concentration 
 
Exclusion criteria 
 
1. Heart failure secondary to circulatory high output conditions 
2. Scheduled for surgery or intervention for both coronary and non-
coronary indication within 6 months of inclusion 
3. Severe renal failure for which dialysis is needed 
4. Known moderate or severe liver disease 
5. COPD Gold stage IV 
6. Coexistent condition with life expectancy ≤ 1 year 
7. Congenital heart disease 
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Blood sampling and biomarker measurement
Blood samples were processed and stored at a temperature of -80°C within 2 hours after 
blood collection. When applicable, samples were transported to the central laboratory 
(Erasmus MC, Rotterdam, The Netherlands) under controlled conditions (at a tempera-
ture of -80°C), until batch analysis was performed. Accordingly, results of the biomarker 
assays were not available to treating physicians at the time of the outpatient visits. Thus, 
the biomarker measurements performed for this study did not lead to drug adjust-
ments, and all patients received usual care. This concurs with Bio-SHiFT being a strictly 
observational study, as described above.
For the purpose of the current analysis, three biomarkers (NT-proBNP, HsTNT, and CRP) 
were measured in one batch in stored serum samples. Plasma NT–proBNP was analysed 
using an electrochemiluminesence immunoassay (Roche Diagnostics, Elecsys 2010, In-
dianapolis, Indiana, USA), which measures concentrations ranging from 5 to 35000 ng/L. 
Cardiac troponin T was also measured using an electrochemiluminesence immunoassay 
(Roche Diagnostics, Elecsys 2010 immunoassay analyser, Indianapolis, Indiana, USA), 
measuring concentrations ranging from 3-10000 ng/L. CRP was measured using an 
immunoturbidimetric assay (Roche Hitachi 912 chemistry analyser, Basel, Switzerland). 
This system measures concentrations ranging from 0.3 to 350 mg/L. All coefficients of 
variation were <5%.
clinical study endpoints
During follow-up, hospitalizations for HF, myocardial infarction (MI), percutaneous 
coronary interventions (PCIs), coronary artery bypass grafting (CABG), arrhythmias, 
and cerebrovascular accidents (CVAs), as well as cardiac transplantation, left ventricular 
assist device implantation (LVAD) and mortality, were recorded in the electronic case re-
port form by trained research physicians, and associated hospital records and discharge 
letters were collected.
Subsequently, hospital records and discharge letters were reviewed by a clinical event 
committee blinded to the biomarker results, and primary and secondary endpoints were 
adjudicated. The primary endpoint comprised the composite of cardiac death, cardiac 
transplantation, LVAD- implantation, and hospitalization for HF, whichever occurred first 
in time. Secondary endpoints included individual components of the primary endpoint, 
and also MI, PCI, CABG, CVA, and all-cause mortality.
Cardiac death was defined as death from MI or other ischemic heart disease (ICD-
10: I20-I25), death from other heart disease including HF (I30-I45 and I47-I52), sudden 
cardiac death (I46), sudden death undefined (R96) or unwitnessed or ill-described death 
(R98, R99). Hospitalisation for acute or worsened HF was primarily based on exacerba-
tion of HF symptoms, requiring hospitalization. On top of this, a combination of 2 of 
the following was required: BNP or NT-proBNP >3x ULN, signs of worsening HF, such as 
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pulmonary rales, raised jugular venous pressure or peripheral oedema, increased dose 
or intravenous administration of diuretics, or administration of positive inotropic agents.
statistical analysis
Distributions of continuous variables, including biomarker concentrations, were tested 
for normality using the Kolmogorov-Smirnov test. Normally distributed continuous 
variables are presented as mean ± standard deviation (SD). Non-normally distributed 
continuous variables are expressed as median and interquartile range (IQR). Categorical 
data are displayed as count and percentage.
In case of skewed distributions, continuous variables were logarithmically transformed 
(log base 2) for further analyses. Associations between patient characteristics and 
baseline biomarker levels were evaluated using univariable linear regression. Associa-
tions between baseline patient characteristics, including baseline biomarker levels, and 
the primary endpoint, were evaluated using Cox proportional hazards models. These 
analyses were first performed univariably. Subsequently, to evaluate independent as-
sociations, all baseline characteristics that showed statistically significant associations 
(with p-values <0.05) were forced into a multivariable Cox model.
Associations between temporal biomarker patterns of each separate biomarker and 
the primary endpoint were assessed using a joint modelling approach, which combines 
a linear mixed-effects (longitudinal) submodel to assess the temporal evolution of the 
repeatedly measured marker, with a Cox proportional hazards submodel to analyze 
the association of this temporal evolution with the study endpoint. In line with the 
logarithmic (base 2) transformation of the biomarker concentrations, the results are 
presented as hazard ratios (HRs) per doubling of the biomarker concentration at any 
point in time, along with the corresponding 95% CIs. First, analyses were performed 
univariably. Subsequently, potential confounders were entered into the joint models. 
These included all variables that were significantly associated with the primary endpoint 
in the multivariable ‘baseline’ Cox proportional hazards model (NYHA class and diabetes 
mellitus), as well as variables selected from existing literature (age, gender, renal func-
tion, body mass index). Covariates were missing in less than 3% of patients. Multiple 
imputation (5 times) of these covariates was performed in the multivariable analyses.
The above-described analysis assesses the predictive value of repeatedly measured 
biomarker levels; specifically, it provides hazard ratios that estimate the risk of the 
endpoint associated with doubling of biomarker level at any point in time. However, 
in the context of serial marker measurements, there could be additional features of the 
marker’s trajectory that better predict the primary endpoint.20 Therefore, we investigated 
the predictive value of: (1) the ‘instantaneous slope’ of the marker’s trajectory, indicating 
whether a marker is decreasing, increasing, or remains stable; and (2) the area under the 
curve of the marker’s trajectory, indicating the cumulative effect of all the values the 
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marker has taken in the past (this area under the curve does not provide information 
on increasing or decreasing biomarker values, which should be derived from the slope).
We chose not to correct for multiple testing, because the selection of the currently in-
vestigated 3 biomarkers was based on previous research and thus hypothesis-driven.2-12
In order to simultaneously investigate the effect of all 3 biomarkers on the primary 
endpoint, and thus to assess their independent predictive value, all individual temporal 
biomarker patterns derived from the adjusted joint models were saved and subsequent-
ly entered simultaneously as time-varying covariates into an extended Cox analysis. 
The same approach was used to investigate the independent predictive value of the 
slope and the area under the curve of the 3 temporal biomarker patterns. Adjustment 
for potential baseline confounders was performed as described above. Additionally, 
these extended Cox models were adjusted for temporally changing total daily doses 
of equivalents of carvedilol, enalapril, furosemide, and spironolactone, which were also 
entered into the models as time-varying covariates.
To illustrate how joint modelling can be applied to estimate prognosis of an individual 
patient based on his or her repeatedly assessed biomarker values, we plotted the tem-
poral patterns of the biomarkers in several individual patients (i.e., example patients 
drawn from our dataset), together with their corresponding dynamic, individual prob-
abilities of survival as estimated by the joint model (which we developed on the total 
study population as described above). As such we graphically demonstrated individual 
survival probabilities, which are updated each time that an additional measurement is 
performed in the patient as he or she visits the outpatient clinic.
Finally, to investigate the discriminative ability of models containing serial measure-
ments and models containing baseline measurements only, we calculated c-indices 
based on extended Cox models containing temporal biomarker patterns derived from 
the adjusted joint models, as well as c-indices based on Cox models containing baseline 
biomarker values only.
All analyses were performed with R Statistical Software using package JM.20 All statisti-
cal analyses were two-sided and p-values <0.05 were considered statistically significant.
Power calculation
The current investigation comprised 263 patients, of whom 70 reached the primary end-
point. For baseline measurements, these numbers are sufficient to detect odds ratios 
around 2 for the upper quintile of a biomarker associated with the endpoint (α-error 
0.05, power of 80%) when comparing cases with non-cases. For repeated measure-
ments, power is further enhanced. A median of 9 samples per patient were available. 
We calculated power for repeated measurements by assuming a linear association and 
a continuous autoregressive correlation matrix. We used NT-proBNP to derive the mea-
surement error standard deviation (sigma, equal to 463) and the input parameter for the 
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autoregressive correlation matrix (rho, equal to 0.49). Based on these input parameters, 
and using 1000 simulations, we calculated that a difference in change of NT-proBNP 
level over time of 51 ng/L per month can be demonstrated between cases and non-cases 
(α-error 0.05, power of 80%). This difference is small in clinical terms, demonstrating that 
the study has high statistical power.
resuLts
Baseline findings
From October 2011 to August 2015, 263 patients were included. Baseline characteristics 
are shown in Table 1. Mean age of the study population was 67 years (SD ±12). The 
majority were men (72%) in New York heart association (NYHA) class I or II (73%). Median 
duration of HF was 4.6 years (IQR 1.7 – 9.9). Median baseline NT-proBNP was 1161 ng/L 
(IQR 439 – 2305), HsTNT 18.0 ng/L (IQR 9.6 – 33.2) and CRP 2.2 mg/L (IQR 0.9 – 4.8). Positive 
associations were found between baseline NT-proBNP level and age (p=0.01), heart rate 
(p=0.01), NYHA class (p<0.001), and renal failure (p<0.001). Inverse associations were 
found between NT-proBNP and diastolic blood pressure (p<0.001) and BMI (p<0.001). 
Baseline HsTNT level was positively associated with age (p<0.001), NYHA class (p<0.001) 
and renal failure (p<0.001). Baseline CRP level showed positive associations with heart 
rate (p=0.01) and renal failure (p=0.045), and inverse associations with systolic (p=0.046) 
and diastolic blood pressure (p<0.001).
table 1 – Baseline characteristics
total (n=263)
No. (%) / Mean (±SD) /
Median (25th – 75th percentile)
demographics
Age 67 (±13)
Male gender 189 (72)
Caucasian ethnicity 244 (94)
clinical characteristics
Body mass index kg/m2 28 (±5)
Heart rate, bpm 67 (±12)
Systolic blood pressure, mmHg 122 (±20)
Diastolic blood pressure, mmHg 73 (±11)
Biomarker level
NT-proBNP (ng/L) 1161 (439 – 2305)
HsTNT (ng/L) 18.0 (9.6 – 33.2)
CRP (mg/L) 2.2 (0.9 – 4.8)
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table 1 – Baseline characteristics (continued)
total (n=263)
No. (%) / Mean (±SD) /
Median (25th – 75th percentile)
features of heart failure
Duration of heart failure, years 4.6 (1.7 – 9.9)
NYHA class I or II 190 (73)
NYHA class III or IV 69 (27)
Left ventricular function
Systolic dysfunction 250 (95)
HFPEF 13 (5)
LVEF* 32 (±10)
etiology of heart failure
Ischemic heart disease 117 (44)
Hypertension 34 (13)
Secondary to valvular heart disease 12 (5)
Cardiomyopathy 68 (26)
Dilated 49 (19)
Hypertrophic 12 (5)
Non compaction 4 (1)
Unclassified 3 (1)
Unknown 19 (7)
Other 13 (5)
medical history
Myocardial infarction 94 (36)
PCI 82 (31)
CABG 43 (16)
Valvular heart disease 136 (53)
Atrial fibrillation 105 (40)
Other arrhythmia 82 (32)
ICD 151 (59)
CRT 78 (30)
Pacemaker 38 (15)
CVA 41 (16)
Chronic renal failure 136 (53)
Diabetes Mellitus 81 (31)
Known hypercholesterolemia 93 (35)
Hypertension 120 (46)
Sleep apnea 26 (10)
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clinical endpoints
During a median follow-up of 2.2 (IQR 1.4–2.5) years, 27 (10%) patients died from 
a cardiovascular cause, 56 (21%) patients were re-hospitalized for worsened HF, 5 
(1.9%) patients underwent heart transplantation and 3 (1.1%) patients received LVAD-
implantation (Table 2). Since 21 patients were re-hospitalized for worsened HF before 
dying from cardiovascular causes eventually during further follow-up, 70 patients (27%) 
reached the composite primary endpoint. Overall all-cause mortality was 32 (12%).
Associations between baseline characteristics and the primary endpoint are shown 
in Table 3. After multivariable adjustment, baseline NT-proBNP (HR 1.02; CI 1.01 – 1.02), 
baseline HsTNT (HR 1.08; CI 1.02 – 1.16), NYHA class (HR 1.61; CI 1.14 – 2.26) and diabetes 
table 1 – Baseline characteristics (continued)
total (n=263)
No. (%) / Mean (±SD) /
Median (25th – 75th percentile)
intoxications
Alcohol consumption (>1 unit/day) 108 (42)
Smoking 185 (71)
Ever 186 (72)
Current 26 (10)
medication use
ACE-i 173 (67)
ARB 75 (29)
Aldosteron antagonist 178 (68)
Diuretic 237 (90)
Beta-blocker 232(88)
Aspirin 45 (17)
Vitamin K antagonist 200 (77)
Nitrates 44 (17)
Digoxin 59 (23)
Antiarrhythmics 39 (15)
Normally distributed continuous variables are presented as mean (± standard deviation). Non-normally 
distributed continuous variables are expressed as median (25th – 75th percentile). Categorical variables are 
expressed as count (percentage). Valid percentages may vary for some counts, because of missing values. 
ACE-I = ace inhibitor; ARB = angiotensin II receptor blocker; CABG = coronary artery bypass grafting; COPD 
= chronic obstructive pulmonary disease; CRP = C-reactive protein; CRT = cardiac resynchronization ther-
apy; CVA = cerebrovascular accident; HFPEF = heart failure with preserved ejection fraction; HsTNT = high 
sensitive cardiac troponin T; ICD = implantable cardioverter / defibrillator; LVEF = left ventricular ejection 
fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide NYHA = New York heart association; PCI = 
percutaneous coronary intervention; SD = standard deviation.
* Baseline echocardiograms were available in 72% of all patients because of logistic reasons.
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table 2 – endpoints
endpoint N (%)
Primary
Combined primary endpoint* 70 (27)
secondary
Hospitalization for acute or worsening heart failure 56 (21)
All-cause mortality 32 (12)
Cardiovascular mortality 27 (10)
Heart transplantation 5 (1.9)
Left ventricular assist device implantation 3 (1.1)
Variables are displayed as count (percentage).
* The primary endpoint comprised heart failure hospitalization, cardiovascular mortality, cardiac transplan-
tation and LVAD-implantation
tabel 3 – Associations between baseline characteristics and the primary endpoint
Variabele crude hr (ci) P Adjusted hr (ci)‡ P
NT-proBNP (pmol/L)* 1.02 (1.02 – 1.03) <0.001 1.02 (1.01 – 1.02) <0.001
HsTNT (pg/mL)* 1.12 (1.08 – 1.16) <0.001 1.08 (1.02 – 1.16) 0.020
CRP (mg/L)* 1.26 (1.06 – 1.50) 0.016 1.18 (0.96 – 1.45) 0.12
Age† 1.02 (1.01 – 1.05) 0.035 1.00 (0.98 – 1.02) 0.86
Male gender 1.27 (0.80 – 2.19) 0.40
Systolic blood pressure† 0.99 (0.98 – 0.99) 0.040 0.99 (0.98 – 1.01) 0.26
Diastolic blood pressure† 0.98 (0.96 – 1.00) 0.055
Heart rate† 1.01 (0.99 – 1.03) 0.24
Body mass index kg/m2† 1.00 (0.96 – 1.05) 0.88
NYHA-class† 2.10 (1.56 – 2.54) <0.001 1.61 (1.14 – 2.26) 0.006
Chronic renal failure 2.11 (1.28 – 3.50) 0.004 1.25 (0.72 – 2.18) 0.42
Diabetes mellitus 2.06 (1.29 – 3.29) 0.003 1.91 (1.17 – 3.11) 0.010
Hypercholesterolemia 1.37 (0.85 – 2.20) 0.20
Hypertension 1.31 (0.82 – 2.10) 0.26
Ever smoker 1.48 (0.84 – 2.62) 0.18
History of CAD 1.56 (0.96 – 2.53) 0.074
History of CVA 1.40 (0.78 – 2.51) 0.26
ICD 1.20 (0.74 – 1.95) 0.47
CRT 0.80 (0.47 – 1.36) 0.42
CRP = C-reactive protein; CRT = cardiac resynchronization therapy; CVA = cerebrovascular accident; HsTNT 
= high sensitive cardiac troponin T; ICD = implantable cardioverter / defibrillator; NT-proBNP = N-terminal 
pro-B-type natriuretic peptide NYHA = New York heart association.
* HR per 10 units increase
† HR per unit increase
‡ All characteristics univariably associated with the primary endpoint (p<0.05) were entered into the mul-
tivariable Cox regression model.
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mellitus type 2 (DM) (HR 1.91; CI 1.17 – 3.11) were independently associated with the 
primary endpoint (Table 3).
temporal biomarker patterns and the primary endpoint
During follow-up, we collected 2193 blood samples, of which 2022 were drawn before 
the occurrence of the primary endpoint (median of 9 (IQR 5-10) samples per patient). 
The associations between the temporal biomarker patterns and the primary endpoint 
are shown in Table 4.
table 4 - Association between temporal patterns of logarithmically transformed Nt-proBNP, hstNt 
and crP and the primary endpoint
Nt-proBNP hstNt crP
hr* (95% ci) p-value hr* (95% ci) p-value hr* (95% ci) p-value
temporal pattern of biomarker level
Adjusted for age and 
gender
2.20 (1.83–2.65) <0.001 2.21 (1.79–2.72) <0.001 1.80 (1.43–2.26) <0.001
Multivariable adjusted† 2.28 (1.82–2.86) <0.001 2.05 (1.63–2.58) <0.001 1.65 (1.30–2.08) <0.001
instantaneous slope of temporal pattern
Adjusted for age and 
gender
2.16 (1.79–2.62) <0.001 2.14 (1.71–2.66) <0.001 1.85 (1.43–2.41) <0.001
Multivariable adjusted† 2.15 (1.71–2.68) <0.001 2.02 (1.58–2.58) <0.001 1.69 (1.32–2.18) <0.001
Area under the curve of temporal pattern
Adjusted for age and 
gender
1.68 (1.45–1.96) <0.001 1.74 (1.46–2.07) <0.001 1.32 (1.13–1.55) <0.001
Multivariable adjusted† 1.54 (1.30–1.83) <0.001 1.55 (1.29–1.86) <0.001 1.28 (1.09–1.51) 0.003
three biomarkers combined
Level, multivariable 
adjusted†
2.06 (1.53–2.79) <0.001 1.41 (0.93–2.13) 0.104 1.38 (1.01–1.89) 0.047
Level, medication 
adjusted‡
2.08 (1.54–2.80) <0.001 1.46 (0.95–2.23) 0.083 1.38 (1.01–1.90) 0.044
Slope, multivariable 
adjusted†
2.04 (1.51–2.78) <0.001 1.47 (0.94–2.16) 0.093 1.41 (1.02–1.94) 0.036
Slope, medication 
adjusted‡
2.06 (1.51–2.80) <0.001 1.44 (0.94–2.21) 0.089 1.42 (1.02–1.99) 0.040
Area, multivariable 
adjusted†
1.99 (1.49–2.66) <0.001 1.42 (0.94–2.13) 0.092 1.32 (0.96–1.80) 0.084
Area, medication 
adjusted‡
2.01 (1.49–2.73) <0.001 1.42 (0.94–2.15) 0.098 1.26 (0.91–1.75) 0.16
HR = hazard ratio.
* Hazard ratios are given per doubling of level, slope or area under the curve at any point in time.
† Adjusted for age, gender, BMI, renal function, NYHA class and diabetes mellitus type 2.
‡ Adjusted for age, gender and temporally changing total daily doses of equivalents of carvedilol, enalapril, 
furosemide, and spironolactone.
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The temporal NT-proBNP pattern derived from the repeated measurements was a 
significant predictor of the primary endpoint after adjustment for age, gender, BMI, 
renal function, NYHA class and DM (HR per doubling of NT-proBNP: 2.28; CI 1.82 – 2.86; 
p<0.001). Figure 2a displays the curves depicting the temporal NT-proBNP pattern of 
patients who reached the primary endpoint versus those who did not.
Figure 2b depicts temporal HsTNT patterns of patients who reached the primary 
endpoint and those who did not. We found an association between the temporal HsTNT 
figure 2 - temporal patterns
The temporal patterns, displayed as time until event, of A) N-terminal pro B-type natriuretic peptide (NT-
proBNP), B) high-sensitive troponin T (HsTNT) and C) C-reactive protein (CRP) of patients who reached the 
primary endpoint versus those who did not.
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pattern and the primary endpoint, which remained present after multivariable adjust-
ment (HR per doubling of biomarker: 2.05; CI 1.63 – 2.58; p<0.001).
As shown in figure 2c, the temporal CRP pattern was also a significant predictor of 
the primary endpoint (HR per doubling of CRP after multivariable adjustment: 1.65; CI 
1.30 – 2.08; p<0.001).
NT-proBNP, HsTNT and CRP patterns and the primary endpoint using a combined 
3-biomarker model
When we combined temporal patterns of all 3 biomarkers in one model, we found in-
dependent associations of NT-proBNP (HR per doubling of NT-proBNP level at any given 
time point: 2.06; CI 1.53 – 2.79; p<0.001) and CRP (HR per doubling of CRP level: 1.38; 
CI 1.01 – 1.89; p=0.047) with the primary endpoint. These associations were also inde-
pendent of temporally changing total daily doses of equivalents of carvedilol, enalapril, 
furosemide, and spironolactone (table 4). However, HsTNT was no longer associated 
with the primary endpoint in this model (HR per doubling of HsTNT: 1.41; CI 0.93 – 2.13; 
p=0.10), illustrating that its predictive value was not independent of NT-proBNP and 
CRP.
Slopes and areas under the curve of temporal patterns
Table 4 displays hazard ratios for the doubling of the instantaneous slopes and areas 
under the curve of the temporal biomarker patterns. The instantaneous slopes of the 
temporal patterns as well as the areas under the curve of NT-proBNP, HsTNT and CRP 
were all associated with the primary endpoint after multivariable adjustment, includ-
ing adjustment for temporally changing total daily doses of equivalents of carvedilol, 
enalapril, furosemide, and spironolactone.
When we entered the instantaneous slopes of the temporal biomarker patterns of the 
3 biomarkers into 1 model, they remained independent predictors for NT-proBNP and 
CRP, but not for HsTNT. Simultaneously entering the areas under the curve of the 3 tem-
poral biomarker patterns into 1 model showed that only NT-proBNP was independently 
associated with the primary endpoint.
Personalized prediction: individual, dynamic risk estimation
Figure 3 shows the temporal patterns of the biomarkers in several individual patients 
from our dataset, together with their corresponding individual probabilities of survival 
as estimated by the joint model. The figure shows that each time an additional mea-
surement is performed in the patient, the individual probability of survival is updated. 
Specifically, rising marker levels and worsening prognosis can be seen in the example 
patients who ultimately reached the composite endpoint, versus stable or decreasing 
marker levels and more favorable prognosis in the example patients who stayed event-
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free. These individual estimates of prognosis can be obtained by clinicians in an easy, 
user-friendly manner. Joint models, like those we have constructed, can be uploaded 
into an app (http://shiny.rstudio.com/) that creates an interface into which a clinician 
can add the characteristics, and consecutive biomarker measurements, of an individual 
patient. Subsequently, the app returns the curve depicting individual prognosis (supple-
mental figure 1).
model performance
Discriminative ability of models containing the temporal patterns of the biomarker 
levels and baseline measurements only is shown in table 5. For all 3 biomarkers, models 
containing temporal biomarker patterns showed higher c-indices than those containing 
baseline measurements only. The highest c-index resulted from the multivariable model 
containing all 3 temporal biomarker patterns as well as age, gender, BMI, renal function, 
NYHA class and DM (c-index 0.84).
temporal patterns of Nt-proBNP, hstNt and crP in relation to hospitalisation 
for acute or worsening hf (secondary endpoint)
All three biomarker patterns were strong individual predictors of HF hospitalisations 
(age- and gender adjusted HRs per doubling of biomarker: NT-proBNP, 2.17; CI 1.57 – 
table 5 – discriminative ability of models containing the temporal patterns of Nt-proBNP, hstNt and 
crP level, as well as models containing baseline measurements only
Baseline measurements temporal patterns
c-index;
multivariable model*
c-index;
multivariable model*
Nt-proBNP 0.78 0.83
hstNt 0.73 0.75
crP 0.67 0.69
combined model† 0.79 0.84
* The multivariable models were corrected for: age, gender, BMI, renal function, NYHA class and diabetes 
mellitus type 2.
† NT-proBNP, HsTNT and CRP are all included in the combined model.
figure 3 - dynamic profiling of an individual patient’s risk using patient-specific temporal trajecto-
ries
The solid red lines depict patients who experienced the study endpoint, and the solid blue lines depict 
patients who did not. The X-axis depicts follow-up time starting from baseline. Biomarker levels (on the 
log scale) are displayed on the left Y-axis and survival probability (%) on the right Y-axis. Patient-specific 
temporal biomarker trajectories are displayed left of the vertical dotted black line. To the right of this line, 
the corresponding conditional survival probability curve is displayed with 95% confidence intervals (grey 
area). To show how this conditional survival probability curve is dynamically updated every time an extra 
measurement is recorded, we provide the curves for three time-points at which risk was updated.
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2.66; p<0.001; HsTNT, 2.18; CI 1.72 – 2.76; p<0.001 and CRP, 1.99; CI 1.53 – 2.59; p<0.001). 
These associations remained statistically significant after multivariable adjustment (HRs 
per doubling of biomarker: NT-proBNP, 2.31; CI 1.77 – 3.01; p<0.001; HsTNT, 1.95; CI 1.49 
– 2.55; p<0.001 and CRP, 1.80; CI 1.37 – 2.35; p<0.001). After creating a time-dependent 
Cox model using all 3 temporal biomarkers patterns, derived from the individual joint 
models, we found that each of the 3 biomarkers remained independent predictors of HF 
hospitalizations (HR per doubling of biomarker: NT-proBNP, 1.51; CI 1.26 – 1.80; p<0.001; 
HsTNT, 1.57; CI 1.24 – 2.00; p=0.001 and CRP, 1.41; CI 1.15 – 1.74; p<0.001). These associa-
tions persisted after adjusting for temporally changing total daily doses of equivalents 
of carvedilol, enalapril, furosemide, and spironolactone (HR per doubling of biomarker: 
NT-proBNP, 1.49; CI 1.23 – 1.80; p<0.001; HsTNT, 1.50; CI 1.18 – 1.91; p=0.001 and CRP, 
1.39; CI 1.11 – 1.74; p=0.004.
discussioN
In this prospective, observational study we demonstrate that the dynamic, temporal 
patterns of serially-measured NT-proBNP and CRP levels are strong and independent 
predictors of adverse clinical events in CHF patients. Moreover, instantaneous slope 
of these biomarkers’ temporal trajectories, as well as the area under the curve of their 
temporal trajectories, are associated with adverse events. The temporal patterns of 
HsTNT also significantly predict adverse events, but lose their predictive capability when 
combined with temporal NT-proBNP and CRP patterns. We also demonstrate, based on 
these dynamic models, how individual, temporal biomarker trajectories can be used for 
calculating patient-specific risk estimates, which are dynamically updated every time a 
patient has a new measurement performed.
Studies on the prognostic value of repeated natriuretic peptide measurements have 
mostly been performed in trial participants,6,13 and studies on the prognostic value 
of repeated biomarker measurements other than natriuretic peptides, are scarce.3,4,12 
Altogether, these existing studies describing temporal changes in biomarkers in 
relation to patient prognosis have three major limitations. Firstly, changes are often 
presented as a difference between just two measurements that are separated in time. 
Such an approach fails to fully capture the true biomarker pattern of the dynamic dis-
ease. Moreover, it fails to expose changes in biomarker level prior to clinically relevant 
endpoints, because on average, a long period time period lies between the last (i.e., 
second) biomarker measurement and the incident endpoint. To properly investigate 
whether an increase in biomarker level is present at the time an endpoint is approach-
ing, and whether this increase truly contributes to an individual’s risk, the time period 
between the last measurement and the endpoint should be kept as brief as possible. 
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This implies that a high frequency of blood sampling during prolonged follow-up is 
needed. Secondly, biomarkers are often studied in isolation, thus actually ignoring the 
different underlying aetiologies that converge to adverse cardiac remodelling and HF 
progression. The third limitation of existing studies is related to the applied methods 
of data analysis. Often, absolute or relative differences between two measurements are 
calculated, or categorical changes across a threshold value are assessed. These various 
approaches to temporal change all render different estimates for associations between 
changes in biomarker level and outcome,1 which is an illustration of their shortcomings. 
At best, Cox models with so called time-dependent covariates are used to analyse the 
effects of temporal biomarker patterns. While time-dependent Cox models assume that 
biomarker levels do not change between measurements, it is known that biomarker 
patterns are dynamic and continuously change over time, parallel to the condition of 
the patient. All these limitations are overcome in Bio-SHiFT: we have performed a large 
number of frequent, repeated measurements (up to 11 trimonthly samples per patient), 
we have studied multiple biomarkers, and we have applied modern statistical methods 
(‘joint modelling’), which, as stated above, take into account the continuous, dynamic 
changes in biomarker patterns and thus result in less bias.21
Several randomized trials have been performed to investigate whether using serial 
natriuretic peptide measurements to titrate medical therapy can improve clinical out-
come of HF patients. However, since the results of these trials were not fully consistent, 
natriuretic peptide guided therapy remains controversial.8-10,15 It should be noted that 
most of these trials were based on protocols that used uniform natriuretic peptide 
targets in the intervention groups.22-26 Existing trials that used individualized treatment 
targets are in the minority, and often based their targets on natriuretic peptide levels 
that were measured briefly after the index episode of decompensation, when titration 
of therapy was still ongoing.27-29 Conversely, our study describes in detail the temporal 
biomarker patterns in stable CHF patients, and reveals significant associations between 
temporal patterns of biomarker levels and adverse events. CHF patients who did not ex-
perience adverse cardiac events during prolonged follow-up were shown to have lower 
levels of NT-proBNP, HsTNT and CRP at any moment in time compared to patients who 
did experience adverse cardiac events during follow-up. Additionally, the instantaneous 
rate of change in biomarker levels (represented by the slope of the temporal biomarker 
patterns), as well as the cumulative values the marker has taken in the past (represented 
by the area under the temporal biomarker patterns), were associated with adverse out-
come. These findings support the concept of an individualized biomarker target level, 
instead of a generally applicable uniform cut-off value for all patients. On top of this, 
they suggest that rate of change in biomarker level as well as duration of biomarker level 
elevation, merit attention in order to provide appropriate individual treatment targets 
104 Chapter 6
as well as correct estimates of prognosis. Our study also demonstrates that temporal 
patterns of CRP predict adverse clinical outcome independently of NT-proBNP.
Future trials on biomarker-guided therapy may benefit from incorporating these find-
ings. Firstly, future trials should use personalized biomarker cut-off values, i.e. interpret a 
patient’s biomarkers level in the context of his or her previous series of levels. This means 
they should not only take into account the absolute biomarker level, but also incorpo-
rate the instantaneous slope of the marker’s trajectory. Secondly, upcoming trials should 
use a combination of multiple biomarkers, representing different pathophysiological 
pathways, to guide HF therapy. Finally, additional research should be performed on the 
frequency of biomarker measurement and tailoring thereof to individual patients; sub-
sequently these findings should be incorporated into biomarker-guided trials as well.
Miller et al. published a study that might be considered comparable to Bio-SHiFT to 
a certain extent, as they evaluated serial measurements of cardiac troponine T and BNP 
in 190 ambulant CHF patients.12 Again, an important limitation of this study is the use 
of time-dependent Cox models. Still, Miller et al. found that cardiac troponine T and 
BNP were both independent predictors of cardiac mortality or cardiac transplantation, 
and that combined elevation of these biomarkers substantially adds to risk. We could 
only partly confirm these results. In Bio-SHiFT, although predictive as a separate marker, 
the HsTNT pattern appeared no longer significantly associated with the primary study 
endpoint after adjustment for the NT-proBNP and CRP patterns (and also after adjust-
ment for NT-proBNP alone; data not shown). This may (at least in part) be due to the 
above-described differences in data analysis.
Some aspects of this study warrant consideration. With 263 patients, sample size is 
limited; and the majority of the patient population was in NYHA class I or II, and had 
systolic dysfunction. Also, a large proportion had concomitant valvular heart disease. 
The results and conclusions should be judged accordingly. Nevertheless, given the 
repeated measures design, over 2000 blood samples were available; and all 3 investi-
gated biomarkers, each having different pathophysiological properties, showed the 
hypothesised rising temporal pattern. This strengthens our findings and makes them 
less likely attributable to bias or chance. Further to this, the current investigation was an 
interim analysis of the patients enrolled in the first inclusion round. The full Bio-SHiFT 
cohort was designed to enrol 400 patients and to have sufficient statistical power to 
perform large-scale, hypothesis-free research on novel, lesser known biomarkers. In 
such cases, correction for multiple testing is warranted. The current investigation, how-
ever, examines 3 well-established biomarkers, which have been extensively implicated 
in heart failure in previous studies and which were chosen based on pathophysiological 
considerations, rendering correction for multiple testing redundant. Furthermore, ad-
ditional investigations are needed to estimate the most efficient frequency of biomarker 
measurement, so that optimal prognostic information can be gained without superflu-
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ous blood sampling. In our study, patients were monitored every 3 months, in order 
to construct a data framework for our joint models. An extension to joint modelling is 
currently being developed to define optimal timeframes for individual patients to return 
for consecutive measurements. In this context, the optimal frequency for biomarker 
measurement is expected to vary from patient to patient; it is likely that once a stable 
biomarker value is found in a patient, this patient could be re-examined after a longer 
time-period, while if for example a biomarker value is found to have risen and thus prog-
nosis is worsening, the patients may need to return more quickly. Finally, in our study, 
repeatedly measured NT-proBNP and CRP were both independently associated with the 
primary endpoint. This implies a multimarker model would benefit monitoring of CHF 
patients (even though a model combining both of these biomarkers seemed to have 
little incremental discriminative value over serial NT-proBNP assessment only as sug-
gested by the C-index; the C-index is known to be rather insensitive to improvements 
in prediction performance, and it has been demonstrated previously that testing for 
improvement in prediction performance is actually redundant if a variable has already 
been shown to be an independent risk factor.30 Future studies should investigate a 
broader spectrum of biomarkers to further improve risk assessment.
In conclusion, detailed temporal patterns of NT-proBNP and CRP are strong, indepen-
dent predictors of adverse clinical events in patients with stable CHF. Not only evolution 
of biomarker level, but also instantaneous rate of change in level of NT-proBNP and CRP 
as well as the area under the curve of the trajectory of NT-proBNP, were associated with 
adverse outcome. These findings suggest that individual patterns of change of biomark-
ers, as well as combinations of multiple biomarkers, should be taken into consideration 
for prognostication in patients with stable CHF Overall, our study illustrates that several 
aspects of biomarker –guided risk stratification have been incompletely addressed so 
far, and that there still seems to be room for improvement with regard to personalized 
risk assessment. Future steps could potentially include determining optimum timing 
of blood sampling, determining optimum combinations of biomarkers, and eventually 
a biomarker guided trial that is based on personalized temporal patterns of multiple 
biomarkers.
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supplemental figure 1 - example of the shiny app
A clinician can add individual, consecutive biomarker measurements of a patient into the Shiny app to 
depict the curve of this patient’s individual prognosis.
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ABstrAct
Background: Several studies have suggested circulating microRNAs (miRs) are associ-
ated with heart failure, but these studies were small, and limited to single miR measure-
ments.
We examined 7 miRs which were previously linked to heart failure, and tested whether 
their temporal expression level predicts prognosis in a prospective cohort of chronic 
heart failure (CHF) patients.
methods: In 2011-2013, 263 CHF patients were included. At inclusion and subsequently 
every 3 months, we measured 7 miRs. The primary endpoint (PE) comprised heart failure 
hospitalization, cardiovascular mortality, cardiac transplantation and LVAD implanta-
tion. Associations between temporal miR patterns and the PE were investigated by joint 
modelling, which combines mixed models with Cox regression.
results: Mean age was 67±13 years, 72% were men and 27% NYHA class III–IV. We 
obtained 873 blood samples (median 3 [IQR 2-5] per patient). The PE was reached in 41 
patients (16%) during a median follow-up of 0.9 [0.6-1.4] years. The temporal pattern 
of miR-22-3p was independently associated with the PE (HR [95% CI] per doubling of 
level: 0.64 [0.47 - 0.77]). The instantaneous change in level (slope of the temporal miR 
pattern) of miR-22-3p was also independently associated with the PE (HR [95% CI] per 
doubling of slope: 0.33 [0.20–0.51]). These associations remained statistically significant 
after adjustment for temporal patterns of NT-proBNP, Troponin T and CRP.
conclusions: The temporal pattern of circulating miR-22-3p contains important prog-
nostic and independent information in CHF patients. This concept warrants further 
investigation in larger series with extended follow-up.
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iNtroductioN
Contemporary treatment of chronic heart failure ((C)HF) generally aims to stabilize or at 
least decelerate disease progression. Adjustment of pharmacotherapy is largely based 
on clinical judgement and thus mostly relies on the worsening of symptoms or signs.1,2 
However, in the context of the complexity of HF therapy, considerable clinical skills, as 
well as cooperation of the patients, are required to recognize opportunities to titrate 
therapies and to implement such changes intervene early and timely.3 Consequently, 
higher-risk patients may be undertreated.3 Blood biomarkers have the potential to 
monitor subtle changes in the heart that reflect and possibly predict adverse changes 
before they become clinically apparent or reported.4 The value of biomarkers, such as B-
type natriuretic peptides (BNP), cardiac troponins and C- reactive protein (CRP), for risk 
stratification of CHF patients has already been demonstrated.5-8 Moreover, natriuretic 
peptide-guided HF therapy has recently been given a class IIa recommendation in US 
HF guidelines to achieve guideline-directed medical therapy.2,9
Nevertheless, the predictive capability of the aforementioned biomarkers for worsen-
ing of CHF still leaves room for improvement. MicroRNAs (miRs) are upcoming novel 
biomarkers that seem promising for early diagnosis and treatment of HF. MiRs are non-
coding, ∼22 nucleotide long RNA sequences, which target messenger RNAs for cleavage 
or translational repression and thereby influence a great variety of biological processes.10 
The stability of miRs in plasma, and consequently their reliable assessment in easily 
accessible samples, potentially makes them attractive biomarkers for a wide range of 
diseases.11 Studies revealing that deletion of Dicer, a gene encoding an RNase III endo-
nuclease essential for miR processing, leads to cardiac remodelling and dilation, were 
the first to show involvement of miRs in HF12,13 and to suggest that miRs might be used 
as biomarkers for cardiovascular diseases.14 Several other studies have subsequently 
shown associations between miRs and myocardial infarction15-18 and HF.19-24 However, 
most studies pertaining to HF were performed in case-control settings and had a limited 
sample size. Furthermore, these studies usually assessed miRs only once. Repeated, lon-
gitudinal miR assessment in CHF patients may, however, provide insight into individual, 
temporal patterns and the patient’s ensuing risk of disease progression. The temporal 
patterns of miRs in patients with known CHF have not yet been investigated.
In the current prospective, observational study, we have performed frequent (up to 8), 
repeated measurements of multiple miRs that were previously linked to HF (miR-1254, 
miR-22-3p, miR-423-5p, miR-486-5p and miR-320a) or have been shown to be cardiac-
enriched (miR-345-5p, miR-378a-3p) in a cohort of 263 outpatients with CHF, and have 
subsequently investigated the associations of the obtained temporal patterns with 
adverse clinical outcome during follow-up.
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methods
Patients
The Serial biomarker measurements and new echocardiographic techniques in chronic heart 
failure patients result in tailored prediction of prognosis (Bio-SHiFT) study was designed to 
investigate the relationship between temporal patterns of biomarkers involved in CHF 
and prognosis. Bio-SHiFT is an ongoing prospective, observational study of stable out-
patients with CHF, conducted in Erasmus MC, Rotterdam, The Netherlands and Medical 
Centre Alkmaar, The Netherlands. Patients were recruited during their regular outpatient 
visits and were in clinically stable condition. Patients were eligible for inclusion if aged 
18 years or older, capable of understanding and signing informed consent, and if CHF 
(including HF with preserved ejection fraction (HFPEF)) was diagnosed ≥ 3 months ago 
according to the guidelines of the European Society of Cardiology (ESC).25-27 Detailed 
inclusion and exclusion criteria are shown in figure 1. The study was approved by the 
medical ethics committees of the participating hospitals and was conducted in accor-
dance with the Declaration of Helsinki. Written informed consent was obtained from 
all patients.The study is registered in ClinicalTrials.gov, number NCT01851538. In the 
current paper, we have performed an analysis on the 263 patients who were enrolled 
during the first inclusion period between October 2011 and June 2013. Follow-up for 
this analysis lasted from October 2011 until November 2013.
Baseline assessment
At baseline patients were evaluated by trained research physicians, who collected in-
formation on HF related symptoms including NYHA class25,26 and performed a physical 
examination, including blood pressure, heart rate and body mass index. Information on 
aetiology of heart failure, presence of systolic dysfunction, cardiovascular risk factors, 
medical history and medical treatment was retrieved primarily from hospital records 
and was completed by anamnesis in case of ambiguities. History of myocardial infarc-
tion, percutaneous coronary intervention (PCI), coronary artery bypass grafting, valvular 
heart disease, atrial fibrillation or other arrhythmias, device implantation, cerebrovas-
cular accident, diabetes mellitus, hypercholesterolemia, hypertension, and sleep apnea 
were defined as a clinical diagnosis of these conditions, as reported by the treating 
physician in the medical chart. History of chronic renal failure was defined as glomerular 
filtration rate less than 60 mL/min/1.73 m2. Alcohol consumption was defined as drink-
ing ≥1 alcoholic consumption per day. Electrocardiography and echocardiography were 
performed. Data were entered into electronic case report forms. Non-fasting blood and 
urine samples were collected.
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follow-up visits
All patients continued routine outpatient visits during the study. Study follow-up visits 
were scheduled every 3 months (a window of ±1 month was allowed), for a maximum 
of 30 months. For patients’ convenience, study visits and routine outpatient visits were 
combined when possible. At each tri-monthly study visit, a short medical evaluation was 
performed and blood and urine samples were collected. Adverse cardiovascular events 
and changes in medication were recorded in electronic case report forms.
Blood sampling and mir measurement
Blood samples were collected at baseline and at each follow-up visit, and were processed 
and stored locally at a temperature of -80°C within 2 hours after blood collection. When 
applicable, samples were transported to the central laboratory (Erasmus MC, Rotterdam, 
The Netherlands) under controlled conditions (at a temperature of -80°C), until batch 
figure 1 - inclusion and exclusion criteria 
 
 
 
 
 
 
 
 
Heart failure with preserved ejection fraction (HFPEF) 
diagnosed ≥ 3 months ago according to the definition of the 
ESC, which includesthe following features: 
 Presence of signs and/or symptoms of HF (as 
described above) 
AND 
 Presence of normal or only mildly abnormal systolic 
function (LVEF ≥ 50%) 
AND 
 Evidence of diastolic left ventricular dysfunction 
according to the criteria of the ESC: 
o E/E’>15 
OR 
o 15> E/E’ > 8 AND 
NT-proBNP > 220pg/ml /  
BNP > 220 pg/ml  
OR  
o E/A < 0.5 and DT > 280 ms  
OR  
o Atrial fibrillation 
Inclusion criteria 
1. Age ≥ 18 years 
2. Diagnosis chronic heart failure ≥ 3 months* 
3. Written informed consent 
Heart failure, diagnosed ≥ 3 months ago according to the 
definition of the European Society of Cardiology (ESC), which 
includes the following features: 
 Symptoms typical of heart failure: breathlessness at 
rest or on exercise, fatigue, tiredness, ankle swelling 
AND 
 Signs typical of heart failure: tachycardia,  
tachypnea, pulmonary rales, pleural effusion,  
raised jugular venous pressure, peripheral oedema, 
hepatomegaly 
AND 
 Objective evidence of a structural or functional 
abnormality of the heart at rest: cardiomegaly, third 
heart sound, cardiac murmurs, abnormality on the 
echocardiogram, raised natriuretic peptide 
concentration 
 
Exclusion criteria 
 
1. Heart failure secondary to circulatory high output conditions 
2. Scheduled for surgery or intervention for both coronary and non-
coronary indication within 6 months of inclusion 
3. Severe renal failure for which dialysis is needed 
4. Known moderate or severe liver disease 
5. COPD Gold stage IV 
6. Coexistent condition with life expectancy ≤ 1 year 
7. Congenital heart disease 
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analysis took place. Accordingly, results of the biomarker assays were not available to 
treating physicians at the time of the outpatient visits. Thus, the biomarker measure-
ments did not lead to treatment adjustments, and all patients received usual care based 
on European guidelines.25,26
For the purpose of the current investigation, stored plasma samples were transported 
under controlled conditions to ACS Biomarker, Amsterdam, The Netherlands, and seven 
miRs were measured in one batch: miR-1254, miR-22-3p, miR-345-5p, miR-378a-3p, miR-
423-5p, miR-486-5p and miR320a. MiR-1254, miR-22-3p, miR-423-5p, miR-486-5p and 
miR-320a were selected because they were associated with HF in previous studies.11,21,24 
MiR-378a-3p and miR-345-5p were selected because of their presence in cardiomyo-
cytes.28 Plasma was thawed on ice and RNA isolation was performed using the TRIZOL 
LS reagent (Life Technology) according to the manufacturer’s protocol, with a starting 
volume of 200ul plasma. Subsequently, 8ul of the eluate from the RNA isolation was 
used for the reverse transcription reaction. The transcription followed the manufac-
turer’s protocol of the miScript Reverse Transcription Kit (Qiagen). For real-time PCR, 2ul 
of 10x diluted cDNA was used in a total volume of 10ul. The real-time PCR reaction was 
performed on a LightCycler 480 using the following program: 5 min of pre-incubation 
at 95°C; 10 sec of denaturation at 95°C, 20 sec of annealing at 58°C and 30 sec of elonga-
tion at 72°C, in a total of 45 cycles. Data were analysed with LinRegPCR quantitative 
PCR data analysis software. MiR values were normalized using exogenous C. elegans 
miR-39 as a spike-in control, which was applied prior to the RNA isolation step. The 
forward primers used were: miR-423-5p: TGAGGGGCAGAGAGCGAGACTTT; miR-22-3p: 
AAGCTGCCAGTTGAAGAACTGT; miR-378a-3p: ACTGGACTTGGAGTCAGAAGG; miR-1254: 
CTGGAAGCTGGAGCCTGC; miR-345-5p: GCTGACTCCTAGTCC; miR-486-5p: TCCTGTACT-
GAGCTG; miR-320a: AAAAGCTGGGTTGAGAGGGCGA.
Batch analysis of N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitive 
cardiac troponin T (HsTNT) and C-reactive protein was performed in the Clinical Chem-
istry Laboratory of the Erasmus MC, Plasma NT–proBNP and cardiac Troponin T were 
analysed using electrochemiluminesence immunoassays (Roche Diagnostics, Elecsys 
2010, Indianapolis, Indiana, USA), measuring concentrations ranging from 5 to 35000 
ng/L and 3 to 10000 ng/L, respectively. CRP was measured using an immunoturbidi-
metric assay (Roche Hitachi 912 chemistry analyser, Basel, Switzerland), which measures 
concentrations ranging from 0.3 to 350 mg/L.
clinical study endpoints
During follow-up, endpoints were recorded in the electronic case report forms by 
trained research physicians, and associated hospital records and discharge letters were 
collected. A clinical event committee blinded to the biomarker results subsequently 
reviewed all collected information and adjudicated primary and secondary endpoints.
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The primary endpoint comprised the composite of cardiac death, cardiac transplanta-
tion, left ventricular assist device implantation, and hospitalization for the management 
of acute or worsened HF. Secondary endpoints included individual components of the 
primary endpoint, as well as myocardial infarction, percutaneous coronary intervention, 
coronary artery bypass grafting, cerebrovascular accident, and all-cause mortality.
Cardiac death was defined as death from myocardial infarction or other ischemic 
heart disease (ICD-10: I20-I25), death from other heart disease including HF (I30-I45 and 
I47-I52), sudden cardiac death (I46), sudden death undefined (R96) or unwitnessed or 
ill-described death (R98, R99). Hospitalisation for acute or worsened HF was defined as 
exacerbation of symptoms typical of HF, in combination with 2 of the following: BNP 
or NT-proBNP >3x ULN, signs of worsening HF, such as pulmonary rales, raised jugular 
venous pressure or peripheral oedema, increased dose or intravenous administration of 
diuretics, or administration of positive inotropic agents.
statistical analysis
Distributions of continuous variables, including biomarker and miR concentrations, 
were tested for normality using the Kolmogorov-Smirnov test. Variables with normal 
distributions are presented as mean±SD. Variables with non-normal distributions are 
presented as median and interquartile range (IQR). Categorical data are displayed as 
count and percentage.
In case of skewed distributions, continuous variables were logarithmically trans-
formed for further analyses. Associations between temporal patterns of each separate 
miR and the primary endpoint were assessed using a joint modelling approach, which 
combines a linear mixed-effects model for the serial miR measurements with a Cox 
proportional hazards model for the occurrence of the primary endpoint. Results are 
presented as hazard ratios (HRs) per doubling of the miR concentration at any point 
in time, along with the corresponding 95% CIs. All analyses were adjusted for age and 
gender. Subsequently, additional multivariable adjustment for potential confounding 
variables was performed. For this purpose, associations between patient characteristics 
and baseline miR levels, as well as associations between patient characteristics and the 
primary endpoint, were identified using univariable linear- or Cox regression analyses, 
when appropriate. All characteristics associated with the miRs or the primary endpoint 
were subsequently used as covariates in the mixed-effects and Cox models used to con-
struct the joint models. Adjustment for repeatedly assessed NYHA class was performed 
by entering NYHA class as a time-dependent variable into the joint model.
The above-described analysis assesses the predictive value of the temporal pattern 
of the actual miR measurements. However, additional features of the miR’s trajectory 
may better predict the primary endpoint.29,30 Therefore, we investigated whether the 
instantaneous rate of change in miR (slope of the miR trajectory) is associated with the 
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risk of the primary endpoint. Furthermore, to assess the predictive value of long-term 
elevation of miR levels, we investigated the associations between the area under the 
miRs’ trajectory and the primary endpoint. This area can be considered as a weighted 
average of the total longitudinal profile of each patient. The results are presented as HRs 
per doubling of the area at any point in time, with 95% CIs.
Subsequently, we assessed whether the predictive value of the temporal miR patterns 
was independent of temporal patterns of NT-proBNP, HsTNT and CRP. For this purpose, 
all individual temporal miR patterns (of miRs significantly associated with the primary 
endpoint), as well as NT-proBNP, HsTNT and CRP patterns, derived from the adjusted 
joint models were saved and subsequently entered simultaneously as time-varying co-
variates into an extended Cox analysis. The same approach was used to investigate the 
independent predictive value of the slope and the area under the curve of the temporal 
miR patterns associated with the primary endpoint.
To investigate the associations between repeated miR measurements and repeated 
NT-proBNP, HsTNT and CRP measurements, we used generalised estimating equations. 
Herewith, we examined whether the miR level at a certain time-point is associated with 
the level of the other biomarkers at that same time-point.
All analyses were performed with R Statistical Software using package JM.29,30 All tests 
were two-tailed and p-values <0.05 were considered statistically significant.
resuLts
Baseline characteristics
From October 2011 to June 2013, 263 patients were included. Mean age was 67 years 
(SD ±13), 72% were men, and 73% were in New York Heart Association (NYHA) class I or 
II (Table 1). Median baseline NT-proBNP was 139.6 pmol/L (IQR 51.9 – 272.9), HsTNT 18.0 
ng/L (IQR 9.6 – 33.2) and CRP 2.2 mg/L (IQR 0.9 – 4.8). Median duration of HF at inclusion 
was 4.6 years (IQR 1.7 – 9.9). Associations between patient characteristics and baseline 
miR measurements are presented in the supplementary table. Of note is the presence 
of a significant association between ischemic cardiomyopathy (ICM) and several miRs. 
This is further illustrated in figure 2. No significant associations were present with other 
baseline characteristics.
clinical endpoints
The primary, composite endpoint was reached by 41 patients (16%), during a median 
follow-up of 0.9 [0.6-1.4] years: 5 patients died from a cardiovascular cause, 35 patients 
were re-hospitalized for worsened HF and 1 patient underwent heart transplantation. Of 
the 35 patients reaching the primary endpoint because of re-hospitalisation for HF, 16 
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table 1 – Baseline characteristics
total (n=263)
demographics
Age 67 (±13)
Male gender 189 (72)
Caucasian ethnicity 244 (94)
clinical characteristics
Body mass index kg/m2 28 (±5)
Heart rate, bpm 67 (±12)
Systolic blood pressure, mmHg 122 (±20)
Diastolic blood pressure, mmHg 73 (±11)
Biomarker level
NT-proBNP (pmol/L) 139.6 (51.9 – 272.9)
HsTNT (ng/L) 18.0 (9.6 – 33.2)
CRP (mg/L) 2.2 (0.9 – 4.8)
features of heart failure
Duration of heart failure, years 4.6 (1.7 – 9.9)
NYHA class I 75 (29)
NYHA class II 115 (44)
NYHA class III or IV 69 (27)
Left ventricular function
Systolic dysfunction 250 (95)
HFPEF 13 (5)
LVEF* 32 (±10)
etiology of heart failure
Ischemic heart disease 117 (44)
Hypertension 34 (13)
Secondary to valvular heart disease 12 (5)
Cardiomyopathy 68 (26)
Dilated 49 (19)
Hypertrophic 12 (5)
Non compaction 4 (1)
Unclassified 3 (1)
Unknown 19 (7)
Other 13 (5)
medical history
Myocardial infarction 94 (36)
PCI 82 (31)
CABG 43 (16)
Valvular heart disease 136 (53)
Atrial fibrillation 105 (40)
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patients died eventually during further follow-up, of whom 12 died from a cardiovascu-
lar cause. Overall all-cause mortality was thus 21 (8.0%).
table 1 – Baseline characteristics (continued)
total (n=263)
Other arrhythmia 82 (32)
ICD 151 (59)
CRT 78 (30)
Pacemaker 38 (15)
CVA 41 (16)
Chronic renal failure 136 (53)
Diabetes Mellitus 81 (31)
Known hypercholesterolemia 93 (35)
Hypertension 120 (46)
Sleep apnea 26 (10)
intoxications
Alcohol consumption (>1 unit/day) 108 (42)
Smoking 185 (71)
Ever 186 (72)
Current 26 (10)
medication use
ACE-i 173 (67)
ARB 75 (29)
Aldosteron antagonist 178 (68)
Diuretic 237 (90)
Beta-blocker 232(88)
Aspirin 45 (17)
Vitamin K antagonist 200 (77)
Nitrates 44 (17)
Digoxin 59 (23)
Antiarrhythmics 39 (15)
Normally distributed continuous variables are presented as mean (± standard deviation). Non-normally 
distributed continuous variables are expressed as median (25th – 75th percentile). Categorical variables are 
expressed as count (percentage). Valid percentages may vary for some counts, because of missing values. 
ACE-I = ace inhibitor; ARB = angiotensin II receptor blocker; CABG = coronary artery bypass grafting; COPD 
= chronic obstructive pulmonary disease; CRP = C-reactive protein; CRT = cardiac resynchronization ther-
apy; CVA = cerebrovascular accident; HFPEF = heart failure with preserved ejection fraction; HsTNT = high 
sensitive cardiac troponin T; ICD = implantable cardioverter / defibrillator; LVEF = left ventricular ejection 
fraction; NT-proBNP = N-terminal pro-B-type natriuretic peptide NYHA = New York heart association; PCI = 
percutaneous coronary intervention.
* Baseline echocardiograms were available in 72% of all patients because of logistic reasons.
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Of all baseline variables, NYHA class (HR 1.98; CI 1.24 – 3.16 for III/IV vs I/II), baseline 
NT-proBNP (HR per two-fold difference of baseline NT-proBNP 1.42; CI 1.09 – 1.86), 
and baseline CRP (HR per two-fold difference of baseline CRP 1.29; CI 1.05 – 1.60) were 
independently associated with the primary endpoint. As shown in table 2, none of the 
baseline miR values were associated with the primary endpoint, or the secondary end-
point comprising HF hospitalisations only.
temporal mir patterns and the primary endpoint
During follow-up, we collected 923 blood samples, of which 885 were drawn before the 
occurrence of the primary endpoint (median of 3 (IQR 2-5) samples per patient). MiRs 
were successfully determined in 873 of these samples. The temporal pattern of miR-22-
3p was inversely associated with the primary endpoint (age and gender adjusted HR 
figure 2 - Associations between baseline microrNA levels and presence of ischemic cardiomyopathy
Odds ratios for doubling of microRNA (miR) expression level
table 2 – Associations between baseline mirs and the primary endpoint and secondary endpoint
Primary endpoint secondary endpoint
hr* (95% ci) P hr (95% ci) P
mir-1254 1.01 (0.92–1.09) 0.91 1.00 (0.91–1.09) 0.99
mir-22-3p 1.02 (0.93–1.12) 0.61 1.00 (0.90–1.09) 0.85
mir-345-5p 0.99 (0.89–1.09) 0.81 0.95 (0.86–1.06) 0.38
mir-378a-3p 1.00 (0.91–1.11) 0.93 0.99 (0.89–1.09) 0.77
mir-423-5p 1.01 (0.91–1.11) 0.92 0.97 (0.87–1.07) 0.53
mir-486-5p 1.04 (0.94–1.15) 0.47 1.00 (0.89–1.11) 0.93
mir-320a 1.04 (0.95–1.13) 0.44 1.02 (0.93–1.12) 0.71
miR = microRNA.
Primary endpoint: cardiac death, cardiac transplantation, left ventricular assist device implantation, and 
hospitalization for the management of acute or worsened heart failure; secondary endpoint: hospitaliza-
tion for the management of acute or worsened heart failure.
* Hazard ratios (HRs) and corresponding confidence intervals (CIs) were calculated using Cox regression 
analyses and are given per doubling of level of miR.
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per doubling of miR-22-3p level, 0.64; CI 0.47 - 0.77; p<0.001), i.e. higher miR-22-3p was 
associated with lower risk of events (table 3). As described above, baseline measure-
ments of several miRs were associated with ICM. On the other hand, NYHA class was 
independently associated with the primary endpoint. Therefore, the baseline variables 
ICM and NYHA class were added to the models. After adjustment for age, gender, NYHA 
class and ICM, the association between the temporal pattern of miR-22-3p and the 
primary endpoint remained present (HR per doubling of miR-22-3p level 0.71; CI 0.44 
- 0.94; p=0.005). When serial NYHA class assessments were added to the model instead 
of baseline NYHA assessments only, the association between miR miR-22-3p and the 
primary endpoint also remained present (HR per doubling of miR-22-3p level, 0.52; CI 
0.44 - 0.61; p<0.001). The temporal patterns of the other 6 miRs were not significantly 
associated with the primary endpoint.
Baseline echocardiograms were available in 72% of all patients due to logistic rea-
sons . After correction for left ventricular ejection fraction in this subgroup, miR-22-3p 
remained significantly associated with the primary endpoint (HR per doubling of miR-
22-3p level, 0.91; CI 0.85 - 0.95; p<0.001).
Figure 3 shows that in the patients who reached the endpoint, miR-22-3p values 
declined as this endpoint approached, while in the patients who did not reach the 
endpoint, miR-22-3p values remained stable.
slope and area under the curve of the temporal mir patterns and the primary 
endpoint
The hazard ratios for the doubling of the slopes and areas under the curve of the tem-
poral miR patterns are displayed in table 3. For 4 of the miRs (miR-345-5p, miR-378a-3p, 
miR-423-5p, and miR-486-5p), slopes remained virtually constant over time, and hazard 
ratios were not calculable. The slope of the temporal pattern of miR-22-3p was inversely 
associated with the primary endpoint after multivariable adjustment (HR per doubling 
of miR-22-3p slope at any given time point, 0.33; CI 0.20–0.51; p<0.001), while the slopes 
of the patterns of miR-1254 and miR-320a were not. None of the areas under the curves 
of the temporal miR patterns were associated with the primary endpoint.
temporal patterns of mirs, Nt-proBNP, hs-tNt and crP combined in a multiple-
marker model
After constructing the multivariable models that corrected for age, sex, ICM and NYHA 
class, we proceeded to additionally adjust the association between the temporal miR-
22-3p pattern and the primary endpoint for temporal patterns of the other biomarkers 
which were measured in this study (NT-proBNP, HsTNT and CRP). We did this by entering 
the multivariably adjusted temporal pattern of miR-22-3p, as well as the multivariably 
adjusted temporal patterns of NT-proBNP, HsTNT and CRP simultaneously into one 
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model. We found an independent association of miR-22-3p (HR per doubling of miR-22-
3p level at any given time point, 0.61; CI 0.51–0.73; p<0.001) with the primary endpoint. 
Temporal patterns of NT-proBNP and CRP level were also independently associated 
with the primary endpoint in the multiple-marker model (HRs: 1.34 (1.04–1.71) and 
2.14 (1.59–2.88), respectively), while the temporal pattern of HsTNT was not (HR: 1.30 
(0.91–1.84)). The slope of the temporal pattern of miR-22-3p also remained significantly 
associated with the primary endpoint after adjustment for the slopes of the temporal 
patterns of NT-proBNP, Troponin T and CRP (HR per doubling of miR-22-3p slope at any 
given time point, 0.55 (0.46–0.65); p<0.001).
repeated mir measurements and other biomarkers
Associations between repeatedly measured miR and repeatedly measured NT-proBNP, 
HsTNT and CRP, calculated using generalised estimating equations, are displayed in 
table 4. Of note are the significant inverse associations between miR-345-5p and CRP 
(β-coefficient [95%CI]: -0.04 [-0.07 – -0.01] 10log(mg/L) per 10log increase in miR-345-
5p level; p=0.012) and miR-22-3p and HsTNT (β-coefficient [95%CI]: -0.01 [-0.02 – -0.00] 
10log(mg/L) per 10log increase in miR-22-3p level; p=0.014; as well as the borderline 
significant inverse association between miR-22-3p and CRP (β-coefficient [95%CI]: -0.02 
[-0.04 – 0.00] 10log(mg/L) per 10log increase in miR-22-3p level; p=0.051). No further 
associations between repeatedly measured miR and repeatedly measured NT-proBNP, 
HsTNT and CRP were found.
table 4 – Associations between repeatedly measured mirs and B-type natriuretic peptide, high sen-
sitive cardiac troponin t and c- reactive protein
Nt-proBNP hstNt crP
Beta coefficient
(95% ci)
P Beta coefficient
(95% ci)
P Beta coefficient
(95% ci)
P
mir-1254 0.07 (-0.05 – 0.02) 0.27 0.00 (-0.01 – 0.01) 0.59 0.00 (-0.02 – 0.02) 0.92
mir-22-3p -0.01 (-0.022 – -0.00) 0.14 -0.01 (-0.02 – -0.00) 0.014 -0.03 (-0.06 – 0.00) 0.051
mir-345-5p -0.04 (-0.02 – 0.01) 0.57 -0.01 (-0.02 – 0.01) 0.35 -0.04 (-0.07 – -0.01) 0.012
mir-378a-
3p
-0.01 (-0.02 – 0.00) 0.12 0.00 (-0.01 – 0.01) 0.91 -0.02 (-0.04 – 0.01) 0.27
mir-423-5p 0.00 (-0.02 – 0.01) 0.81 -0.01 (-0.02 – 0.00) 0.17 -0.01 (-0.04 – 0.03) 0.63
mir-486-5p -0.01 (-0.02 – 0.01) 0.43 -0.01 (-0.02 – 0.01) 0.37 -0.03 (-0.06 – 0.00) 0.070
mir-320a 0.00 (-0.01 – 0.02) 0.69 0.00 (-0.01 – 0.01) 0.74 0.01 (-0.02 – 0.03) 0.71
Beta coefficients and corresponding 95% confidence intervals (CIs) were calculated using generalised es-
timating equations with 10log transformed microRNAs (miRs) as independent variables and 10log trans-
formed N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitive cardiac troponin T (HsTNT) 
and C- reactive protein (CRP) as dependent variables.
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discussioN
In this prospective, observational cohort of CHF patients, temporal miR-22-3p patterns 
were inversely and independently associated with adverse outcome. The association 
was independent of temporal NT-proBNP, HsTNT and CRP patterns. The instant rate 
of change in miR-22-3p level (in terms of the slope of the temporal pattern) was also 
inversely associated with adverse outcome. Moreover, we found inverse associations of 
temporal patterns of miR-22-3p with temporal patterns of HsTNT and CRP. An additional 
finding of this study was the significant, inverse association between ICM and miR-1254, 
miR486-5p and miR-320a.
Our study has several strengths. Although the number of incident endpoints was lim-
ited, this is the largest study to date that has examined miRs in a prospective cohort of 
patients with chronic HF. NT-proBNP, HsTNT and CRP were measured concomitantly, and, 
in addition, frequent repeated measurements were performed during follow-up, both 
of the miRs and of the established blood biomarkers. Statistical models containing all 
these, repeatedly measured, biomarkers were constructed and modern statistical meth-
ods were applied (‘joint modelling’), which take into account the continuous, dynamic 
changes in biomarker patterns and thus result in less bias than simpler analyses such as 
delta’s between two measurements. Herewith, the study expands existing evidence with 
regard to miRs and cardiovascular disease in several respects.
MiR-22-3p has previously received attention in the cancer field; it has been implicated 
in the regulation of various cellular processes, including cell growth, apoptosis, motility, 
and the cell cycle.31 With regard to cardiovascular disease, fundamental experiments 
have demonstrated that expression of miR-22-3p is enriched in striated muscle tissues 
(i.e. cardiac and skeletal muscles); and miR-22-3p is thought to be required for normal 
cardiac remodelling in response to stresses.32 A recent study in miR-22 deficient mice 
demonstrated that miR-22 depleted hearts quickly progress to adverse cardiac remodel-
ling and develop cardiac dilation, with increased cardiomyocyte loss and deposition of 
fibrotic tissue, and signs of heart failure.33 Another study also found that mice without 
miR-22 develop dilatation of myocardium more quickly.34 Interestingly, several animal 
models have shown that miR-22 may potentially serve as a therapeutic target in cardiac 
hypertrophy.33 Recently, Gupta et al found that pharmacological inhibition of miR-22 
post-infarction activated cardiac autophagy, led to improved cardiac function, and 
inhibited cardiac remodelling in older mice.35 They also found that circulating miR-22 
provides prognostic information in HF patients. Specifically, they demonstrated an as-
sociation between higher baseline levels of circulating miR-22 and mortality in154 HF 
patients. Repeated measurements were not performed. In the present study, although 
we saw a temporal decline of miR-22-3p levels in patients with adverse clinical outcome, 
we could not demonstrate a significant association between higher baseline miR-22-3p 
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and clinical outcome. The shorter follow-up duration of our study (median of approx. 
1 year, versus 3 years follow-up in the study of Gupta et al) may have contributed to 
this. Furthermore, in an earlier study, Goren et al, demonstrated that elevated serum 
levels of miR-22-3p identify patients with systolic heart failure using 30 stable chronic 
systolic heart failure patients and 30 controls.24 This seeming discrepancy with our study 
could possibly be explained by differences in study design. While Goren et al focused 
on diagnostic properties of miR-22-3p by comparing cases and controls, we focused 
on prognostic value of miR-22-3p in patients with established CHF. To the best of our 
knowledge, other cardiovascular studies on miR-22-3p in human subjects are lacking. 
Altogether, our study is in line with previous fundamental experiments which demon-
strated that loss of miR-22-3p leads to dilatation of myocardium and progressive HF. Our 
study confirms that lower levels of miR-22-3p are associated with worsening of CHF, and 
that miR-22-3p may complement established HF biomarkers in prognostication.
Previously, several studies using animal models have shown decreased levels of miR-
378a-3p during cardiac remodelling36 and in HF due to cardiac hypertrophy.37-39 Further-
more, a significant down-regulation of miR-378a-3p in hearts with dilated cardiomyopa-
thy compared to non-failing control hearts has been observed.23 Since the presence of 
miR-378a-3p is required to resist ventricular remodelling during cardiac stress, it may 
offer therapeutic potential for the management of HF.38 It has been suggested, that 
up-regulation of miR-378a-3p could serve as a potential novel treatment for apoptosis 
and ischemic heart disease, since up-regulation of this miR enhanced cell viability, and 
inhibited apoptosis and necrosis in myocardium of rats.40 In the current study, we also 
observed a tendency towards an inverse association between the temporal pattern of 
miR378a-3p and the primary endpoint in univariable models. These results concur with 
the aforementioned studies.
Another miR that has previously been associated with HF, is miR-423-5p.19,21,22,24 How-
ever, in our study, there was no association between the temporal pattern of miR-423-5p 
and the primary endpoint. Existing studies on miR-423-5p in humans all compared single 
measurements in (C)HF patients with measurements in healthy controls, and imply that 
this miR has diagnostic value for HF.19,21,24 We did not evaluate the diagnostic value of 
miRs, but the prognostic value of serial miR measurements in patients with known CHF. 
Although miR-423-5p may discriminate between HF patients and healthy controls, it 
may lack prognostic value in patients with longstanding CHF. Earlier findings support 
this hypothesis.20 Bauters et al serially measured serum levels of circulating miR-423-5p 
in 246 patients with a first anterior Q-wave myocardial infarction, at discharge and sub-
sequently at 3 months and 1 year. They found no association between miR-423-5p levels 
and indices of left ventricular function and left ventricular remodelling, which were 
serially assessed during a 1 year period after the index myocardial infarction, nor with 
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B-type natriuretic peptide. They concluded that miR-423-5p is not a useful biomarker of 
left ventricular remodelling after myocardial infarction.20
The selection of the miRs for the current investigation was based on previous studies, 
which used animal models and relatively small patient groups. Some of these studies 
have shown associations between miR-1254, miR-345-5p, miR-486-5p and
miR-320a and heart failure.19,21,24,41,42 Again, these were mostly studies that compared 
HF patients to healthy controls. In our study, we did not find any associations between 
these miRs and poor outcome in CHF. Multiple other miRs, such as miR-133a,43 have pre-
viously been associated with HF.44 Serial measurements of these other miRs, which were 
not investigated in this study, warrant further investigation. This could lead to further 
improvements in CHF prognostication, as well as tailored adjustment of treatment.
Some aspects of this study warrant consideration. For the current investigation we 
only used the first round of inclusions of the ongoing Bio-SHiFT study (n=263). It should 
be noted that the full Bio-SHiFT cohort is designed to have sufficient statistical power 
to enable correction for multiple testing in case of application of modern, large-scale 
biomarker measurement methods. However, the current investigation examines only 7 
miRs, which were chosen based on pathophysiological considerations. Thus, the current 
investigation was hypothesis-driven and not data-driven, rendering correction for mul-
tiple testing unnecessary in this particular case. Furthermore, with an average follow-
up ~1 year, the number of primary endpoints in the current investigation (n=41) was 
limited, and consequently so was the number of covariables that could be entered into 
the models. The lack of a replication population is another limitation of the study. Finally, 
the majority of the patient population was in NYHA functional class I or II, and thus at 
relatively low risk. Accordingly, the primary outcome was predominantly composed of 
heart failure hospitalizations. This may have hampered the prognostic information of 
the other miRs tested in this study. Future studies using high-risk patient populations 
should therefore re-investigate the prognostic information carried by repeated assess-
ment of these miRs.
Remarkably, in the present study, the rate of HFPEF was very low compared to other 
epidemiological studies. This can most likely be attributed to the fact that in the Neth-
erlands, most HFPEF patients are treated by the general practitioner or in secondary 
referral centres, while the current study was performed in two centres which were both 
tertiary referral centres. Potential inclusion bias is not a likely reason for the low HPEF 
rate, because consecutive patients were screened in both participating centres. More-
over, the number of patients on vitamin K antagonists was quite high in this study, most 
likely due to the high number of patients with left ventricular aneurysms and thrombi, 
as well as the high number of patients with atrial fibrillation.
In conclusion, in patients with stable CHF, the temporal pattern of circulating
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miR-22-3p is a strong and independent predictor of prognosis. Thus, the use of indi-
vidual patterns of change of circulating miR-22-3p for CHF prognostication, as well as for 
tailored adjustment of treatment, warrants further investigation.
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ABstrAct
Background: Previous studies have identified candidate circulating microRNAs (circ-
miRs) as biomarkers for heart failure (HF) by relatively insensitive arrays, validated in 
small cohorts. We used RNA sequencing to identify novel candidate circmiRs and com-
pared this to previously identified circmiRs in a large, prospective cohort of acute HF 
(AHF) patients.
methods: RNA sequencing of plasma from instrumented pigs was used to iden-
tify circmiRS produced by myocardium, and found production of known myomirs and 
microRNA(miR)-1306-5p. We next tested the prognostic value of this and 11 other 
circmiRs in a prospective cohort of 496 AHF patients, from whom blood samples were 
collected at several time points (max 7) during the study’s 1-year follow-up. The primary 
endpoint (PE) was the composite of all-cause mortality and HF rehospitalization.
results: In the prospective AHF cohort, 188 patients reached the PE, and higher values 
of repeatedly measured miR-1306-5p were positively associated with the risk of the PE 
at that same time-point (HR(95%CI):4.69(2.18–10.06)), independent of clinical charac-
teristics and NT-proBNP. Baseline miR-1306-5p did not improve model discrimination/
reclassification significantly compared to NT-proBNP. For miR-320a, miR-378a-5p, miR-
423-5p and miR-1254 associations with the PE were present after adjustment for age 
and sex (HRs(95%CI):1.38(1.12–1.70), 1.35(1.04–1.74), 1.45(1.10–1.92),1.22(1.00–1.50), 
respectively). Detection rate of myomiRs miR208a-3p and miR499a-5p was very low.
conclusions: Repeatedly-measured miR-1306-5p was positively associated with ad-
verse clinical outcome in AHF, even after multivariable adjustment including NT-proBNP. 
Yet, baseline miR-1306-5p did not add significant discriminatory value to NT-proBNP. 
Low-abundant, heart-enriched myomiRs are often undetectable which mandates more 
sensitive assays.
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iNtroductioN
To date, natriuretic peptides are the only circulating biomarkers which are routinely used 
for diagnosis and prognostication of heart failure (HF).1 Improved HF prognostication 
may identify patients that could benefit from closer follow-up and from more aggressive 
treatment. Therefore, exploration of novel prognostic markers of HF can improve clinical 
management.
Circulating microRNAs (circmiRs) have been proposed as an attractive new class of 
biomarkers because of their stability in the circulation, and their ensuing reliable as-
sessment in easily accessible samples.2 However, most published studies to date involve 
relatively small numbers of HF patients with most often discrepant findings between 
separate studies.3-7 Larger studies are scarce and have not investigated the temporal 
patterns of microRNAs (miRs) in patients with HF.8 Importantly, longitudinal circmiR 
measurements in HF patients may provide further insight into individual, temporal pat-
terns and the patient’s ensuing risk of disease progression and adverse outcome.
In the present study, we used an RNA sequencing discovery experiment in pigs to 
identify circmiRs produced by the myocardium. Subsequently, we tested the potential 
for prognostication of the most promising novel circmiR (miR-1306-5p) in a set of 475 
patients who were prospectively included for serial sampling after an AHF admission 
and compared it to multiple miRs known to be cardiac-enriched or already previously 
linked to HF (miR-1254, miR-22-3p, miR-345-5p, miR-378a-3p, miR-423-5p, miR-320a, 
miR-133a-3p, miR-133b, miR-499a-5p, miR-622, and miR-208a-3p).
methods
Part i: Preclinical study design
Aortic Banding and plasma and tissue harvesting
Experiments were performed in Aortic Banding (AoB)-treated (n=29) and sham-operat-
ed (n=21) Yorkshire x Landrace swine (see Supplemental Material for details, including 
surgical procedures and sacrifice of the animals). Briefly, following thoracotomy, the 
proximal ascending aorta was dissected free and, in AoB animals a band was placed.9 Up 
to eight weeks later, swine were instrumented for simultaneous arterial and coronary 
venous blood sampling, followed by excision of the heart and harvesting of myocardial 
tissue samples from the left ventricular anterior wall.
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rNA sequencing
RNA was isolated from myocardial tissue and from arterial and coronary venous plasma 
samples of AoB-treated (n=4) and sham-operated (n=4) swine at 8 weeks follow-up after 
sham and AoB. For subsequent sequencing, RNA was pooled from myocardial tissue 
samples and from plasma obtained from arterial and coronary venous samples from 
AoB-treated and sham-operated samples, respectively. Pooled RNA from each sample 
was then divided into two, to have 2 technical replicates per sample. This resulted in a 
total of 16 samples, which were sent to BGI Shenzhen (China) for sequencing of small 
RNAs. At the BGI, libraries were prepared using the NEBNext® Multiplex Small RNA 
Library Prep Set for Illumina® kit. Samples were sequenced on an Illumina NextSeq 500 
platform and base-calling was performed using the bcl2fastq 2.0 Conversion Software 
from Illumina.
Quality control of fastq files was performed using FASTQC (http://www.bioinformatics.
bbsrc.ac.uk/projects/fastqc/). Trimmomatic version 0.32 was used to carry out 3´ adapter 
clipping of reads, using a phred score cut-off of 30 in order to trim low quality bases 
whilst ensuring that reads with a length below 18 bases were discarded.10
differential mir expression analysis
We analyzed differential expression in the RNA sequencing data using the R Biocon-
ductor package, DESeq2.11 MiRs were selected based on next-generation sequencing 
results. Only miRs that were differentially expressed or had a high abundance in heart 
tissue were analyzed. We used quantitative polymerase chain reaction (PCR) to analyze 
expression levels of selected miRs in coronary venous and arterial plasma samples from 
21 sham pigs and 29 AoB pigs. Plasma samples were analyzed to obtain a trans-coronary 
gradient in a comparable fashion; sham arterial plasma vs. coronary venous plasma, and 
AoB arterial plasma vs. coronary venous plasma. Owing to the availability of replicates, 
the dispersion method “pooled” from DESeq2 was used to accurately estimate dispersion 
between each comparison. DESeq2’s negative binomial model was used to estimate 
differentially expressed miRs for each analysis. At the end, only those miRs passing a 
fold-change (log2) cut-off of 1.0 together with a False Discovery Rate cut-off of 0.05 were 
deemed significantly differentially expressed.
Part ii: clinical study design
TRIUMPH was an observational, prospective study enrolling patients admitted with 
acute HF in 14 hospitals in The Netherlands, between September 2009 and Decem-
ber 2013. The study was designed to allow analysis of novel potential biomarkers for 
prognostication of HF patients, with a particular interest directed towards changes in 
blood-biomarker patterns over time and their value for prognostication in HF patients. 
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The study was approved by the medical ethics committee at all participating centers. All 
patients provided written informed consent.
Patients
Patients were eligible if ≥18 years old and hospitalized for acute HF, resulting from 
decompensation of known, chronic HF or newly diagnosed HF, and all three of the 
following criteria were met: (1) natriuretic peptide levels elevated to ≥3 times the up-
per limit of normal (determined in each individual hospital); (2) evidence of sustained 
left ventricular dysfunction, defined as moderate to poor systolic function or grade II 
(pseudonormal) to grade IV (fixed restrictive) diastolic dysfunction on echocardiogra-
phy during hospitalization; and (3) treatment with intravenous diuretics. Patients were 
excluded in case they suffered from HF precipitated by a non-cardiac condition, by an 
acute ST-segment elevation myocardial infarction or by severe valvular dysfunction 
without sustained left ventricular dysfunction. Furthermore, patients were excluded 
if they were scheduled for coronary revascularization, listed for heart transplantation, 
suffered from severe renal failure for which dialyses was needed, or had a coexistent 
condition with a life expectancy <1 year.
Patient management
Patient management was at the discretion of the treating clinician, in accordance with 
the guidelines of the European Society of Cardiology.12 Of note, biomarker data obtained 
in the context of this study were unknown to the treating physicians and thus were not 
used for clinical decisions.
study procedures
Blood samples were obtained from all patients during hospitalization at admission 
(day 1), once during days 2 to 4 and subsequently at discharge; thus, 3 samples per 
patient were drawn during hospitalization. Additionally, blood samples were obtained 
at outpatient clinic follow-up visits, planned 2 to 4 weeks, 3 months, 6 months, and 9 
to 12 months after discharge; thus, 4 samples were drawn during follow-up. As such, 
a total of 7 samples were obtained for each patient, unless a patient was censored or 
died before all samples could be taken. A short medical evaluation was performed and 
blood samples were collected at every follow-up visit. Adverse cardiovascular events 
and changes in medication were recorded in electronic case report forms.
mir- and Nt-proBNP measurements
MiRNAs were measured in all separate plasma samples as described in detail in the 
Supplemental Material. MiR-1254, miR-22-3p, 423-5p, miR-320a and miR-622 were 
selected because they were associated with HF in previous studies,5,7,13 miR-378a-3p and 
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miR-345-5p because of their enrichment in cardiomyocytes,14 and miR133a-3p, miR133b, 
miR208a-3p and miR499a-5p are muscle specific miRs (so-called ‘myomiRs’), of which 
the latter two are heart specific and are released during myocardial injury.15,16 MiR486-5p 
was used for normalization of the other miRs, because endogenous miRs have been 
shown to carry advantages for normalization compared to spike-in (e.g. Cel39) or small 
RNAs.17 In the RNA-sequencing experiment we noticed that miR486-5p is exceptionally 
abundant (representing the vast majority of all detected miRs in the circulation, see 
Results below) and stable compared to other miRs, making it a suitable candidate to use 
as a normalizer (details of normalization are described in the Supplementary Material 
NT-proBNP measurements are also described in the Supplemental Material.
Quality control of human mir measurements
PCR of circulating miRs is sensitive to false or inaccurate signals, which may result in 
missing values.18 Missing values may result from technical errors, but are most often 
due to template levels that are too low to measure reliably with qPCR. Therefore, we 
used a quality assessment algorithm to ensure the validity of each measurement. This 
algorithm is described more extensively elsewhere.19 In brief, we distinguished three 
groups of measurements: ‘detectable’, ‘non-detectable’ (signal too low) and ‘invalid’. If 
the measurement passed all the quality checks, it was considered valid and was marked 
‘detectable’. In case of a ‘non-detectable’ signal, the measurement was set to a low value, 
which was based on the PCR experiment parameters. If the measurement did not pass 
the quality controls of the algorithm, it was defined as ‘invalid’. Such measurements were 
not used in further analyses.
endpoints
The primary endpoint comprised the composite of all-cause mortality and readmission 
for HF. The latter was defined as an unplanned rehospitalization due to acute HF, with at 
least two of the following three criteria: (1) elevated natriuretic peptide levels ≥3 times 
the upper limit of normal, (2) symptoms of cardiac decompensation (e.g. rales, edema 
or elevated central venous pressure), and (3) administration of intravenous diuretics. 
Secondary endpoints included the individual components of the primary endpoint and 
additionally cardiovascular mortality.
During follow-up, information on vital status and hospital readmissions was obtained 
until at least 9 months with a maximum of 400 days after the index hospital admission. 
We approached the civil registry, screened all medical records, and asked patients for 
information during their follow-up visits. A clinical event committee blinded to the bio-
marker results subsequently reviewed all collected information and adjudicated primary 
and secondary endpoints.
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statistical analysis
The associations between the baseline miR measurements and the risk of a study 
endpoint were assessed using Cox proportional hazards models. Abundant miRs were 
examined as continuous variables, while low-abundance miRs were entered into the 
models as dichotomous variables (detectable versus non-detectable, as defined by the 
algorithm described above), For repeated miR measurements, associations between the 
current level of each separate miR at a particular time point and the risk of an endpoint at 
that same time point were assessed using a joint modeling approach, which combines a 
linear mixed-effects model for the repeated miR measurements with a Cox proportional 
hazards model for the risk of experiencing the event of interest.20 A detailed description 
of the statistical analysis is provided in the Supplemental Material.
resuLts
rNA sequencing in pigs samples
Post-quality control, the total number of reads per sample successfully aligned to pig-
specific hairpin sequences ranged from 83.7 to 97.3 %. Combining all reads together, 
followed by discarding sequences longer than 25 nucleotides and those with low 
abundance (< 4 reads per sample) resulted in 373 x 106 reads that were successfully 
mapped to pig hairpin sequences. Aligning unmapped reads to hairpin sequences of 
other species increased the alignment rate by a negligible fraction (0.46%), suggesting 
that known hairpin sequences of Sus Scrofa were close to complete. We therefore, only 
used those sequences that were mapped to Sus scrofa hairpins.
Whilst calculating the number of reads aligned to each hairpin and mature miR se-
quence, a high abundance of miR-486-5p was observed in plasma samples (constituting 
92.5-97% of all reads). There were a number of circmirs with a positive and significant 
trans-coronary gradient (figure 1). Among these were also known myomirs like miR-
133a. In addition, less known circmirs like miR-1306 also showed a positive gradient. A 
comparison of next-generation sequencing based miR expression across tissue samples 
revealed a total of 16 miRs differentially expressed in sham-operated tissue compared 
to AoB-treated tissue (Table 1) among which miR-1306-5p was also significantly upregu-
lated.
Given the positive trans-coronary gradient of miR-1306-5p and its significant up-
regulation in myocardial tissue of AoB compared to Sham pigs, we further evaluated 
the potential role of miR-1306-5p as a circulating biomarker. We compared the values 
obtained for miR-1306 in the control samples that are routinely taken along on the qPCR 
plates with the measurement of the HF samples, which showed that levels of circulating 
miR-1306-5p were significantly higher in the HF patients OR [95%CI] = 1.43 (1.033 – 1.98) 
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in arbitrary unit)/ln(pg/ml), p<0.05), further increasing the probability that circulating 
miR-1306-5p could serve as a novel biomarker for HF.
Prospective clinical study: Baseline characteristics
A total of 496 patients were enrolled in the TRIUMPH clinical cohort and provided 
written informed consent. Three patients withdrew their informed consent. Eighteen 
patients were withdrawn from statistical analyses due to inclusion violation. These 
patients had no evidence of sustained systolic or diastolic left ventricular dysfunction 
on echocardiography. Accordingly, 475 patients compose the analysis set. Median age 
was 74 years (interquartile range (IQR) 65-80), 63% were men and median left ventricular 
ejection fraction was 30% (IQR 21-42) (Table 2). Median baseline NT-proBNP level was 
4135 pg/mL (IQR 2123–9328).
clinical endpoints
The composite primary endpoint was reached by 188 patients (40%) during a median 
follow-up of 325 (IQR 85–401) days. A total of 113 patients died, of which 77 were con-
firmed to die from a cardiovascular cause, and 123 patients were re-hospitalized for 
decompensated HF.
figure 1 - trans-coronary gradients in plasma microrNAs
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The number indicates the number of pigs (out of a total of 44 pigs) with both a detectable venous and 
arterial microRNA value. The gradient is calculated as arterial minus venous Ct value of the microRNA, and 
shown as Mean±SEM. A negative value indicates release of the microRNA by the myocardium, and a posi-
tive value indicates uptake. The p-value is calculated using a paired samples T-test, and indicates the differ-
ence between arterial and venous Ct value of the microRNA.
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circulating mir measurements
A total of 2214 blood samples were available for the current investigation. Median (IQR) 
number of miR measurements per patient was 3 (IQR 2–5). Supplemental table 1 displays 
the number of measurements that were detectable per miR. MiRs that were detectable 
in less than 700 out of 2214 samples were not used as continuous variables in further 
analyses but were dichotomized (detectable vs. non-detectable) as described above. 
MiRs that were examined as continuous variables were: miR-320a, miR-1254, miR-22-3p, 
miR-378a-3p, miR-423-5p, miR-345-5p and miR-1306-5p. MiRs that were dichotomized 
were: miR-133a-3p, miR-133b, and miR-499a-5p. MiR-486-5p was used for normalization 
of these miR levels. MiR-622 and miR-208a-3p were only detectable in 56 and 6 out of 
table 1 – differentially expressed microrNAs across tissue samples
mir fold change* Adjusted p-value
306-5p 1,354 0.002
132 1,554 0.013
133a-3p 1,107 0.004
142-5p 1,992 <0.001
144 1,457 0.004
144-5p 2,621 <0.001
150 1,767 0.006
15b 1,996 <0.001
15b-5p 1,922 <0.001
342 1,932 <0.001
365-3p 1,507 <0.001
451 3,015 <0.001
532-3p 1,956 0.001
7139-3p 1,889 <0.001
92b-3p 1,04 0.015
99b-3p -1,225 0.023
133b 0,69 0,07
103 -0,198 0,72
143-3p -0,251 0,75
143-5p -0,297 0,755
28-3p -0,347 0,53
486-5p 0,166 0,77
7f 0,472 0,51
99 -0,53 0,11
Myocardial samples were obtained from the left ventricular free wall and compared between sham-oper-
ated and TAC-treated swine. P-values were calculated using the negative binomial model from DESeq. MiR 
= microRNA.
* Log2 fold change
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2214 samples, respectively. This low expression did not allow for meaningful statistical 
analysis of these miRs. Additionally, supplemental table 2 shows the baseline character-
istics stratified by invalid versus valid measurement of baseline miR-1306-5p.
Finally, miR expression levels in patients with HF with reduced ejection fraction (HFrEF) 
vs. HF with preserved ejection fraction (HFpEF) are presented in supplemental table 3.
Associations between baseline mir levels and clinical endpoints
Figure 2 shows the difference in the risk of experiencing the primary endpoint for pa-
tients in different quartiles of baseline miR1306-5p levels (p< 0.001). This was confirmed 
in the subsequently fitted Cox models, where baseline miR1306-5p levels were sig-
nificantly and independently associated with the primary endpoint (hazard ratios (HRs)
(95%CI)): 1.13(1.03-1.23) (Table 3). From the other known miRs, only the baseline levels 
of miR-320a were significantly and independently associated with the primary endpoint 
(HRs(95%CI): 1.10(1.00-1.21)). Associations with secondary endpoints are shown in 
Supplemental Table 4. A sensitivity analysis on the subgroup of HFrEF patients, rendered 
table 2 – Baseline characteristics
Variables overall sample (n=475)
demographic characteristics, median [iQr] or number (%)
Age, years 73 [64 - 80]
Female, % 36.6 (167)
Caucasian, % 94.3 (430)
measurements at baseline, median [iQr] or number (%)
Body mass index, kg/m2 27.5 [24.7 - 31.1]
Systolic blood pressure, mmHg 125 [110 - 147]
Diastolic blood pressure, mmHg 75 [65 - 85]
Heart rate, bpm 85 [72 - 100]
eGFR 46 [34.4 - 61.7]
Left ventricular ejection fraction, % 30 [21 - 42]
Heart failure with reduced ejection fraction, % 79.8 (289)
NT-proBNP (pg/ml) 4143.7 [2097.5 - 9053.2]
medical history, number (%)
Previous heart failure admission within 6 months 19.8 (90)
Ischemic heart failure 48.1 (219)
Myocardial infarction 40.4 (184)
Hypertension 50 (228)
Atrial fibrillation 42.5 (194)
Diabetes Mellitus 36.5 (166)
Stroke 17.5 (80)
IQR = Inter-quartile range, eGFR = estimated glomerular filtration rate.
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figure 2 - Kaplan-meier survival curves for the primary endpoint of death or readmission for hf in 
the four quartiles of baseline mir-1306-5p levels
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table 3 - Associations between baseline microrNA levels and primary endpoint
mir
hazard ratio (95% ci)
model 1 model 2 model 3
320a* 1.19 (1.09 – 1.30) 1.18 (1.08-1.29) 1.10 (1.00 – 1.21)
1254* 1.06 (0.98 – 1.14) 1.05 (0.97 – 1.14) 1.00 (0.92 – 1.08)
22-3p* 1.04 (0.96 – 1.12) 1.05 (0.97 – 1.14) 1.02 (0.94 – 1.10)
378a-3p* 1.08 (0.98 – 1.18) 1.07 (0.97 – 1.18) 1.03 (0.93 – 1.14)
423-5p* 1.08 ( 0.98 – 1.18) 1.09 (0.98 – 1.20) 1.05 (0.95 – 1.16)
345-5p* 1.03 (0.97 – 1.11) 1.03 (0.96 – 1.10) 0.99 (0.93 – 1.07)
1306-5p* 1.19 (1.09 – 1.30) 1.18 (1.09 – 1.29) 1.13 (1.03 – 1.23)
133a-3p† 0.84 (0.56 – 1.24) 0.89 (0.60 – 1.34) 1.00 (0.66 – 1.53)
499a-5p† 1.49 (0.79 2.84) 1.53 (0.81 – 2.92) 1.25 (0.64 – 2.42)
133b† 0.97 (0.40 – 2.36) 0.97 (0.40 – 2.36) 1.07 (0.43 – 2.67)
NT-proBNP 1.47 (1.27 – 1.71) 1.46 (1.25 – 1.69) 1.36 (1.15 – 1.60)
Model 1 unadjusted; model 2 adjusted for age and sex; model 3 adjusted for age, sex, systolic blood pres-
sure, diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 6 months, isch-
emic HF, baseline eGFR, and baseline NT-proBNP level. BMI = Body mass index, HF = Heart failure, miR = 
MicroRNA. Primary endpoint: composite of all-cause mortality and readmission for heart failure
* Hazard ratio per per ln[arbitrary unit] of miR level
† Hazard ratio of detectable vs. non-detectable miR level
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a HR for baseline miR1306-5p in relation to the primary endpoint that was similar to the 
HR in the total group, but with a wider CI ((HR(95%CI): 1.09(0.95–1.25) (supplemental 
table 5). This was most likely caused by a decrease in statistical power in this subgroup.
Associations between temporal mir patterns and clinical endpoints
Repeatedly measured miR1306-5p level was positively and independently associated 
with the primary endpoint (HR(95%CI): (4.69(2.18–10.06)), p< 0.001 (Table 4). The tem-
poral patterns of miR-320a, miR-378a-3p and miR-423-5p were positively associated with 
the primary endpoint after adjustment for age and sex. However, these associations dis-
appeared after multivariable adjustment. The temporal pattern of miR-1254 displayed 
a borderline significant association with the primary endpoint after adjustment for age 
and sex (HR(95%CI): 1.22(1.00-1.50). Associations of temporal patterns with secondary 
endpoints are shown in Supplemental Table 6.
incremental prognostic value of mir-1306-5p
Adding miR-1306-5p to a model containing NT-proBNP age, sex, systolic blood pressure, 
diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 
6 months, ischemic HF, and baseline eGFR, we found a change in C-statistic of 0.012 
(95%CI: -0.006–0.029), a continuous net reclassification (cNRI) improvement of 0.125(-
0.016–0.267), and an integrated discrimination index (IDI) improvement of 0.020(-
0.013–0.053), as shown in supplemental table 7. Thus, the incremental prognostic value 
of miR1306-5p on top of NT-proBNP did not reach statistical significance.
table 4 - Associations between repeated microrNA measurements and primary endpoint
mir
hazard ratio (95% ci)
model 1 model 2 model 3
320a 1.40 (1.14 – 1.72) 1.38 (1.12 – 1.70) 1.13 (0.91 – 1.40)
1254 1.26 (1.03 – 1.55) 1.22 (1.00 – 1.50) 1.00 (0.82 – 1.22)
22-3p 1.25 (0.97 – 1.63) 1.27 (0.99 – 1.64) 1.18 (0.91 – 1.52)
378a-3p 1.39 (1.07 – 1.80) 1.35 (1.04 – 1.74) 1.01 (0.76 – 1.34)
423-5p 1.45 (1.10 – 1.90) 1.45 (1.10 – 1.92) 1.08 (0.81 – 1.44)
345-5p 1.11 (0.93 – 1.34) 1.10 (0.92 – 1.32) 1.00 (0.89 – 1.12)
1306-5p 5.16 (2.58 – 10.31) 3.05 (1.58 – 5.88) 4.69 (2.18 – 10.06)
Model 1 unadjusted; model 2 adjusted for age and sex; model 3 adjusted for age, sex, systolic blood pres-
sure, diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 6 months, isch-
emic HF, baseline eGFR, and baseline NT-proBNP level. BMI = Body mass index, HF = Heart failure, miR = 
MicroRNA. Primary endpoint: composite of all-cause mortality and readmission for heart failure
Hazard ratios per ln[arbitrary unit] of miR level
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discussioN
Direct RNA sequencing of plasma from instrumented pigs revealed a number of circmiRs 
to be produced by the pig myocardium, including miR-1306-5p which had not yet been 
identified as a miR related to the heart. Subsequently, we found in a prospective AHF co-
hort that repeatedly-assessed circulating miR-1306-5p is positively and independently 
associated with all-cause mortality and HF hospitalization. This association was indepen-
dent of NT-proBNP. However, a model containing baseline miR-1306-5p measurements 
did not significantly improve model discrimination or reclassification when compared 
to NT-proBNP. Repeatedly-assessed circulating miR-320a, miR-378a-3p, miR-423-5p 
and miR-1254 were associated with the primary endpoint after adjustment for age and 
sex (albeit borderline for miR-1254), but not after further multivariable adjustment for 
clinical characteristics. Furthermore, an independent association was found between 
baseline values of miR-1306-5p and miR-320a and the primary endpoint.
Importantly, our findings are in line with those described in a manuscript where two 
large cohorts have been studied (Bayes-Genis et al, submitted back-to-back). In those 
two independent cohorts, miR-1306-5p was also positively and significantly associated 
with the risk of all-cause mortality or HF hospitalization. This further strengthens our 
findings and for the first time we see reproducible results on circulating miRs across 
three large cohorts. This contrasts with previous studies where usually one, mostly 
smaller cohort was analyzed,21 and results have most often been discrepant between 
separate studies. To the best of our knowledge, the association between miR-1306-5p 
and cardiovascular disease has not been previously investigated in other studies, and 
further research is warranted on its expected targets.
RNA sequencing using plasma-derived RNA led to the discovery of miR-1306-5p 
produced by the heart. Akat et al also used RNA sequencing to analyze miRs potentially 
produced by the human heart.22 However, their study was not designed to assess the 
clinical value of circmiRs as biomarkers. A word of caution concerns the large proportion 
of invalid and undetectable miR-1306-5p measurements which reduces power and illus-
trates the need for more sensitive methods of miR assessment to enable optimal use of 
this marker for clinical prognostication. Nevertheless, the current study carried sufficient 
statistical power to demonstrate a significant association between repeatedly measured 
miR-1306-5p and the primary and secondary endpoints in spite of the proportion of 
invalid and undetectable measurements.
In line with our results, the study by Bayes-Genis et al. also found an association be-
tween miR-1254 and clinical outcome. Other existing data on miR-1254 are limited; of 
note is that Tijsen et al demonstrated upregulation of miR-1254 in HF cases compared 
to healthy controls.5 An association between higher baseline miR423-5p levels and signs 
of progressive HF has been demonstrated in animal models,6 and human studies with 
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limited sample size.3,5 Rising miR423-5p has also been related to worsening left ven-
tricular function and has been shown to be upregulated in non-ST elevation myocardial 
infarction patients.23 Our results agree with the findings of the aforementioned stud-
ies. Conversely, in recent a study in 236 acute HF patients, an inverse association was 
observed between miR423-5p and hospital readmission.8 However, this finding could 
not be reproduced in the validation cohort which was examined.8 Smaller studies have 
previously demonstrated higher circulating levels of miR-320a in HF patients compared 
to healthy individuals.7,24 In addition, rat models have proven that overexpression of 
miR-320a leads to a greater loss of cardiomyocytes during infarction and that inhibition 
of miR-320a leads to reduced infarction size.25 Furthermore, miR-320a showed a protec-
tive effect on left ventricular remodeling after myocardial ischemia-reperfusion injury in 
a rat model.26 The results of the current study are in line with these previous studies, and 
further expand the evidence concerning miR-320a by showing that baseline measure-
ments are independently associated with adverse prognosis in patients with HF, and 
that repetitively-measured miR-320a is independently associated with heart failure 
hospitalization in particular. The temporal pattern of miR-378a-3p was also associated 
with the primary endpoint. Naga Prasad et al showed downregulation of miR-378a-3p in 
left ventricular free wall tissue of HF patients with dilated cardiomyopathy.4 In contrast, 
in the current study we examined circulating levels of miR-378a-3p. In addition, Weber 
et al found higher levels of circulating miR-378a-3p in 5 patients with coronary artery 
disease, compared to 5 healthy controls.27 However, studies other than ours on the 
prognostic value of miR-378a-3p in patients with HF are lacking.
Repeatedly measured, highly-abundant miRs only showed age-and sex-adjusted 
significant associations with the primary endpoint, and associations disappeared after 
multivariable adjustment. Possibly, prognostic information of these circmiRs, which are 
probably not produced by the heart, can be easily diluted. Conversely, myomiRs, i.e. miRs 
which are skeletal- and cardiac-muscle specific, carry potential to provide prognostic 
information that is incremental to clinical characteristics. Such myomiRs play a central 
role in myogenesis regulation and muscle remodeling.28,29 Although the main sources of 
circulating myomiRs, and in particular the relationship between myomiRs in tissue and 
plasma have yet to be fully elucidated, an association between cardiac damage (caused 
by myocardial infarction or myocarditis) and upregulation of circulating myomiRs has 
been previously demonstrated.15 Moreover, circulating myomiR levels have been as-
sociated with skeletal muscle wasting.30 We examined several myomiRs in the current 
investigation (miR133a-3p, miR133b, miR208a-3p and miR499a-5p). However, myomiRs 
are lowly expressed in the circulation, as illustrated by the fact that they were non-
detectable in a large proportion of the samples available in our study. Thus, we were 
forced to perform a simplified analysis and examined the association between presence 
of detectable myomiR levels at baseline and occurrence adverse events. The loss of 
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information inherent to such an analysis may have obscured potential associations with 
the outcome. Therefore, more sensitive assays are needed to properly examine the roles 
of myomiRs in HF.
To remove noise by less robust QPCR results we designed and implemented a strict 
and conservative algorithm to remove unreliable QPCR data, and at the same time retain 
reliable assessment of ‘too low to detect’ signals. Furthermore, we used miR486-5p to 
normalize our data, as using such endogenous miRs for this purpose has been shown 
to carry advantages.17 We have separately described our quality control algorithm we 
used here (provided for review purposes) and given the strong concordance between 
three large cohorts we have thus measured strengthens the point of view that such 
algorithms help to remove noise and improve reproducibility.
Some aspects of this study warrant consideration. First, aortic banding has been used 
to model heart failure. This is a model that shows strong similarity to the TAC model in 
mice and has previously been used in multiple studies as a model for pressure-overload 
hypertrophy.31-34 This model may not be fully representative of human left ventricular 
dysfunction. However, our observation that miR 1306-5p, identified in our swine model, 
does provide prognostic potential in the clinic, underscores the validity of our approach. 
Second, we did not adjust our analyses for multiple comparisons, because the miRs we 
examined were not selected in a hypothesis-free manner but had resulted from previ-
ous fundamental and clinical studies. Nevertheless, if we applied Bonferroni correction, 
the results would remain statistically significant. The association between repeated 
miR1306-5p and the primary endpoint rendered a HR(95%CI) of 4.69(2.18–10.06) and 
a p-value < 0.0001; since we examined 7 repeatedly measured miRs, the Bonferroni 
threshold for the p-value would be 0.05/7=0.007. Furthermore, we focused on patients 
with known heart failure. Studies using a healthy control group may provide insights 
into temporal miR patterns in healthy persons.
In conclusion, in patients hospitalized for AHF, baseline and repeatedly-assessed miR-
1306-5p was independently associated with adverse clinical outcome. Associations of 
temporal patterns of miR-320a, miR-378a-5p, miR-423-5p and miR-1254 with adverse 
clinical outcome were not independent of clinical characteristics. Myocyte-specific miRs 
were non-detectable in a large proportion of the samples. More sensitive myomiR assays 
are needed in order to precisely estimate the risk associated with elevated levels of miRs 
such as miR1306-5p, and to investigate whether cardiac specific myomiRs on their part 
are capable of providing additional information to established, clinical risk predictors.
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suPPLemeNtAL methods
Preclinical study in pigs
Aortic banding and plasma and tissue harvesting
Experiments were performed in AoB-treated (n=29) and sham-operated (n=21) York-
shire x Landrace swine of either sex weighing 25-30 kg. All procedures were performed 
in compliance with the “Guiding principles in the care and use of animals” as approved by 
the Council of the American Physiological Society and under the regulations of the Ani-
mal Care Committee of the Erasmus University Medical Center. Swine were sedated with 
ketamine (20 mg/kg, i.m.) and midazolam (1 mg/kg, i.m.), Under isoflurane anesthesia, a 
left thoracotomy was performed and the proximal ascending aorta was dissected free, 
and, in AoB-animals a band was placed, resulting in a systolic pressure gradient of 68±3 
mmHg. Subsequently, the chest was closed and the animals were allowed to recover. Up 
to eight weeks later, swine we re-anesthetized with sodium pentobarbital (15 mg/kg, 
i.v.), intubated, and placed on a positive-pressure ventilator (O2:N2=1:3 v/v). Catheters 
were inserted into the right external jugular vein for infusion of physiological saline and 
sodium pentobarbital (10-15 mg/kg/h) to maintain anesthesia. Following sternotomy, 
fluid-filled catheters were surgically inserted into the aorta for measurement of aortic 
blood pressure and sampling of arterial blood. The anterior interventricular vein was 
cannulated with a 20-gauge catheter for coronary venous blood sampling. Subsequent-
ly, arterial and coronary venous blood samples were simultaneously obtained, followed 
by arresting and excision of the heart and harvesting of myocardial tissue samples from 
the left ventricular anterior wall.
Swine were sacrificed at three time-points, being 1, 3 and 8 weeks after AoB. The pres-
sure gradient across the aortic banding did not result in overt heart failure at any of 
these time-points in the present study. Retrospective analysis did not show differences 
in miR expression between the different time point (although our study may not have 
been sufficiently powered to detect such differences).
Alignment of rNA-seq reads to the genome
All known hairpin sequences belonging to Sus Scrofa (pig), Homo Sapiens (human), Bos 
Taurus (cow) and Equus Caballus (horse) were downloaded from release 20 of miRBase. A 
blast database containing these species-specific hairpin sequences was generated. First, 
reads from all RNA-seq fastq files were aligned to pig hairpin sequences using BLASTN. 
Reads failing to map to pig hairpins were then aligned to human, cow and horse hairpin 
sequences using BLASTN. To further increase alignment efficiency, reads that remained 
unaligned were mapped to version 10.2 of the Sus Scrofa ncRNA and cDNA database, 
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downloaded from Ensembl. In cases where a sequence was mapped to multiple hairpins, 
the one with the higest bitscore, i.e. the best alignment, was chosen.
QPcr measurement of selected mirs for assessment of trans-coronary gradient
RNA was extracted from 200µl plasma using 750µl TRIzol LS reagent (Invitrogen Corp., 
Carlsbad, CA) and was incubated for 10 minutes at room temperature followed by 200µl 
chloroform. The mixture was centrifuged at 12,000 g for 10 minutes, and the aqueous 
layer was transferred to a new tube. RNA was precipitated by isopropanol and washed 
with 75% ETOH subsequently. RNA pellet was dissolved in 50 µl RNAse free water.
The primers used for qPCR were: 133b: TTTGGTCCCCTTCAACCAGCTAT; miR-28-3p: 
CACTAGATTGTGAGCTCCTGGA; miR-99: AACCCGTAGATCCGATCTTGTG; miR-486-5p: 
TCCTGTACTGAGCTGCCC CGAG; miR-133a: TTGGTCCCCTTCAACCAGCTG; miR-103: 
AGCAGCATTGTACAGGGCTATGA; miR-1306-5p: CCACCTCCCCTGCAAACGTCC A; miR-7f: 
TGAGGTAGTAGATTGTATAGTT; miR-143: TGAGATGAAGCACTGTAGCTC.
Number of animals sacrificed: considerations
A total of 8 swine were used for next generation sequencing (NGS), and a total of 50 
swine for qPCR. The number of animals used may thus seem quite large for identifying 
a single novel miR. However, with NGS, we detected a much larger number of miRs that 
were either differentially regulated or highly expressed in the myocardium, of which a 
smaller number was tested with qPCR, to identify a transcoronary gradient. Only the most 
promising one was subsequently tested as a clinical biomarker. Furthermore, it should 
be noted that the swine material used in the present study was not specifically collected 
for this study alone, but is part of a biobank that was developed as part of a larger study 
aimed at correlating changes in tissue morphology, proteomics, metabolomics and ge-
nomics to well-characterized hemodynamics in an animal model of pressure-overload 
hypertrophy. This means that a large number of samples was available, and only part of 
these samples were used for validation of our NGS results.
clinical study
Blood collection
Non-fasting blood samples were obtained by venipuncture and transported to the clini-
cal chemistry laboratory of each participating hospital for further processing according 
to a standardized protocol. Blood aliquots were subsequently stored at a temperature 
of -80ºC within 2 hours after venipuncture. Subsequently, stored EDTA plasma samples 
were transported under controlled conditions to ACS Biomarker BV, Amsterdam, The 
Netherlands, where a selection of miRs was measured batch-wise.
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mir measurements
Reverse transcriptase of miRs
cDNA was obtained from high abundant miRNAs (miR-1254, -378a-3p, -423-5p, -320a, 
-345-5p, -22-3p, -486-5p) using the miScript reverse transcription kit (Qiagen, Venlo, 
Netherlands) according to the manufacturer’s instruction. More specifically, the RT reac-
tion consisting of 7.5μl RNA from the isolation, 0.5µl miscript RT and 2µl of 5x RT Buffer 
was incubated at 37 °C for 60 minutes and at 95°C for 5 minutes and the held at 4°C for 
5 minutes.
For less abundant miRNAs (miR-133a-3p, -133b, -208a-3p, -499a-5p, -622, -1306-5p), 
qScript™ microRNA cDNA Synthesis Kit (Quanta BioSciences, Gaithersburg, USA) was 
used, according to the manufacturer’s protocol. Specifically, first, a poly(A) tailing reac-
tion was performed using 3 µl of RNA, 2µl of poly(A) tailing Buffer (5x) 4µl of nuclease-free 
water and 1µl Poly(A) polymerase. This was incubated for 60 minutes at 37 °C followed 
by 5 minutes on 70 °C. Subsequently, 10 µl of this poly(A) tailing reaction, 9 µl of miRNA 
cDNA reaction mix and 1 µl of qscript RT were incubated for 20 minutes at 42 °C followed 
by 5 minutes at 85 °C. Both a non-template control and a no-RT control were included in 
the sample tot ensure that products were not the results of genomic DNA of RNA.
Quantification of miRNA expression by RT-qPCR
Expression levels of miRNAs of each miRNA were quantified by RT-qPCR using Sybr 
Green (Roche, Basel, Switzerland) and miRNA primers (Eurofins, Ebersberg, Germany) in 
a total mix of 10µl according to the manufacturer’s instruction. This mix contained 5 µl 
of SybrGreen dye, 0.5 µl of forward primer, 0.5 µl of reverser primer, 2 µl of RNase-free 
water and 2 µl of template DNA. RT-qPCR reactions were run in duplicates on the Light 
cycler 480. The reaction mixture was pre-incubated at 5 °C for 10 seconds, followed by 
45 cycles of 95 °C for 10 seconds, 58 °C or 55 °C for 20 seconds (dependent on the primer 
character) and 72 °C for 30 seconds . Melting curve analysis was done by hand and 
melting curves were marked as bad when the melting curve deviated from the tissue 
control or showed multiple peaks that could not be distinguished from the amplicon. 
Data were analyzed using LinRegPCR quantitative qPCR data analysis software version 
2014.61. The primers used were: miR-133b: TTGGTCCCCTTCAACCAGCTA; miR-1254: 
CTGGAAGCTGGAGCCTGC; miR-378a-3p: ACTGGACTTGGAGTCAGAAGG; miR-423-5p: 
TGAGGGGCAGAGAGCGAGACTTT; miR-320a: AAAAGCTGGGTTGAGAGGGCGA; miR-
345-5p: GCTGACTCCTAGTCC; miR22-3p: AAGCTGCCAGTTGAAGAACTGT; miR-1306-5p: 
CCACCTCCCCTGCAA ACGTCCA; miR-133a-3p: TTGGTCCCCTTCAACCAGCTG; miR-622: 
ACAGTCTGCTGAGGTTG; miR-499a-5p: GACTTGCAGTGATGTT; miR-208a-3p: ATAAGAC-
GAGCAAAAAGCTTGT; miR-486-5p: TCCTGTACTGAGCTG.
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Normalization using miR-486-5p
In a previous study, we showed that for normalization endogenous miRNAs are preferred 
over normalization with a spike-in (e.g. Cel39 spike-in) or small RNAs (e.g. RNU6B).1 To 
date, however no plasma normalization panel with endogenous miRNAs has been de-
scribed in the literature. To function as a good normalizer, an endogenous miRNA must 
be stably expressed and abundant in plasma.2 In the current study, RNA sequencing of 
plasma samples revealed that miR-486-5p was the most abundant miRNA (>90% of all 
measured miRNAs) in plasma. Next, we used the geNorm algorithm3 to calculate the 
M-value and coefficient of variation and used these characteristics to assess which miR-
NAs were most stable and suitable for normalization in 2 clinical cohorts (Bayes-Genis 
et al, manuscript submitted back-to-back). Among the measured miRNAs, miR-486-5p, 
displayed highest stability (see supplemental table 8). We compared its stability to miR-
320a as in these large cohorts miR-320 appeared also as very stable. It should be noted 
that miR-320a has been identified as a putative biomarker for HF so that we did not 
choose this microRNA for normalization, but merely to assess the effect of using a dif-
ferent normalizer. Therefore, miR-486-5p (mean M-value 0.68) was used as the primary 
normalizer.
Nt-proBNP measurements
For batch analysis of NT-proBNP, heparin plasma samples were transported under 
controlled conditions to the Canisius Wilhelmina Hospital, Nijmegen, The Netherlands, 
where measurements were conducted using the Elecsys NT-proBNP assay on a Cobas 
8000 analyzer (Roche Diagnostics Limited, Rotkreuz, Switzerland)
statistical analysis
Normally distributed continuous variables are presented as mean ± standard deviation 
(SD). Non-normally distributed continuous variables are expressed as median and inter-
quartile range (IQR). Categorical data are displayed as count and percentage.
The associations between the baseline miR measurements and the risk of a study 
endpoint were assessed using Cox proportional hazards models. First, analyses were 
performed unadjusted. Subsequently, we corrected for age and gender. Finally, addi-
tional multivariable adjustment was performed. Potential confounders were selected 
based on previous literature and included systolic blood pressure, diabetes mellitus, 
atrial fibrillation, BMI, previous hospitalization for HF during the last 6 months, ischemic 
HF, baseline eGFR, and baseline NT-proBNP level. Individual covariates each contained 
less than 7% missing values. Data on all covariates were complete in 87% of the patients. 
Multiple imputation was applied to account for missing covariates. For abundant miRs 
(miR-1254, miR-22-3p, miR-345-5p, miR-378a-3p, miR-423-5p, miR-320a, miR-1306-5p), 
the results are presented as hazard ratios (HR) per ln[arbitrary unit] of miR level with 
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95% confidence intervals (CI). For low-abundance miRs, a different approach had to be 
chosen because their low expression levels did not allow for these miRs to be entered 
into the models as continuous variables. Thus, they were entered into the models as 
dichotomous variables (detectable versus non-detectable, as defined by the algorithm 
described above), and HRs were presented accordingly. First, analyses were performed 
in the full cohort. Subsequently, a sensitivity analysis was performed in the patients with 
HF with reduced ejection fraction.
Subsequently, repeated miR measurements were examined in relation to the risk of a 
study endpoint. The primary endpoint consisted of all-cause mortality and readmission 
for HF, whichever occurred first. Thus, all measurements drawn up to the moment of 
the first readmission for HF, or mortality, were used for these analyses. Specifically, as-
sociations between the current level of each separate miR at a particular time point and 
the risk of an endpoint at that same time point were assessed using a joint modeling 
approach, which combines a linear mixed-effects model for the repeated miR measure-
ments with a Cox proportional hazards model for the risk of experiencing the event of 
interest. For the mixed model, we used cubic splines, with knots set at 1 week and 1 
month after initial hospitalization. Analyses were first performed without adjustment, 
and were subsequently adjusted for the potential confounding variables listed above. 
The results are presented as hazard ratios (HRs) per ln[arbitrary unit] miR concentration 
at any point in time, along with the corresponding 95% CIs. These analyses were not 
performed for low-abundance miRs, because their low expression levels did not allow 
so.
To assess incremental predictive value of baseline miR-1306-5p and baseline NT-
proBNP levels for the primary endpoint, C-statistics, continuous Net Reclassification In-
dices (NRIs) and Integrated Discrimination Indices (IDIs) were calculated for subsequent 
addition of these biomarkers to a model containing age, sex, systolic blood pressure, 
diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 6 
months, ischemic HF, and baseline eGFR.
All analyses were performed with R Statistical Software using package JM.4,5 All tests 
were two-tailed and p-values <0.05 were considered statistically significant.
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supplemental table 1 – Number of detectable, non-detectable and missing mir measurements
N = 2214 detectable Non-detectable invalid
miR-486-5p 1677 99 438
miR-320a 1599 20 595
miR-1254 1574 31 609
miR-22-3p 1444 319 451
miR-378a-3p 1409 363 442
miR-423-5p 1408 205 601
miR-345-5p 884 1066 264
miR-1306-5p 727 650 837
miR-133a-3p 494 1488 232
miR-499a-5p 103 1946 165
miR-133b 85 1959 170
miR-622 56 1848 310
miR-208a-3p 6 2100 108
MiR = MicroRNA.
supplemental table 2 – Baseline characteristics stratified by invalid versus valid for baseline mir-1306-5p
Variable invalid (n=166) Valid (n=290) p-value
demographic characteristics [iQr] or (%)
Age 73 [63 - 78] 74 [65 - 80] 0.12
Female 38.6 (64) 35.5 (103) 0.52
Caucasian 92.2 (153) 95.5 (277) 0.14
measurements at baseline [iQr] or (%)
Body mass index 27.6 [24.6 - 31.8] 27.5 [24.8 - 30.9] 0.68
Systolic blood pressure 130 [110 - 150] 124 [110 - 145] 0.22
Diastolic blood pressure 75 [66 - 90] 73 [64 - 85] 0.09
Heart rate 85 [72 - 101] 85 [71 - 100] 0.59
eGFR 45 [31.9 - 61.1] 46.7 [35.7 - 61.9] 0.29
Left ventricular ejection fraction 31 [23 - 45] 30 [21 - 40] 0.54
Heart failure with reduced ejection fraction 79.2 (103) 80.2 (186) 0.83
NT-proBNP 4046.5 [1943.2 - 9835] 4165 [2173 - 8556.8] 0.78
medical history (%)
Previous heart failure admission within 6 months 26.5 (44) 15.9 (46) 0.006
Ischemic heart disease 48.2 (80) 48.1 (139) 0.98
Myocardial infarction 40.4 (67) 40.3 (117) 1
Hypertension 51.2 (85) 49.3 (143) 0.7
Atrial fibrillation 41 (68) 43.4 (126) 0.61
Diabetes Mellitus 39.2 (65) 34.9 (101) 0.37
Stroke 19.3 (32) 16.6 (48) 0.46
IQR = Inter-quartile range, eGFR = estimated glomerular filtration rate.
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supplemental table 3 – mir expression levels in patients with hfref versus patients with hfpef
mir
expression values of
hfpef patients (n=352)
median [iQr]
expression values of
hfref patients (n=1457)
median [iQr] p-value
1254 2.6 [1.4 – 4.9] 2.3 [1.3 - 4.6] 0.3
486.5p 37 [98 - 920] 20 [13 - 150] <0.001
423.5p 1.5 [0.48 - 5.5] 2.0 [0.55 – 7.0] 0.044
378a-3p 0.18 [0.046 – 0.49] 0.21 [0.065- 0.67] 0.031
345.5P 0.12 [0.12 – 1.4] 0.12 [0.12 – 3.1] <0.001
320a 19 [6.6 - 49] 27 [8.7 – 72] 0.0019
22.3p 2.9 [0.19 – 21] 5.7 [0.42 - 36] 0.017
208a 0.02 [0.02 – 0.02] 0.02 [0.02 – 0.02] 0.27
499a.5p 0.009 [0.009 – 0.009] 0.009 [0.009 – 0.009] 0.95
1306-5p 0.04 [0.012 – 0.19] 0.04 [0.012 – 0.19] 0.7
622 0.012 [0.012 -0.012] 0.012 [0.012 -0.012] 0.43
133b 0.014 [0.014 – 0.014] 0.014 [0.014 – 0.014] 0.88
133a-3p 1.0 [1.0 – 1.0] 1.0 [1.0 – 1.0] 0.67
All expression values were multiplied by 108.
HFrEF = Heart failure with preserved ejection fraction, HFrEF = Heart failure with reduced ejection fraction, 
IQR = Inter-quartile range, miR = microRNA
supplemental table 4 - Associations between baseline microrNA levels and secondary endpoints
miR
Hazard ratio (95% CI)
Model 1 Model 2 Model 3
All-cause mortality 320a* 1.10 (0.98 - 1.23) 1.08 (0.96 – 1.21) 0.98 (-0.87 – 1.10)
1254* 0.99 (0.90 – 1.10) 0.98 (0.88 – 1.08) 0.93 (0.84 – 1.04)
22-3p* 1.00 (0.90 – 1.11) 1.01 (0.91 – 1.12) 0.99 (0.89 – 1.11)
378a-3p* 0.98 (0.86 – 1.11) 0.97 (0.85 – 1.10) 0.92 (0.80 – 1.06
423-5p* 1.00 (0.88 – 1.13) 1.01 (0.89 – 1.15) 0.98 (0.87 – 1.10)
345-5p* 0.97 (0.89 – 1.06) 0.97 (0.88 – 1.06) 0.92 (0.83 – 1.02)
1306-5p* 1.10 (0.98 – 1.25) 1.09 (0.97 – 1.23) 1.03 (0.90 – 1.17)
133a-3p† 0.82 (0.49 – 1.39) 0.92 (0.54 – 1.57) 1.11 (0.64 – 1.92)
499a-5p† 2.25 (1.09 – 4.66) 0.92 (0.54 – 1.57) 2.04 (0.96 – 4.43)
133b† 1.40 (0.52 – 3.82) 1.40 (0.51 – 3.82) 1.55 (0.54 – 4.43)
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supplemental table 4 - Associations between baseline microrNA levels and secondary endpoints 
(continued)
miR
Hazard ratio (95% CI)
Model 1 Model 2 Model 3
Heart failure 
hospitalizations
320a* 1.26 (1.13 – 1.40) 1.27 (1.14 – 1.41) 1.19 (1.06 – 1.33)
1254* 1.12 (1.03 – 1.23) 1.12 (1.03 – 1.29) 1.06 (0.97 – 1.17)
22-3p* 1.05 (0.96 – 1.15) 1.06 (0.97 – 1.16) 1.02 (0.93 – 1.12)
378a-3p* 1.15 (1.03 – 1.29) 1.15 (1.03 – 1.29) 1.13 (1.00 – 1.28)
423-5p* 1.20 (1.06 – 1.35) 1.20 (1.06 – 1.36) 1.16 (1.02 – 1.31)
345-5p* 1.06 (0.98 – 1.15) 1.06 (0.98 – 1.15) 1.03 (0.94 – 1.12)
1306-5p* 1.27 (1.15 – 1.40) 1.27 (1.15 – 1.40) 1.22 (1.10 – 1.36)
133a-3p† 0.73 (0.44 – 1.21) 0.73 (0.44 – 1.22) 0.75 (0.44 – 1.29)
499a-5p† 1.09 (0.45 – 2.68) 1.09 (0.44 – 2.69) 0.89 (0.35 – 2.25)
133b† 0.56 (0.14 – 2.29) 0.56 (0.14 – 2.28) 0.71 (0.17 – 2.99)
Model 1 unadjusted; model 2 adjusted for age and sex; model 3 adjusted for age, sex, systolic blood pres-
sure, diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 6 months, isch-
emic HF, baseline eGFR, and baseline NT-proBNP level. BMI = Body mass index, HF = Heart failure, miR = 
MicroRNA. Primary endpoint: composite of all-cause mortality and readmission for heart failure
* Hazard ratio per per ln[arbitrary unit] of miR level
† Hazard ratio of detectable vs. non-detectable miR level
supplemental table 5 - Associations between baseline microrNA levels and primary endpoint in the 
subgroup of hfref fraction patients
mir
hazard ratio (95% ci)
model 1 model 2 model 3
320a* 1.14 (1.01 – 1.29) 1.13 (1.00 – 1.29) 1.08 (0.95 – 1.24)
1254* 1.01 (0.91 – 1.11) 0.99 (0.89 – 1.10) 0.96 (0.86 – 1.07)
22-3p* 1.00 (0.91 – 1.11) 1.01 (0.92 – 1.12) 0.95 (0.85 – 1.06)
378a-3p* 1.01 (0.88 – 1.15) 1.00 (0.87 – 1.14) 0.96 (0.83 – 1.11)
423-5p* 0.99 (0.87 – 1.13) 1.00 (0.88 – 1.15) 1.01 (0.89 – 1.16)
345-5p* 0.98 (0.89 – 1.07) 0.96 (0.88 – 1.05) 0.95 (0.86 – 1.04)
1306-5p* 1.13 (1.00 – 1.27) 1.12 (0.99 – 1.27) 1.09 (0.95 – 1.25)
133a-3p† 0.64 (0.36 – 1.15) 0.71 (0.39 – 1.29) 0.94 (0.51 – 1.77)
499a-5p† 1.34 (0.54 – 3.29) 1.41 (0.57 – 3.47) 1.20 (0.47 – 3.07)
133b† 0.63 (0.15 – 2.55) 0.63 (0.16 – 2.57) 1.04 (0.24 – 4.59)
Model 1 unadjusted; model 2 adjusted for age and sex; model 3 adjusted for age, sex, systolic blood pres-
sure, diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 6 months, isch-
emic heart failure, baseline eGFR, and baseline NT-proBNP level. BMI = Body mass index, HFrEF = Heart 
failure with reduced ejection fraction, miR = MicroRNA. Primary endpoint: composite of all-cause mortality 
and readmission for heart failure
* Hazard ratio per ln[arbitrary unit] of miR level
† Hazard ratio of detectable vs. non-detectable miR level
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supplemental table 6 - Associations between repeated microrNA measurements and secondary 
endpoints
Endpoint MiR Hazard ratio (95% CI)
Model 1 Model 2 Model 3
All-cause mortality 320a 1.20 (0.93 – 1.54) 1.16 (0.90 – 1.50) 0.89 (0.69 – 1.15)
1254 1.21 (0.94 – 1.56) 1.17 (0.91 – 1.52) 0.87 (0.66 – 1.15)
22-3p 1.17 (0.82 – 1.67) 1.24 (0.88 – 1.76) 1.16 (0.81 – 1.65)
378a-3p 1.28 (0.89 – 1.75) 1.22 (0.90 – 1.66) 0.86 (0.61 – 1.22)
423-5p 1.25 (0.89 – 1.75) 1.21 (0.87 – 1.68) 0.83 (0.57 – 1.19)
345-5p 0.99 (0.79 – 1.24) 0.94 (0.75 – 1.18) 0.82 (0.64 – 1.05)
1306-5p 2.78 (1.43 – 5.38) 1.83 (1.15 – 2.90) 2.31 (1.15 – 4.64)$
Heart failure 
hospitalizations
320a 1.54 (1.20 – 1.98) 1.54 (1.20 – 1.98) 1.30 (1.00 – 1.69)
1254 1.30 (1.02 – 1.66) 1.29 (1.01 – 1.66) 1.06 (0.83 – 1.35)
22-3p 1.27 (0.93 – 1.73) 1.26 (0.93 – 1.70) 1.14 (0.83 – 1.55)
378a-3p 1.43 (1.05 – 1.95) 1.43 (1.05 – 1.95) 1.06 (0.77 – 1.47)
423-5p 1.71 (1.22 – 2.41) 1.71 (1.21 – 2.40) 1.30 (0.92 – 1.84)
345-5p 1.18 (0.95 – 1.47) 1.19 (0.95 – 1.48) 1.10 (0.88 – 1.37)
1306-5p 5.50 (2.21 – 13.69) 3.95 (1.89 – 8.26) 4.95 (2.02 – 12.12)
Model 1 unadjusted; model 2 adjusted for age and sex; model 3 adjusted for age, sex, systolic blood pres-
sure, diabetes mellitus, atrial fibrillation, BMI, previous hospitalization for HF during the last 6 months, isch-
emic HF, baseline eGFR, and baseline NT-proBNP level. BMI = Body mass index, HF = Heart failure, miR = 
MicroRNA. Primary endpoint: composite of all-cause mortality and readmission for heart failure
* Hazard ratio per per ln[arbitrary unit] of miR level
† Hazard ratio of detectable vs. non-detectable miR level
supplemental table 7 - Added predictive value of baseline mir-1306-5p and baseline Nt-proBNP 
levels for the primary endpoint
c -statistic
(95% ci)
change in 
c-statistic (95% ci)
cNri (95% ci) idi (95% ci)
miR-1306-5p 0.619
(0.562 – 0.677)
NT-proBNP 0.607
(0.566 – 0.648)
Model 0.677
(0.634 – 0.721)
Model + miR-1306-5p 0.694
(0.649 – 0.739)
0.017
(-0.004, 0.038)
0.138
(-0.004 – 0.280)
0.024
(-0.012 – 0.059)
Model + NT-proBNP 0.698
(0.655 – 0.740)
0.020
(0 – 0.041)
0.074
(-0.053 – 0.201)
0.027
(-0.005 – 0.058)
Model + NT-proBNP + 
miR-1306-5p
0.709
(0.665 – 0.754)
0.012
(-0.006 – 0.029)
0.125
(-0.016 – 0.267)
0.020
(-0.013 – 0.053)
Model: age, sex, systolic blood pressure, diabetes mellitus, atrial fibrillation, BMI, previous hospitalization 
for HF during the last 6 months, ischemic HF, and baseline eGFR
BMI = Body mass index, cNRI = continuous net reclassification improvement, HF = Heart failure, IDI = inte-
grated discrimination improvement, miR = MicroRNA
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Part III
Novel insights in characteristics 
associated with favorable outcome in 
defibrillation therapy and response to 
cardiac resynchronization therapy

Chapter 9
Functional response to cardiac 
resynchronization therapy is associated 
with improved clinical outcome and 
absence of appropriate shocks
Nick van Boven, Kjell Bogaard, Jaap H. Ruiter, Geert P. Kimman, Dominic A. Theuns, 
Isabella Kardys, Victor A. Umans
J Cardiovasc Electrophysiol. 2013 Mar;24(3):316-22
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ABstrAct
Background: We evaluated clinical outcome and incidence of (in)appropriate shocks 
in consecutive chronic heart failure (CHF) patients treated with CRT with a defibrillator 
(CRT-D) according to functional response status. Furthermore, we investigated which 
factors predict such functional response.
methods: In a large teaching hospital, 179 consecutive CHF patients received CRT-D in 
2005-2010. Patients were considered functional responders if left ventricular ejection 
fraction (LVEF) increased to ≥35% post-implantation. Analysis was performed on 142 
patients, who had CRT-D as primary prevention, complete data and a baseline LVEF 
<35%. Endpoints consisted of all-cause mortality, heart failure (HF) hospitalizations, 
appropriate shocks and inappropriate shocks.
results: Median follow-up was 3.0 years (interquartile range (IQR)1.6 – 4.4) and median 
baseline LVEF was 20% (IQR 18 – 25%). The functional response-group consisted of 42 
patients. In this group no patients died, none were hospitalized for HF, none received ap-
propriate shocks and 3 patients (7.1%) received ≥1 inappropriate shocks. In comparison, 
the functional non-response-group consisted of 100 patients, of whom 22 (22%) died 
(p=0.003), 17 (17%) were hospitalized for HF (p=0.007), 17 (17%) had ≥1 appropriate 
shocks (p=0.003) and 8 (8.1%) received ≥1 inappropriate shocks (p=0.78). Multivariable 
analysis showed that left bundle-branch block (LBBB), QRS duration ≥150ms and no 
need for diuretics at baseline are independent predictors of functional response.
conclusions: Functional responders to CRT have a good prognosis and rarely need ICD 
therapy. LBBB, QRS duration ≥150ms and lack of chronic diuretic use predict functional 
response.
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iNtroductioN
Several large studies have demonstrated that cardiac resynchronization therapy (CRT) 
improves overall survival, reduces heart failure (HF) hospitalizations and induces cardiac 
reversed remodeling in patients suffering from chronic heart failure (CHF) and wide 
QRS-complexes.1-5 Some patients respond very well to CRT and reach a left ventricular 
ejection fraction (LVEF) of ≥35% after implantation. In this paper we refer to these 
patients as functional responders. Not much is known about differences in prognosis 
between functional responders and functional non-responders.
Most patients are assigned to a CRT device with a defibrillator (CRT-D) as a backup, 
which increases survival by means of appropriate defibrillator-shocks, but also carries 
the negative effects of inappropriate shocks. If functional responders could be shown 
to have an excellent prognosis in terms of clinical outcomes, patients could be assigned 
to CRT-P instead of CRT-D once they have reached functional response and a device 
change is needed. Furthermore, if functional response to CRT could be predicted be-
forehand, one may even consider assigning patients likely to functionally respond to 
CRT-P primarily.
In this paper, we investigated whether functional response to CRT-D therapy is associ-
ated with a favorable outcome. For, this purpose, we retrospectively studied a cohort of 
consecutive patients treated with CRT-D in a large teaching hospital. In this cohort we 
evaluated the difference in clinical outcome (mortality and heart failure hospitalizations) 
and incident (in)appropriate shocks between functional responders and functional non-
responders. Secondly, we identified patient characteristics associated with a functional 
response.
methods
study design, patients and baseline characteristics
The population of this retrospective, single-center, follow-up study consisted of 179 
patients that were consecutively assigned to CRT-D in a large teaching hospital between 
February 2005 and December 2010. Therapy assignment was based on the ESC guide-
lines for cardiac pacing and cardiac resynchronization therapy.6 All patients suffered from 
chronic heart failure for at least 3 months and were receiving optimal pharmacologic 
therapy. The pharmacologic treatment consisted of diuretics, angiotensin-converting–
enzyme inhibitors or Angiotensin II antagonists, beta-blockers, and spironolactone, 
unless one of these was not tolerated or contraindicated. Diuretics were only prescribed 
if needed. Coronary angiography was performed on all patients before CRT-D implanta-
tion and patients underwent revascularization if needed and possible.
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Baseline characteristics of all patients were collected by reviewing hospital records 
and included demographics, medical history, medication use, cardiovascular risk factors 
and pacing and electrocardiographic characteristics. Patients were only considered us-
ers of specific medication if they used the drug chronically.
LVEF was measured with the biplane Simpson’s method in the apical 4- and 2-cham-
ber views and averaged. Baseline echocardiograms used were generally performed 2-3 
months (with a maximum of 1 year) prior to CRT-D implantation. After implantation, 
echocardiographic optimization of atrioventricular (AV) delay was performed at 4 weeks 
follow-up. Subsequently, echocardiographic assessment of LV-function was performed 
3 months after this AV optimization according to protocols used in literature.2,7,8 This 
last echocardiogram, performed 3 months after AV optimization, was used to measure 
follow-up LVEF and used to consider patients as functional responders or functional 
non-responders.
Intraventricular conduction disorders (IVCD) were defined according to the AHA/
ACCF/HRS recommendations for the standardization and interpretation of the electro-
cardiogram.9 Left bundle branch block (LBBB) criteria are: QRS duration ≥120 ms; QS or 
rS in lead V1; wide R (frequently notched) waves in leads I, aVL, V5, or V6; and absent q 
waves in leads V5 and V6. Right bundle branch block (RBBB) required QRS duration ≥120 
ms; rsr’, rsR’, rSR’, or qR in leads V1 or V2; and occasionally, a wide and notched R wave 
and wide S waves in leads I, V5, and V6. Not specific IVCD (NS-IVCD) is defined as: QRS 
duration >120ms, not meeting criteria for either LBBB or RBBB. Patient ECG’s with QRS 
duration<120 ms 1 day before implantation were counted as no-IVCD.
Placement procedure and icd follow-up
All patients received a CRT-D device (Medtronic inc. or Boston Scientific inc). First, the 
right ventricular (shock-) lead was positioned, mostly in the right ventricular apex us-
ing a cephalic cut down technique. Next, the LV pacing lead was inserted through the 
coronary sinus and positioned in the venous system, preferably in the (postero-)lateral 
vein. Finally, the atrial lead was positioned in the right atrial appendage. If transvenous 
LV pacing lead placement failed, an epicardial procedure was scheduled and performed. 
No major complications occurred. For each patient, both the atrioventricular interval to 
maximize mitral inflow duration and the interventricular mechanical delay, defined as 
the time interval between the onset of antegrade blood flow in the right ventricular out-
flow tract and the onset of antegrade blood flow in the LV outflow tract, were optimized 
by echocardiography 2 to 4 months after implantation.
As part of usual care, during follow-up, ICD printouts were obtained every 3 months 
to determine the number and type of arrhythmias and the number of appropriate and 
inappropriate shocks.
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follow-up and definition of endpoints
Follow-up on clinical events lasted until May 2011 and was performed by reviewing 
hospital records and by contacting general practitioners. Endpoints comprised death 
from any cause, heart failure (HF) leading to hospitalization, appropriate shocks and 
inappropriate shocks. Heart failure was defined as signs and symptoms consistent with 
congestive heart failure leading to hospitalization and requiring either intravenous or 
a (temporary) dose increase of oral diuretics. All heart failure events and therapy that 
followed were assessed by the attending cardiologist.
Patients were considered functional responders if LVEF improved to ≥35% post-
implantation. This definition was based on the inclusion criteria of several large CRT-D 
and ICD trials.1,1,10-12 In these trials, patients with an LVEF ranging from ≤30% to ≤35% 
were included.
Patients were excluded from the analyses if: 1) defibrillator therapy was assigned for 
secondary prevention, 2) pre-implantation LVEF was ≥35% according to echocardio-
graphic data, or 3) echocardiographic follow-up data were missing.
statistical analysis
Continuous patient characteristics were tested for normality by using the Kolmogorov-
Smirnov test. Subsequently, if skewed, continuous patient characteristics of functional 
responders and functional non-responders were compared using Mann-Whitney’s test. 
Categorical characteristics were compared by using the χ2 test.
Univariable and multivariable logistic regression were used to examine the association 
between patient baseline characteristics and functional response to CRT. Characteristics 
were entered into the multivariable model if they showed a statistically significant as-
sociation with the outcome during univariable analysis (P value <0.05). We investigated 
the performance of the combination of independent risk factors, resulting from the mul-
tivariable analysis, in the prediction of functional response. For this purpose a C-index 
was calculated using the area under the receiver operating characteristic (ROC) curve.
Kaplan-Meiers log-rank test was used to compare the differences in outcomes (all-
cause mortality, HF hospitalizations, appropriate shocks and inappropriate shocks) 
between functional responders and functional non-responders.
Overall statistical significance was set at a 2-tailed P value <0.05. SPSS 20.0 (SPSS Inc, 
Chicago, IL) was used for the statistical analysis.
resuLts
Of the 179 patients that were consecutively assigned to CRT-D, 13 were excluded, be-
cause they had backup defibrillation therapy as secondary prevention, 9 because LVEF 
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at baseline was ≥35% and 15 because of missing echocardiographic data (baseline or 
outcome) (figure 1). Functional response to CRT occurred in 42 patients and 100 patients 
were considered functional non-responders. Median overall improvement of LVEF of all 
142 study patients was 7.0% (IQR 0.0 – 15%). In the functional non-responders group 
the median improvement in LVEF was 3.0% (IQR -1.8 – 7.0%), compared to a median 
improvement of 20% (IQR 15 – 23%) in the functional responders group, P<0.001.
comparison of baseline characteristics between functional responders and 
functional non-responders
Baseline characteristics of the study population are shown in table 1. Median follow-up 
of the 142 consecutive patients was 3.0 (interquartile range (IQR) 1.6 – 4.4) years, and 
did not differ between both groups (P=0.64). Median age was 69 (IQR 61 – 74) years 
(P=0.40), and 70% was male (P=0.15).
In the functional responders group, non-ischemic cardiomyopathy (non-ICM) 
was more frequent, 41% vs. 62%, P=0.02, chronic diuretics use before CRT was less 
frequent, 96% vs 71%, P<0.001, and NYHA class was lower, P=0.03. In the functional 
non-responders group, median urea was 8.3 mmol/l and median creatinine 110 μmol/l. 
In comparison, median urea in the functional responders group was 6.1 mmol/l, P=0.001 
and median creatinine was 92 μmol/l, P=0.001. Finally, median baseline LVEF in the func-
tional responders group was 23%, compared to 20% in the functional non-responders 
group, P=0.003.
figure 1 - inclusion and exclusion of patients
* Patients who had a LVEF of ≥35% or very close to 35% during revision of the echocardiogram.
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comparison of electrocardiographic baseline characteristics between 
functional responders and functional non-responders
Table 2 displays the pacing and electrocardiographic baseline characteristics. The 
number of patients with an LBBB conduction disorder was significantly higher in the 
functional responders group, 93% vs. 62%, P<0.001. Another significant difference was 
found in the number of patients with a QRS duration ≥150ms, which was 88% in the 
functional responders group vs. 64% in the functional non-responders group, P=0.01.
A history of atrial fibrillation was found in 26% of all patients, which did not differ sig-
nificantly between both groups, P=0.42. An upgrade from CRT-P to CRT-D was found in 
3.5% and another 3.5% of all patients received an epicardial lead, because transvenous 
placement of the LV lead was considered sub-optimal. All patients with a NS-IVCD had 
wide left anterior fascicular blocks.
table 1 - Baseline characteristics
Variable total functional
non-responders 
(n=100)
functional
responders
(n=42)
P value
Age (years) 69 (61 – 74) 70 (61 – 74) 68 (61 – 73) 0.40
male gender 100 (70) 74 (75) 26 (62) 0.15
NYhA class i 15 (13) 6 (7,5) 9 (25) 0.03
ii 45 (39) 30 (38) 15 (42)
iii 52 (45) 40 (50) 12 (33)
iV 4 (3.4) 4 (5.0) 0 (0)
Non-icm 67 (47) 41 (41) 26 (62) 0.02
follow-up 3.0 (1.6 – 4.4) 3.1 (1.7 – 4.4) 2.9 (1.4 – 4.4) 0.64
hypertension 73 (51) 48 (48) 25 (60) 0.21
diabetes mellitus 30 (21) 21 (21) 9 (21) 0.95
smoking 68 (48) 50 (50) 18 (43) 0.44
Ace-i/Atii-a 139 (98) 97 (97) 42 (100) 0.56
diuretics 126 (89) 96 (96) 30 (71) <0.001
B-Blocker 129 (91) 92 (92) 37 (88) 0.46
serum urea (mmol/l) 8.1 (6.1 – 11) 8.3 (6.7 – 11) 6.1 (4.7 – 8.9) 0.001
serum creatinine (μmol/l) 105 (88 – 129) 110 (95 – 131) 92 (81 – 105) 0.001
serum BNP(ng/l) 402 (128 – 690) 467 (153 – 852) 219 (112 – 517) 0.17
LVef 20 (18 – 25) 20 (16 – 25) 23 (20 – 28) 0.003
Categorical variables are expressed as count (percentage). Valid percentages may vary for some counts, 
because of missing values. Continuous variables are expressed as median (first quartile - third quartile). 
Non-ICM = non-ischemic cardiomyopathy; ACE-I = Ace inhibitor; ATII-a = Angiotensin II antagonist; LVEF = 
left ventricular ejection fraction.
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difference in clinical outcome
The difference in clinical outcome between functional responders and functional non-
responders is shown in figure 2. In the functional responders group no patients died, 
no patients were hospitalized for HF, no patients had appropriate shocks and 3 patients 
(7.1%) had ≥1 inappropriate shocks. In comparison, in the functional non-response-
group 22 (22%) patients died, P=0.003, 15 (15%) of these were cardiac deaths (related 
to a cardiac cause, e.g. MI, low-output failure, fatal arrhythmia), 17 patients (17%) were 
hospitalized for HF, P=0.007, 17 patients (17%) had ≥1 appropriate shocks, P=0.007, and 
9 (9.0%) received ≥1 inappropriate shocks, P=0.77.
Logistic regression analyses
The association between baseline characteristics and cumulative probability of func-
tional response is shown in table 3. Although all baseline variables were analyzed, only 
the significant univariable predictors of functional response, which were subsequently 
also entered into the multivariable analysis, are displayed in this table.
Multivariable analysis showed that a LBBB conduction disorder (OR 14.7; CI 1.55 – 
140), no need for chronic diuretics at baseline (OR 0.05; CI 0.01 – 0.52) and QRS dura-
tion ≥150ms (OR 8.04; CI 1.15 – 56.4), were independently associated with functional 
response. A model containing these 3 independent predictors of functional response 
displayed discriminative ability, with a C-index of 0.88 (figure 3).
Given that LBBB and QRS duration ≥150ms often occur concurrently, and both char-
acteristics were found to be significant predictors, we performed an additional analysis 
table 2 – Pacing and electrocardiographic baseline characteristics
V
Variable
total functional
non-responders
(n=100)
functional
responders
(n=42)
P value
history of Af 37 (26) 28 (28) 9 (21) 0.42
LBBB 98 (71) 61 (62) 37 (93) <0.001
rBBB 7 (5.1) 7 (7.1) 0 (0) 0.08
Ns-iVcd 12 (8.7) 11 (11) 1 (2.5) 0.10
Pacemaker rhythm 18 (13) 16 (16) 2 (5.0) 0.07
No iVcd 3 (2.2) 3 (3.1) 0 (0) 0.56
Qrs >150ms 96 (71) 61 (64) 35 (88) 0.01
epicardial lead 5 (3.5) 3 (3.0) 2 (4.8) 0.63
crt-P 5 (3.5) 5 (5.0) 0 (0) 0.14
Variables are expressed as count (percentage). Valid percentages may vary for some counts, because of 
missing values. AF = Atrial fibrillation; LBBB = left bundle branch block; RBBB = right bundle branch block; 
NS-IVCD = not specific intraventricular conduction disorder; IVCD = intraventricular conduction disorder; 
CRT-P = Cardiac resynchronization therapy with a pacemaker only, upgraded to cardiac resynchronization 
therapy with a defibrillator.
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figure 2 - Kaplan-meier hazard curves of A) All-cause mortality; B) heart failure hospitalizations; c) 
Appropriate shocks; d) inappropriate shocks
table 3 – Association between patient characteristics and functional response
Variable crude or
(95% ci)
Adjusted or
(95% ci)
P-value
NYhA class 0.45 (0.26 – 0.78) 0.73 (0.32 – 1.67) 0.46
Non-icm 2.34 (1.12 – 4.90) 1.16 (0.32 – 4.18) 0.83
diuretics 0.10 (0.03 – 0.35) 0.05 (0.01 – 0.52) 0.01
serum urea (mmol/l) 0.81 (0.69 – 0.95) 0.97 (0.72 – 1.30) 0.84
serum creatinine (μmol/l) 0.82 (0.70 – 0.96) 0.83 (0.62 – 1.09) 0.18
LVef 1.10 (1.03 – 1.18) 1.05 (0.93 – 1.17) 0.45
LBBB 6.86 (1.55 – 30.5) 14.7 (1.55 – 140) 0.02
Qrs >150ms 3.90 (1.40 – 10.9) 8.04 (1.15 – 56.4) 0.04
Functional response occurred in 42 out of 142 patients. HR = hazard ratio; CI = confidence interval; Non-
ICM = non-ischemic cardiomyopathy; LVEF = left ventricular ejection fraction; AF = Atrial fibrillation; LBBB 
= left bundle branch block; CRT-P = Cardiac resynchronization therapy with a pacemaker only upgraded to 
cardiac resynchronization therapy with a defibrillator. Patients, who had no AF, had a sinus rhythm.
*Odds ratio for every 10 units increase.
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to further evaluate the role of their simultaneous presence. An LBBB combined with 
QRS≥150ms was observed in 73 patients, of whom 33 showed functional response. With 
univariable analysis, the functional non-responders with a LBBB and QRS≥150ms were 
found to be older (OR 1.08; CI 1.01 – 1.15), to more often have ischemic cardiomyopathy 
(OR 2.63; CI 1.01 – 6.80), and to have worse renal function (OR 1.23; CI 1.00 – 1.50).
In the population of patients with a LBBB, QRS≥150ms was a significant predictor 
of response (p=0.01), in contrast to the population without a LBBB (p=0.87), where 
QRS≥150ms was not a significant predictor of response. It should be noted that the non-
LBBB group was relatively small (n=37).
discussioN
In this retrospective study, performed on a population of CHF patients treated with CRT-
D, we found that 30% of heart failure patients with CRT-D therapy appeared to achieve a 
LVEF ≥35% after receiving CRT. During a median follow-up period of 3.0 years, these CRT 
functional responders were found to have a good prognosis, as none of them died and 
none of them was hospitalized for HF. Furthermore, none of these functional responders 
received appropriate shocks, while 7.1% received ≥1 inappropriate shocks. Secondly, we 
found that LBBB conduction disorder, QRS duration ≥150ms and no need for chronic 
figure 3 - roc curve depicting discriminative value of the multivariable model for functional re-
sponse
The multivariable model contains LBBB, QRS duration ≥150ms and no need for chronic diuretics at baseline.
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diuretics at baseline are independent predictors of functional response. A model con-
taining these 3 independent predictors of functional response has discriminative ability, 
with a C-index of 0.88.
clinical implications
The above-mentioned findings from our study suggest that CRT functional responders 
may not need backup defibrillation therapy in terms of clinical outcomes during the first 
3 years after device implantation. Incidence of inappropriate shocks was similar among 
functional responders and functional non-responders. Defibrillator-shocks, whether 
appropriate or not, have adverse consequences for patients and lead to more frequent 
hospitalization and thereby higher costs. Altogether, our findings thus raise the hy-
pothesis that functional responders may be assigned to CRT-P when a device change is 
needed, or that ICD therapy may be switched off to prevent unnecessary inappropriate 
shocks without compromising clinical outcome. However, to confirm this hypothesis, 
large, prospective, randomized studies with longer term follow-up are warranted.
Furthermore, it should be noted that the implication that a return in LVEF to ≥35% 
constitutes subsequent protection from arrhythmia is not well established in the litera-
ture. Nevertheless, there is growing evidence that anatomic remodeling due to CRT is 
accompanied by electrical remodeling and could thereby reduce the risk of ventricular 
arrhythmias.13-17 Our study contributes to the evidence that remodeling achieved by CRT 
leads to a reduced risk of life threatening arrhythmias.
Moreover, although there is a growing body of evidence on predictors of response 
to CRT, accurate response prediction remains challenging. Should functional response 
prediction be improved in the future, then assignment of patients likely to achieve 
functional response to CRT-P, without backup defibrillation therapy, may be considered. 
Schaer et al have previously described this issue, and have also stated that patients who 
reach a LVEF >35% could be assigned to CRT-P, when a device change is needed.13 Unlike 
Schaer et al, we focused on primary prevention patients and chose to examine appropri-
ate shocks and mortality as endpoints, instead of all ICD-therapy.
Prediction of functional response
We showed that cardiomyopathy etiology, diuretics use, serum urea, serum creatinine, 
LVEF, LBBB and QRS duration ≥150ms were factors univariably associated with functional 
response. Multivariable analysis showed that only LBBB, QRS duration ≥150ms and no 
need for chronic diuretics at baseline were independently associated with functional 
response. This is in line with previous findings. Patients with a LBBB are more likely to 
have left ventricular dyssynchrony and patients with wide QRS complexes, i.e. QRS com-
plexes of ≥150ms, probably have more intraventricular dyssynchrony. Since CRT corrects 
intraventricular dyssynchrony, patients with both an LBBB and QRS duration ≥150ms 
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are more likely to benefit from CRT in terms of LVEF and are consequently more likely 
to become functional responders. LBBB is a known predictor of response to CRT-D18-20 
and our study contributes to the evidence, although the confidence interval is large.18-20 
Moreover, Goldenberg et al recently identified QRS duration ≥150ms as a predictor of 
response.19 Not all patients with a LBBB and QRS duration ≥150ms showed functional 
response. In our study population, posterolateral scarring by ischemic heart disease was 
the main cause of functional non-response in these patients.
Patients not requiring chronic diuretics use before receiving CRT probably had less 
signs of HF, possibly because of a better cardiac function at baseline. More remark-
able is the fact that baseline LVEF was not independently associated with functional 
response. A possible explanation for this is that in this population, patients with a very 
poor baseline LVEF are just as likely to become functional responders as patients with 
a moderately reduced baseline LVEF. Alternatively, the reliability of LVEF as a marker of 
outcome may be questioned; however, since the inter-observer variability of the LVEF 
measurements made by our echocardiography laboratory is 5%, we believe use of this 
marker is justified.
further specification of clinical outcomes
In the functional non-response group, 22 patients died. Of these, 7 were non-cardiac 
deaths. Occurrence of all of these 7 non-cardiac deaths in the functional non-response 
group is probably due to chance.
Of the patients in the functional response group, 7.1% received inappropriate shocks, 
and this was similar in both groups. Most of the inappropriate shocks in both groups 
were due to atrial fibrillation or lead crushes.
Limitations
Several issues concerning this study warrant further consideration. The study popula-
tion of 142 patients is relatively small, retrospective and derived from a single center. 
Larger, prospective, multicenter studies are needed to confirm our exploratory findings 
and to provide further grounds for statements about prognosis of functional responders 
and about prediction of functional response.
The use of LVEF as a marker of response is inherently an issue, given the known 
limitations in reproducibility of this method. Nevertheless, the marker of response we 
use in this exploratory study is comparable to other CRT trials using echocardiographic 
markers. Furthermore, since the inter-observer variability of the LVEF measurements 
made by our echocardiography laboratory is only 5%, which justifies the use of an 
echocardiographic marker. Our criterion of an LVEF ≥35% post implantation appears to 
discriminate better between patients with a high or low risk for arrhythmias, than criteria 
such as an improvement in LVEF of ≥10%. Echocardiograms to assess the effect of CRT 
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were performed 3 months after AV optimization. Most remodeling and hemodynamic 
changes must have been achieved, but occasionally remodeling takes more time.
Although the current study tentatively suggests that functional responders may be 
assigned to CRT-P when a device change is needed, this statement should be interpreted 
with caution. The battery life of a typical CRT-D device is approximately 4-5 years, and 
the median follow-up of our study population was 3 years. Still, we expect this follow-up 
period to cover the timeframe in which risk of arrhythmias is highest. Cardiac reversed 
remodeling for the greatest part takes place in the first few months after implantation, 
lasting generally until 1 year after implantation which is congruent with the frequency 
of occurrence of the arrhythmias (75% in the first year after CRT-D implantation).13
conclusion
In our study population, functional responders displayed a good prognosis during a 
median follow-up of 3 years, and did not need backup from defibrillation therapy. As 
such, our study suggests it may be worthwhile to further investigate whether functional 
responders could be assigned to CRT-P when a device change is needed and whether 
ICD therapy could be switched off in these patients. This would require large, prospec-
tive, randomized studies with longer-term follow-up.
Furthermore, our study shows that LBBB conduction disorder, QRS duration ≥150ms 
and no need for chronic diuretics at baseline are independent predictors of functional 
response. Response prediction to CRT currently remains challenging, but if response 
prediction becomes more precise in the future, one may consider primarily assigning 
probable functional responders to CRT-P.
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ABstrAct
Background: Knowledge about predictive factors for mortality and (in)appropriate 
shocks in cardiac resynchronization therapy with a defibrillator (CRT-D) should be avail-
able and updated to predict clinical outcome.
methods: We retrospectively analyzed 550 consecutive patients assigned to CRT-D in 
2 tertiary medical centers. The aim of this study was to assess risk factors for all-cause 
mortality, appropriate and inappropriate shocks.
results: Mean follow-up was 3.2 (±1.8) years. A total of 112 (20%) patients died, 72 
(13%) received ≥1 appropriate shocks, and 33 (6.0%) received ≥1 inappropriate shocks. 
No patients received a His bundle ablation and biventricular pacing percentage was not 
analysed. Multivariable Cox regression analysis showed that a history of atrial fibrilla-
tion (AF) (HR 1.68 CI 0.98-2.72), higher creatinine (HR 1.11; CI 1.07-1.16) and a poorer 
left ventricular ejection fraction (LVEF) (HR 0.97; CI 0.94-1.01) independently predict 
all-cause mortality. In the entire cohort, history of AF and secondary prevention were 
independent predictors of appropriate shocks and variables associated with inappropri-
ate shocks were history of AF and QRS ≥150ms. In primary prevention patients, history of 
AF also predicted appropriate shocks as did ischemic cardiomyopathy and poorer LVEF. 
History of AF, QRS ≥150ms and lower creatinine were associated with inappropriate 
shocks in this subgroup. Appropriate shocks increased mortality risk, but inappropriate 
shocks did not.
conclusions: In symptomatic CHF patients treated with CRT-D, history of AF is an in-
dependent risk factor for mortality, but also for appropriate and inappropriate shocks. 
Further efforts in AF management may optimize the care in CRT-D patients.
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iNtroductioN
Over the past years, several large studies have demonstrated the benefits of cardiac 
resynchronization therapy (CRT) in patients suffering from chronic heart failure (CHF) 
and left ventricular dyssynchrony. It reduces mortality and morbidity, and increases 
left ventricular ejection fraction (LVEF).1-5 However, uncertainty exists about which 
pre-implantation patient and particularly rhythm and conduction characteristics are 
associated with mortality and (in)appropriate shocks. Most data on the survival of CRT 
patients are limited to post hoc analyses of large randomized controlled trials. These 
trials have applied specific inclusion criteria with predominance of patients without 
atrial fibrillation (AF), which complicate extrapolation of their results to the more 
diverse, real-life population of patients treated with CRT. Patients assigned to CRT, 
have a poor left ventricular function6,7, which is also an indication for an implantable 
cardioverter-defibrillator (ICD).8-10 Based upon this, patients assigned to CRT receive 
a cardiac resynchronization defibrillator (CRT-D). This increases survival by means of 
appropriate defibrillator-shocks, but also carries the negative effects of inappropriate 
shocks, which consequently increases the number of hospitalizations. These device-
related hazards may be reduced by a more appropriate selection of device therapy and 
optimal care for CRT-D device patients. In addition, CRT-D is an expensive therapy and 
to provide maximum benefit from the device, optimal care is necessary. Therefore, we 
conducted a retrospective cohort study in order to assess the effect of baseline demo-
graphic variables and rhythm and conduction characteristics on mortality, appropriate 
and inappropriate defibrillation shocks in a general, unselected group of CHF patients, 
treated with CRT-D on top of optimal medication.
methods
Patients and study design
The population of this retrospective, multi-centre, observational, follow-up study con-
sisted of 550 patients that were consecutively assigned to CRT-D in Erasmus Medical 
Centre, Rotterdam, the Netherlands and Medical Centre Alkmaar, Alkmaar, the Nether-
lands, between February 2005 and March 2011. Therapy assignment was based on the 
ESC guidelines for cardiac pacing and cardiac resynchronization therapy.11 All patients 
suffered from chronic heart failure for at least 3 months and were treated with optimal 
medication. Follow up on mortality lasted until December 2011.
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Baseline data collection
Baseline characteristics of all patients were collected by reviewing hospital records and 
included demographics, medical history, medication use, cardiovascular risk factors and 
pacing and electrocardiographic characteristics.12
Intraventricular conduction disorders (IVCD’s) were defined according to the AHA/
ACCF/HRS recommendations for the standardization and interpretation of the electro-
cardiogram.13 Left bundle branch block (LBBB) criteria are: QRS duration ≥120 ms; QS 
or rS in lead V1; wide R (frequently notched) waves in leads I, aVL, V5, or V6; and absent 
q waves in leads V5 and V6. Left anterior fascicular blocks (Frontal plane axis deviation 
between -45° and -90°; qR pattern in aVL; and R-peak time in lead aVL of 45ms or more) 
with QRS duration ≥120ms were also counted as LBBB. Right bundle branch block (RBBB) 
required: QRS duration ≥120 ms; rsr’, rsR’, rSR’, or qR in leads V1 or V2; and occasionally, a 
wide and notched R wave and wide S waves in leads I, V5, and V6.
Placement procedure and icd follow-up
The placement procedure was similar in the two participating Medical Centers.
First, the right ventricular ICD-lead was positioned, mostly in the right ventricular apex 
using a cephalic cut down technique. Next, the LV pacing lead was inserted through the 
coronary sinus and positioned in the venous system, preferably in the (postero-)lateral 
vein. Finally, the atrial lead was positioned in the right atrial appendage. If transvenous 
LV pacing lead placement failed, an epicardial procedure was scheduled and performed.
During in-hospital and remote ICD follow-up, as part of usual care, ICD printouts were 
obtained every 3 months to determine the number and type of arrhythmias and the 
number of appropriate and inappropriate shocks. In Alkmaar, the majority of devices 
had a 3-zone configuration. The first zone was a monitor zone only, which was set to 160 
±10 bpm, the VT zone was set to 190 ±12 bpm and the VF zone was set to >209 ±15 bpm. 
In Rotterdam, a two-zone configuration was programmed in 83% of the patients, 16% 
had a 3-zone configuration. A monitoring zone was activated in the majority of patients 
with a 3-zone configuration. Mean VT detection rate was 171 ±11 bpm, the mean VF 
detection rate was set to 216 ±15 bpm. In the Medtronic Inc., Minneapolis, MN, USA, 
devices, the number of intervals to detect was set to 18/24 episodes in all zones. In the 
Boston Scientific inc., Indianapolis, IN, USA, devices, the number of intervals to detect 
was set to 8/10 intervals, with a duration of 8s in the VT zone and 5s in the VF zone. For all 
patients, ICD programming was intended to avoid inappropriate therapy by activating 
the available discriminators, e.g. dual-chamber algorithms, onset, stability and morphol-
ogy. For each patient, programming was tailored according to the clinical presentation.
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definitions
The aim of this study was to assess risk factors for all-cause mortality, appropriate 
and inappropriate shocks. A shock was considered appropriate if it was delivered on 
ventricular fibrillation or ventricular tachycardia. ICD interrogations were performed 10 
days, 3, 6, 9, and 12 months after implantation and then also every 6 months. Every ar-
rhythmia in the ICD memory was interpreted by two experienced physicians per centre 
and declared as either appropriate or inappropriate.
statistical analysis
Normality of distribution was determined by Kolmogorov-Smirnov’s test. Continuous 
data are expressed as mean ± SD, if normally distributed, otherwise by median and 
interquartile range (IQR). Continuous data were analyzed with Student’s t test or Mann-
Whitney U test, when appropriate. Categorical data were compared by using the χ2 test 
or Fisher’s exact test when appropriate. Multivariable Cox proportional hazards regres-
sion was used to analyze the effect of patient baseline characteristics on the outcome 
measures, eg mortality, appropriate and inappropriate shocks. A backward elimination 
procedure was used and variables were withdrawn from the model if the corresponding 
p-value was ≥0.1 until all factors had a p value <0.1. All available baseline characteristics 
were used for the backward elimination procedure, except for the variable ‘CRT-P up-
graded to CRT-D’, due to the small number of patients in whom this occurred.
The preventive cardioverter/defibrillator function of the device is always indicated in 
patients, who have CRT-D as secondary prevention for life-threatening arrhythmias.14 
For this reason, we repeated our analysis on appropriate and inappropriate shocks, on 
solely the group of patients who had received CRT-D as primary prevention.
The influence of appropriate and inappropriate shocks on mortality was investigated 
by Cox regression analysis. For this purpose, appropriate and inappropriate shocks were 
treated as two separate time-dependent covariates, which allowed us to take into ac-
count the occurrence of multiple shocks that occurred consecutively in time.
We investigated the performance of the combination of independent risk factors, 
resulting from the multivariable analyses described above. For this purpose a C-index 
was calculated using the area under the receiver operating characteristic (ROC) curve.
SPSS 14.0 (SPSS Inc, Chicago, IL) was used for statistical analysis.
resuLts
Baseline characteristics
Baseline characteristics of the patients are shown in table 1. Mean age of the study 
population was 64 ±11 years and 74% was male. The majority of the patients had re-
186 Chapter 10
table 1 - Baseline characteristics
Variable total study population
(n= 550)
Patients with crt-d for 
primary prevention
(n= 482)
Age (years) 64 ± 11 64 ± 11
male gender 404 (74) 357 (74)
NYhA class
I 21 (4.1) 17 (3.8)
II 180 (35) 151 (33)
III 308 (60) 276 (61)
IV 8 (1.5) 8 (1.8)
ischemic cardiomyopathy 297 (54) 252 (52)
hypertension 199 (36) 170 (35)
diabetes mellitus 133 (24) 118 (25)
Ace-i/Atii-a 524 (99) 459 (99)
diuretics 457 (83) 408 (85)
B-Blocker 456 (83) 396 (82)
serum urea (mmol/l) 9.8 ± 4.8 9.6 ± 4.8
serum creatinine (μmol/l) 115 ± 50 113 ± 49
hb (mmol/l) 8.5 ± 1.1 8.6 ± 1.1
LVef (%) 24 ± 7.2 24 ± 7.0
history of Af 156 (28) 136 (28)
LBBB 414 (82) 364 (83)
rBBB 27 (5.3) 22 (5.0)
Pacemaker rhythm 57 (10) 49 (10)
iVcd with Qrs <120ms 10 (2.0) 9 (2.0)
Qrs ≥150ms 387 (72) 340 (72)
LV Lead position
Posterolateral 305 (57) 270 (58)
Lateral 54 (10) 50 (11)
Posterior 89 (17) 71 (15)
Anterolateral 67 (13) 59 (13)
RVOT 7 (1.3) 7 (1.5)
Epicardial 10 (1.8) 9 (1.9)
crt-P 14 (2.5) 11 (2.3)
Continuous variables are expressed as mean ± standard deviation. Categorical variables are expressed as 
count (percentage). Valid percentages may vary for some counts, because of missing variables. ACE-I = ace 
inhibitor; ATII-a = angiotensin II antagonist; LVEF = left ventricular ejection fraction; AF = atrial fibrillation; 
LBBB = left bundle branch block; RBBB = right bundle branch block; IVCD = intraventricular conduction 
disorder; LV = left ventricular; RVOT = right ventricular outflow tract; CRT-P = Cardiac resynchronization 
therapy with a pacemaker only, upgraded to cardiac resynchronization therapy with a defibrillator.
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ceived CRT-D for primary prevention, while a mere 68 patients (12%) had received CRT-D 
as secondary prevention for cardiac arrest. Mean LVEF was 24 ±7.2%. A history of AF 
was found in 156 patients (28%), of whom 60 patients (11%) had permanent AF and 96 
patients (17%) had paroxysmal AF. Of all patients, 82% had a LBBB conduction disorder.
A total of 10% of all patients had a dual chamber pacemaker before receiving CRT-D 
and 2.5% was upgraded from CRT-P to CRT-D. An epicardial lead was placed in 1.8% of 
all patients, because transvenous placement of the LV lead was considered sub-optimal.
occurrence of outcome measures
Mean follow-up of the study population of 550 consecutive patients was 3.2 ±1.8 years.
During follow-up, 112 patients (20%) died and the one-year mortality rate was 5.4%.
A total of 72 of all patients (13%) received one or more appropriate shocks, as did 55 
(11%) of all 482 primary prevention patients.
A total of 33 (6.0%) patients received one or more inappropriate shocks. Of these, 15 
(46%) had a known history of AF at baseline. The trigger for these inappropriate shocks 
was the occurrence of paroxysmal AF in 5 patients and rapid ventricular response in 10 
patients with known permanent AF. In 45%, these inappropriate shocks were not related 
to AF.
cox proportional hazards analyses
The association between baseline characteristics and all-cause mortality is shown in 
figure 1. Three baseline characteristics remained in the multivariable model after the 
backward elimination procedure, history of AF (HR 1.68; CI 1.03 – 2.72) serum creatinine 
(HR 1.11;CI 1.07 – 1.16) and LVEF (HR 0.97; CI 0.94 - 1.01),
Factors associated with appropriate shocks were history of AF (HR 2.32; CI 1.29 – 4.18) 
and secondary prevention (HR 2.61; CI 1.32 – 5.17), as shown in figure 2. In primary 
prevention patients, history of AF (HR 2.00; CI 1.00 – 3.98), ischemic cardiomyopathy 
figure 1 - Association between patient characteristics and mortality
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(ICM) (HR 2.03; CI 0.98 – 4.20) and LVEF (HR 0.95; CI 0.90 – 1.00) were associated with 
appropriate shocks.
Variables that were associated with inappropriate shocks are shown in figure 3 and 
included history of AF (HR 2.29; CI 0.95 – 5.55) and QRS ≥150ms (HR 2.74; CI 1.14 – 6.58). 
In primary prevention patients, history of AF (HR 3.31; CI 1.29 – 8.49), QRS ≥150ms (HR 
2.72; CI 1.08 – 6.86) and serum creatinine (HR 0.84; CI 0.70 – 1.01) were associated with 
inappropriate shocks.
Finally, an association was present between the occurrence of appropriate shocks and 
increased mortality (HR 4.15; CI 2,69 – 6,40), even when corrected for baseline variables 
significantly associated with increased mortality (HR 3.69; CI 2.24 – 6.09). Inappropriate 
shocks however, were not associated with increased mortality (HR 1.07; CI 0.47 – 2.46).
discriminative ability
The combination of the 3 independent risk factors for mortality, a history of AF, LVEF and 
serum creatinine , displayed discriminative ability for mortality, with a C-index of 0.72 
(figure 4).
In the full patient cohort, we found that the prognostic model that contained his-
tory of AF and CRT-D as secondary prevention discriminated between those with and 
without appropriate shocks with a C-index of 0.74. In patients who had received CRT-D 
as primary prevention, the model containing ICM, history of AF and LVEF displayed 
discriminative ability, with a C-index of 0.75.
figure 2 - Association between patient characteristics and appropriate shocks; a) all patients; b) pri-
mary prevention patients
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Furthermore, in the full patient cohort, the model containing a history of AF and QRS 
duration ≥150ms discriminated between those with and without inappropriate shocks, 
with a C-index of 0.78. In primary prevention CR-D patients , we found a C-index of 0,80, 
using a prediction model containing a history of AF, QRS duration ≥150ms and serum 
creatinine for inappropriate shocks.
figure 3 - Association between patient characteristics and inappropriate shocks; a) all patients; b) 
primary prevention patients
figure 4 - roc curve for a model predicting all-cause mortality containing left ventricular ejection 
fraction, serum creatinine and history of atrial fibrillation
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discussioN
We performed a retrospective, multi-centre, observational, follow-up study, on 550 
real-life CHF patients, treated with CRT-D. A history of AF appears to be an important 
determinant not only for mortality, but also for appropriate and inappropriate shocks, 
as shown in figure 5. Forty-six percent of all patients receiving inappropriate shocks 
appeared to have a history of AF at baseline. Other independent predictors of all-cause 
mortality included higher pre-implantation creatinine and poor LVEF.
risk stratification for all-cause mortality
Our findings regarding predictors of mortality may represent the detrimental effects of a 
reduced cardiac function and progressive heart failure. AF is presumably a sign of gener-
ally worse cardiac status, particularly in CHF patients and therefore can be correlated 
with mortality, which has been shown in ICD trials.15-19 Recently, Botto et al also found an 
association between a history of AF and all-cause mortality in CRT-D patients.20 The fact 
that AF appears to be a risk factor for mortality in CRT-D patients could also be due to a 
reduced amount of biventricular pacing in patients with AF which consequently leads to 
less reversed cardiac remodeling and electrical remodeling.
Mean LVEF in our study population was 24%, which is comparable to the MADIT-CRT 
trial.5 LVEF is currently the main criterion for eligibility for a primary preventive ICD or 
CRT-D device, mainly because a poor LVEF has proven to be one of the primary markers 
of cardiac death in patients.16,17,21 We found a trend towards similar results in our real-life 
population of CHF patients treated with CRT-D.
Renal failure is generally associated with higher mortality, but can also be an expres-
sion of a poor cardiac function. Saxon et al also showed in the COMPANION trial that a 
poor renal function is associated with a higher mortality.22 We have now extended these 
findings to a real-life population of patients treated with CRT-D.
Finally, appropriate shocks were independently associated with increased mortal-
ity. These shocks may by themselves cause damage to the myocardium, but receiving 
appropriate shocks is more likely an expression of a poor cardiac function and occurs 
probably in the sickest patients where clinical deterioration could be expected. The fact 
that inappropriate shocks were not associated with mortality also adds to the assump-
tion that it is probably not the shock itself that is harmful, but more likely its underlying 
cause. It is also possible that the number of inappropriate shocks in our study was to low 
or the follow-up time was to short to find significant differences in mortality, because 
in contrast, MADIT RIT recently found a decreased mortality in patients receiving less 
inappropriate therapy.23
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figure 5 - hazard curves of patients with and without atrial fibrillation and a) all-cause mortality; b) 
appropriate shocks; and c) inappropriate shocks.
Hazard ratios were derived from Cox proportional hazards models. All baseline variables were entered into 
the model and variables were withdrawn from the model if p≥0.1 until all factors had a p value <0.1.
192 Chapter 10
risk stratification for appropriate shocks
The occurrence of appropriate shocks may be considered as an important outcome 
given its effect on patient outcome, its potential detrimental effect on LV function and 
its socio-economic effects.
Appropriate shocks are related to a history of AF, which may be an expression of a poor 
cardiac function, but this relation could also be due to a reduced amount of biventricu-
lar pacing during periods of paroxysmal or persistent AF with subsequent less electrical 
remodeling. This could not only lead to mortality, but also result in a higher frequency 
of ventricular arrhythmias and consequently of appropriate shocks. AF can also initiate 
ventricular arrhythmias and consequently induce the need for appropriate shocks. The 
impact of AF on appropriate shocks has been shown before in an ICD study.15 Also, a 
recent CRT-D trial displayed an association between recurrent or new atrial arrhythmias 
and the development of ventricular arrhythmias.20 We found similar results in a popu-
lation of CHF patients treated with CRT-D. Antiarrhythmics did not change the risk of 
having appropriate shocks in AF patients.
Currently, LVEF is the main criterion for assigning patients to CRT-D or an ICD. Several 
large trials have shown that ICD’s improve survival among patients with a depressed 
LVEF but who have not previously had sustained ventricular arrhythmias.24,25 This study 
adds to this information and shows that an even more depressed LVEF increases the 
risk of life threatening arrhythmias and consequently the need for backup defibrillation 
therapy.
Cardiac ischemia causes myocardial scarring and greater myocardial scarring tends to 
be at augmented risk for ventricular arrhythmias.26 As a result, patients with an ischemic 
cardiomyopathy are more prone to ventricular arrhythmias, which is shown by the trend 
we found towards a higher vulnerability to appropriate shocks in patients with ICM.
inappropriate shocks
Atrial fibrillation and other supraventricular tachycardia’s are the leading cause of inap-
propriate shocks.15,27-32 The device misdiagnoses AF as a potentially lethal ventricular ar-
rhythmia and subsequently discharges inappropriately. In our series, 15 (46%) of the 33 
patients receiving inappropriate shocks had a history of AF at baseline. Further studies 
are warranted to investigate whether optimal medical AF care may improve the balance 
of appropriate and inappropriate device therapy in CRT-D patients.
In the current study, multivariate analysis showed a positive correlation between a 
QRS duration of ≥150ms and the occurrence of inappropriate shocks. Wide QRS com-
plexes express a slow conduction and are a sign of progressive cardiac dysfunction and 
dilatation of the ventricles and indirectly the atria. Such dilatation of the atria creates 
a substrate that could lead to AF which may acts as a trigger and subsequently induce 
inappropriate discharges.
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Finally, previous studies have found, apart from AF, that several other variables may 
be associated with inappropriate shocks. These findings were not always as consistent. 
For example, both low and high NYHA class have been associated with inappropriate 
shocks.29,31 In the current study, we have found an association between lower pre-
implantation creatinine and inappropriate shocks. Such an association has not been 
previously demonstrated. This finding may be due the fact that 33% of all inappropriate 
shocks were caused by abnormal sensing or sinus tachycardia. Creatinine was lower 
in patients receiving inappropriate shocks due to these causes compared to the other 
patients in our cohort. Possibly, patients with a preserved renal function were more 
physically active, leading to a higher number of shocks from sinus tachycardia or ab-
normal sensing.33 These patients were also younger, which has been associated with 
inappropriate shocks before.28
Studies on risk factors of having inappropriate shocks in real-life patients treated with 
CRT-D are scarce, and further research with larger cohorts and longer follow-up is war-
ranted to provide more information on variables associated with inappropriate shocks 
to avoid device related hazards.
To the best of our knowledge, such an association have not yet been demonstrated in 
previous studies.
clinical implications
Our findings may be helpful in predicting the prognosis of patients treated with CRT-D, 
and could assist clinicians in more optimal and appropriate patient selection for CRT.
A history of AF was associated with all-cause mortality as well as appropriate and 
inappropriate shocks. This increased mortality risk together with the greater need for 
defibrillation therapy implies a definite indication for CRT-D therapy. On the other hand, 
patients with a history of AF carry a high risk of receiving inappropriate device therapy.
Therefore, these results suggest that benefit may be derived from an optimal me-
dicinal policy to keep patients in sinus rhythm, prevent AF, and possibly a His bundle 
ablation may be considered. A his bundle ablation would prevent a fast ventricular 
response rate, which could otherwise trigger the device to discharge inappropriately. 
An additional advantage of a His bundle ablation, is the fact that it could increase the 
amount of biventricular pacing in patients with AF and has proven to reduce mortality 
in CRT patients with AF.34 None of the patients in our study population had received a 
His bundle ablation.
study limitations
The first patient received CRT-D in February 2005 and the last consecutive patient re-
ceived CRT-D in March 2011. Within this period of time, multiple publications on heart 
failure treatment and device based therapy have changed the guidelines for selecting 
194 Chapter 10
patients for CRT-D.7,11 This could have caused heterogeneity in the study population, 
which may have affected the outcome.
A second limitation, is the fact that this study was performed retrospectively, which 
makes data collection challenging. Nevertheless, all data on primary and secondary 
outcome could be collected without loss to follow-up.
Even though all debatable ICD events have been double-checked by multiple experts 
and discussed at a weekly meeting, the absence of a core laboratory adjudicating all 
ICD events and therapy, may have caused heterogeneity in the interpretation of events. 
Moreover, despite the quite uniform device programming, it should be stated that vari-
ability in configuration could have influenced our outcome. Also, we did not investigate 
antitachycardia pacing rates, so we can not draw any conclusions regarding the influ-
ence of antitachycardia pacing rates on the outcome.
Finally, information on the biventricular pacing percentage was absent, which made 
it impossible to draw conclusions on the effect of biventricular pacing on outcomes in 
AF patients.
conclusion
In symptomatic CHF patients treated with CRT-D, AF is an independent risk factor for 
mortality and appropriate shocks. However AF also is an independent risk for inappro-
priate shocks. Further efforts in AF management may optimize the appropriate care in 
CRT-D device patients.
Appropriate shocks were associated with mortality while inappropriate shocks were 
not.
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ABstrAct
Background: Since several large trials have proven the effectiveness of implantable 
cardioverter-defibrillators (ICDs) in patients with left ventricular dysfunction, disad-
vantages have become more apparent. As prognosis of patients with cardiovascular 
diseases is improving, assessment of ICD patients and re-evaluation the current guide-
lines, is mandatory. We aimed to evaluate differences in mortality and occurrence of 
(in)appropriate shocks in ICD patients with coronary artery disease (CAD) or dilated 
cardiomyopathy (DCM).
methods: In a large teaching hospital, all consecutive patients with systolic dysfunction 
due to CAD or DCM who received an ICD with and without resynchronisation therapy, 
were collected in a database.
results: A total of 320 consecutive patients (age 67±10 years) were classified as CAD 
patients and 178 (63±11 years) as DCM patients. Median follow-up was 40 months 
(interquartile range [IQR] 23 – 57 months). All cause mortality was 14% (CAD 15% vs 
DCM 13%).
Appropriate shocks occurred in 13% of all patients (CAD 15% vs DCM 11%, p=0,12) 
and inappropriate shocks occurred in 10% (CAD 8% vs DCM 12%, p=0,27).
Multivariate analysis demonstrated impaired LVEF, QRS>120, age ≥75 years and low 
eGFR as predictors for all-cause mortality.
Predictors for inappropriate shocks were permanent and paroxysmal atrial fibrillation.
conclusions: Mortality rates were similar in patients with CAD and DCM, who received 
an ICD. Furthermore, no differences in the occurrence of appropriate and inappropriate 
ICD interventions between these patient groups were found.
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iNtroductioN
An implantable cardioverter-defibrillator (ICD) improves survival in patients with an 
impaired left ventricular function.1-4 Despite these achievements, disadvantages, i.e. 
inappropriate therapy or non-benefit,5-8 of ICDs have become more apparent over the 
years and cost-effectiveness should be optimized.9 As prognosis of patients suffering 
from cardiovascular diseases is improving, current guidelines should be re-evaluated. 
For this purpose, follow-up data of patients who were assigned to ICD therapy according 
to the current guidelines are very helpful.
In the current guidelines for device-based therapy and prevention of sudden car-
diac death,10 the indication for ICD-therapy in patients with an impaired left ventricular 
function due to a dilated cardiomyopathy (DCM) and those for patients with systolic 
dysfunction due to coronary artery disease (CAD) closely resemble. Therefore, it is of 
interest to compare the outcome of ICD patients with DCM to ICD patients with CAD, to 
verify whether the current guidelines are still valid.
The aim of this study was to evaluate mortality and occurrence of both appropriate 
and inappropriate ICD shocks in patients with an impaired left ventricular function due 
to CAD and DCM. Furthermore, we assessed predictors for mortality, appropriate and 
inappropriate shocks.
methods
study population
A database was constructed including all consecutive patients who received an ICD 
between January 2005 and June 2012 in a large teaching hospital. Follow-up lasted until 
October 2012.
Therapy assignment was based on the ESC guidelines for device based therapy.10 
Baseline characteristics of all patients were collected by reviewing hospital records and 
included demographics, medical history, medication, cardiovascular risk factors and 
electrocardiographic characteristics.
Fifty-two patients who received their ICD for other reasons than coronary artery 
disease or dilated cardiomyopathy (e.g. idiopathic ventricular fibrillation, hypertrophic 
cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, 
Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia) were 
excluded.
Patients were considered CAD patients if they had a history of myocardial infarction 
(including Q-wave or enzyme positive), a history of coronary artery disease at coronary 
angiography or one or more coronary artery bypass grafts (CABG) or percutaneous 
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coronary interventions (PCI). Renal function was assessed by estimating the baseline 
glomerular filtration rate (eGFR) using the abbreviated Modification of Diet in Renal 
Disease (MDRD) Study equation: eGFR (mL/min/1.73 m2 of body surface area) =186× 
(serum creatinine in mg/dL)−1.154 × (age)−0.203 ×0.742 in female subjects. Renal fail-
ure was defined as an eGFR <60 mL/min/1.73 m².
icd follow-up
The majority of devices had a 3-zone configuration. The first zone was a monitor zone 
only, which was set to 160 ±10 bpm, the VT zone was set to 190 ±12 bpm and the VF 
zone was set to >209 ±15 bpm. In the Medtronic Inc., Minneapolis, MN, USA, devices, 
the number of intervals to detect was set to 18/24 episodes in all zones. In the Boston 
Scientific inc., Indianapolis, IN, USA, devices, the number of intervals to detect was set to 
8/10 intervals, with a duration of 8s in the VT zone and 5s in the VF zone. For all patients, 
ICD programming was intended to avoid inappropriate therapy by activating the avail-
able discriminators, e.g. dual-chamber algorithms, onset, stability and morphology. For 
each patient, programming was tailored according to the clinical presentation.
During in-hospital and remote ICD follow-up, as part of usual care, ICD printouts were 
obtained every 3 months to determine the number and type of arrhythmias and the 
number of appropriate and inappropriate shocks. Patients were advised to contact the 
hospital after experiencing ICD therapy or mandated to visit the hospital if an ICD shock 
was detected by remote-monitoring. ICD therapy was only considered appropriate 
when delivered for ventricular tachyarrhythmias. All debatable ICD events were double-
checked by multiple experts and discussed at a weekly meeting.
statistical analysis
Continuous data was analyzed with Student’s t test or Mann-Whitney U test, when ap-
propriate. Categorical characteristics were compared by using the χ2 test.
Kaplan-Meier’s log-rank test was used to compare differences in all-cause mortality, 
appropriate shocks and inappropriate shocks between CAD and DCM patients. Fur-
thermore, multivariable Cox proportional hazards regression was used to examine the 
association between patient characteristics and outcome (HRs). Characteristics were 
entered into the multivariable model if they showed a statistically significant association 
with the outcome during univariable analysis (P value <0.05).
Overall statistical significance was set at a 2-tailed P value <0.05. SPSS 20.0 (SPSS Inc, 
Chicago, IL) was used for the statistical analysis.
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resuLts
study population
The study population consisted of 498 consecutive patients who received an ICD be-
tween January 2005 and June 2012 in a large teaching hospital. Baseline characteristics 
are displayed in table 1. The CAD group comprised 320 patients (64%). The DCM group 
consisted of 178 (36%) patients. The CAD group contained more males than the DCM 
group (CAD 85% vs. DCM 62%, p<0.001) and were older (CAD 67±10 vs DCM 63±11, 
p<0.047). Mean left ventricular ejection fraction was 24%±7% and was not significantly 
lower in one of the groups (25±6 vs 23±8, p<0.131). Permanent atrial fibrillation was 
more frequent in DCM patients (8% vs 18%, p=0.002).
The use of beta-blockers (CAD 93% vs DCM 93%, p=0.76) and ace-inhibitors/ARBs 
(CAD 96% vs DCM 97%, p=0.59) did not significantly differ between the groups, but the 
use of diuretics was higher in patients with DCM (CAD 74% vs DCM 84%, p=0.008). A 
total of 166 patients (33%) received cardiac resynchronization therapy (CRT) (CAD 28% 
vs DCM 43%, p<0.001).
mortality
Figure 1 displays the results of our outcome on mortality, appropriate and inappropriate 
shocks. Overall mortality of the total study population was 14.5% (72 patients), during 
a median follow-up of 40 months (IQR 23-57 months) with a median survival time of 31 
months (IQR 20 - 44 months). There were no significant differences in mortality between 
CAD (49 patients, 15%) and DCM (23 patients, 13%) patients (p=0.46) (Figure 2).
Univariable analysis displayed the following predictors for mortality: age≥75 years, 
LVEF, NYHA class III-IV, permanent AF, QRS>120ms, eGFR and haemoglobin. Multivariate 
analyses showed that impaired LVEF (HR 0.94, CI 0.90-0.99), age≥75 years (HR 2.18, CI 
1.19-3.97), QRS>120ms (HR 2.50, CI 1.21-5.16) and low eGFR (HR 0.98, CI 0.97-0.99) were 
independent predictors for mortality.
Appropriate icd therapy
A total of 67 patients (13.5%) received ≥1 appropriate shock and 43 Patients (9%) 
received >1 appropriate shock during follow-up. The median interval to first appropri-
ate shock after ICD implantation was 21.8 months (IQR 4.9-35.0 months). Cumulative 
incidence of appropriate shocks was 4.4%, 7.2% and 13.1% at 1, 2 and 5 years follow-up. 
There were no significant differences in the occurrence of appropriate shocks between 
CAD patients and DCM patients (CAD 15.0% vs DCM 10.7%, p=0.12)(Figure 3a).
Use of digoxin (15% vs 4%, HR 2.97, CI 1.50-5.88) and a history of smoking (62% vs 
48%, HR 2.00, CI 1.77-2.98) predicted appropriate shocks.
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inappropriate icd therapy
Inappropriate ICD shocks occurred in 48 patients (9.6%). Twenty-four patients (5%) had 
>1 episode of inappropriate shocks. The median time between implantation and the 
first inappropriate shock was 6.1 months (IQR 2.3-26.6 months). Cumulative incidence 
of inappropriate shock therapy was 5.4%, 7.2% and 9.0% at 1, 2 and 5 years follow-up.
table 1 - Baseline characteristics
characteristic All (n=498) cAd (n=320) dcm (n=178) P Value
Age, years 66±10 67±10 63±11 0,047
Male gender 382(77) 272(85) 110(62) <0,001
LVEF, 24±7 25±6 23±8 0,13
NYhA classification
I-II 359(80) 233 (81) 126(79) 0,62
III-IV 87 (20) 54(19) 33(21)
history of atrial fibrillation
Permanent 59(12) 27(8) 32(18) 0,002
Paroxysmal 52(10) 39(12) 13(7) 0,09
QRS duration, ms 132±32 130±31 136±35 0,003
QRS > 120ms 254(53) 159(52) 95(57) 0,29
Serum creatinin (µmol/L) 117±79 123±90 105±51 0,06
eGFR (ml/min/1.73m²) 65±23 63±23 68±22 0,73
Renal Failure 176(40) 121(43) 55(35) 0,13
Hemoglobin (mmol/L) 8,6±1,0 8,6±1,0 8,6±1,1 0,53
implanted device
Atrial lead 353(71) 223(70) 130(73) 0.43
CRT 166(33) 89(28) 77(43) <0,001
risk factors
Diabetes 95(19) 69(22) 26(15) 0,06
History of smoking 213(50) 144(53) 69(45) 0,12
Hypertension 147(42) 136(44) 75(44) 0,90
cardiovascular medication
Amiodarone 56(11) 42(13) 14(8) 0,08
Beta-blocker 457(93) 294(93) 163(93) 0,95
Digoxin 29(6) 12(4) 17(10) 0,008
ACE inhibitor/ATII antagonist 474(96) 304(96) 170(97) 0,59
Diuretics 382(77) 234(74) 148(84) 0,008
Continuous variables are expressed as mean ± standard deviation. Categorical variables are expressed as 
count (percentage). Valid percentages may vary for some counts, because of missing values. ACE indicates 
angiotensin-converting enzyme; ATII, angiotensin-II; eGFR, estimated glomerular filtration rate; ICD, Im-
plantable cardioverter-defibrillator; LVEF, Left ventricular ejection fraction; NYHA, New York Heart Associa-
tion.
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There was no significant difference in occurrence of inappropriate shock therapy 
between CAD patients and DCM patients (CAD 8% vs DCM 12%, p=0.27) (Figure 3b).
Inappropriate shocks occurred significantly more in patients with permanent AF (22% 
vs 8%, p=0.001), and also in patients with paroxysmal AF (17% vs 9%, p=0.048). Most 
figure 1 - All-cause mortality, appropriate and inappropriate shocks in coronary artery disease 
(cAd) and dilated cardiomyopathy (dcm) patients
figure 2 - Kaplan-meier survival curve of all-cause mortality.
Coronary artery disease (CAD) versus dilated cardiomyopathy (DCM) patients.
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inappropriate shocks in this study were caused by supraventricular tachyarrhythmias 
(78%), mainly AF. Other causes of inappropriate shocks were shock lead dysfunction 
(18%) and T wave oversensing (4%).
Multivariate analyses displayed permanent AF (HR 2.85, CI 1.16-7.01) and paroxysmal 
AF (HR 2.84, CI 1.20-6.74) as independent predictors for inappropriate shocks.
figure 3 - Kaplan-meier hazard curve of a) appropriate shocks and b) inappropriate shocks.
Coronary artery disease (CAD) versus dilated cardiomyopathy (DCM) patients.
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discussioN
We performed a retrospective, observational, follow-up study, on 498 real-life patients, 
treated with an ICD and evaluated the difference in mortality and occurrence of ICD 
shocks in patients with left ventricular dysfunction due to CAD versus DCM. All patients 
received their ICD according to the current guidelines.
The major findings of this study were: (1) Mortality rates are equal in CAD and DCM 
patients. (2) Incidence of appropriate and inappropriate shocks was similar in both 
groups. (3) Predictors for mortality in ICD patients were impaired LVEF, age≥75 years, 
QRS>120ms and low eGFR. (4) Predictors for inappropriate ICD intervention were per-
manent and paroxysmal AF.
mortality
Overall cumulative incidence of all-cause mortality of the total study population was 
14.5% and at 1, 2 and 5 years, mortality rates were 2.2%, 4.2% and 13.5% respectively. 
For CAD patients, mortality rates at 1, 2 and 5 years were 2.5%, 5.3% and 14.1% respec-
tively, and for DCM patients 1.7%, 2.8% and 12,4%. Compared to the landmark trails, 
the cumulative incidence off all-cause mortality was relatively low. The Sudden Cardiac 
Death in Heart Failure Trial SCD-HeFT found a total mortality rate of 29% at 5 year follow-
up and the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) reported 
a mortality-rate of 16% at 2 years follow-up and 52% at 8 years.2,3,11 This lower mortality 
could explained by the fact that treatment of patients with systolic dysfunction has 
improved over time, which may have contributed to a lower mortality in our study 
population compared to the trials mentioned. Another factor contributing to the lower 
mortality could be due to the fact that 33% of our study population received CRT, which 
improves left ventricular function and reduces mortality.12
As ICD implantation and follow-up is expensive and as costs in medical practise are 
rising, a stricter selection of eligible patients is mandatory. The relatively low mortality 
in our study population calls for reassessment of the indications for an ICD. Therefore, 
further studies and registries of real-life ICD patients are required to make a more ap-
propriate selection of patients eligible for ICD implantation possible.
Finally, whereas ICDs only act as “safety net” and antiarrhythmic medication has 
potential side effects and requires close monitoring, the search for other methods to 
withstand arrhythmias continues. Catheter ablation is an accepted technique and 
nowadays commonly used in treatment of arrhythmias. Catheter ablation has proven its 
effectiveness in treatment of VTs in patients with structural heart disease due to CAD or 
DCM with even higher success rates in CAD patients.13
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Appropriate intervention
In our study, 13.5% of all patients received appropriate shocks, and this number did 
not significantly differ between CAD and DCM patients. The SCD-HeFT trial reported a 
total number of appropriate shocks of 21%, which is higher than the 13% of all patients 
receiving appropriate shocks we reported. This difference might be clarified by the fact 
that device programming has improved over time and anti-arrhythmic medication has 
been enhanced. Also, as stated before, 33% of our study population received CRT, which 
could also have had a beneficial effect on the number of appropriate shocks by increas-
ing LVEF.
There is some evidence that the number of ventricular tachyarrhythmias are compa-
rable in CAD patients and DCM patients.14,15 This had also been shown by some small 
previous studies.16,17 Our study adds to these findings by showing that the number 
of ICD shocks are also equivalent in these both groups, even though one third of our 
patients received CRT, which may have a more beneficial effect on LVEF in DCM patients 
compared to CAD patients.18 Our findings confirm the validity of the current guidelines.
Recently, studies have shown that medication indeed reduces appropriate ICD therapy 
in patients with ischemic heart disease.19-21 Since ventricular tachyarrhythmias are the 
major cause of sudden cardiac death, it is important to reduce these arrhythmias and 
therefore appropriate shocks, which have also proven to be an independent predictor 
of mortality.22
Our study shows history of smoking is a predictor for appropriate shocks, which has 
been shown before in previous studies.23 Smokers have increased atherosclerosis, which 
increases the occurrence of ischemic events, and myocardial scarring, eventually result-
ing in more tachyarrhythmias and consequently more appropriate shocks.
Finally, most of the patients who received an ICD never received shock therapy, sug-
gesting that a more patient-focused risk stratification could improve clinical benefits 
and cost-effectiveness. 24
inappropriate intervention
In this study, inappropriate shocks occurred in 9.6% of all patients, mostly caused by 
atrial tachyarrhythmias classified as ventricular tachyarrhythmias, which subsequently 
caused inappropriate discharges.
Age <75 years was also associated with inappropriate shocks. Younger age is associ-
ated with sinus tachycardia and abnormal sensing. This finding has been reported be-
fore,25 and is most likely the explanation for the association between age <75 years and 
inappropriate shocks. Patients who had an ICD as secondary prevention had a slightly 
better left ventricular ejection fraction compared to the primary prevention patients and 
a lower NYHA class. Possibly, these patients were more physically active, which could 
also lead to a higher number of shocks from sinus tachycardia or abnormal sensing.
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Most frequent causes of inappropriate therapy have been studied, and can result in 
reduced quality of life and even provocation of ventricular arrhythmias.5,26 An additional 
phenomenon is phantom shocks - the sensation of an ICD discharge in the absence of 
an actual discharge – which occur, though not significant, more in patients who received 
appropriate or inappropriate shocks.27 Therefore, the occurrence of inappropriate shocks 
should be minimized as much as possible. Recent studies have shown that enhanced 
programming algorithms during follow-up reduces inappropriate therapy and even 
mortality.28,29
Limitations
Present study has several limitations. Patients were included in the period between 
January 2005 and June 2012, so follow-up of the last included patients was only 3 
months while some patients have a follow-up of up to 7 years. Within this period of time, 
multiple publications on treatment of ventricular tachyarrhythmias and device based 
therapy have changed the selection of eligible patients for ICD treatment. This could 
have caused heterogeneity in the study population, which may have affected the out-
come. This limitation did not influence the aim of the study, since this limitation applies 
to both CAD and DCM patients.
A second limitation, is the fact that this study was performed retrospectively, which 
makes data collection challenging. Nevertheless, all data on primary and secondary 
outcome could be collected without loss to follow-up.
conclusion
This study shows that mortality and occurrence of appropriate and inappropriate ICD 
shocks are similar in patients with an ischemic or a dilated cardiomyopathy. An impaired 
LVEF, age ≥ 75 years, QRS>120ms and low eGFR predicted mortality. Use of digoxin and a 
history of smoking predicted appropriate shocks. Permanent AF and paroxysmal AF are 
predictors for inappropriate shocks.
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ABstrAct
Background: The beneficial effects of cardiac resynchronization defibrillator (CRT-D) 
in patients with heart failure, low LVEF, and wide QRS have clearly been established. 
Nevertheless, mortality remains high in some patients. The aim of this study was to 
develop and validate a risk score to identify patients at high risk for early mortality who 
are implanted with a CRT-D.
methods: For predictive modeling, 1282 consecutive patients from 5 centers (74% male; 
median LVEF 25%; NYHA class III-IV 60%; median QRS-width 160 ms) were randomly 
split into a derivation and validation group (50%/50%). A risk score was developed using 
logistic regression.
results: In the total cohort, 181 patients died over 3years of follow-up. After multivariate 
analysis, a risk score was developed based on myocardial infarction, LVEF ≤ 25%, COPD, 
chronic kidney disease (CKD), hyponatremia and anemia. At 3 years, mortality was 4.6%, 
13.2% and 29.7% by ascending tertile of risk score. Compared with the lowest tertile 
(T1), mortality was significantly higher in the other tertiles (T2 odds ratio (OR) = 3.1; T3 
OR = 8.4; both P < 0.001). Discrimination was modest (C-statistic 0.73) and the Hosmer-
Lemeshow chi-square was 0.95 (P = 0.33).
conclusions: A risk score based on routine, readily available clinical variables can reliably 
identify patients at high risk for early mortality within 3 years after CRT-D implantation.
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iNtroductioN
Heart failure (HF) is a progressive disease associated with high morbidity and mortal-
ity. The prevalence of HF is increasing and the associated costs are rising.1,2 Data from 
randomized and observational studies have shown the beneficial effect of cardiac 
resynchronization therapy (CRT) in selected patients with drug refractory HF, reduced 
left ventricular ejection fraction (LVEF), and electrical dyssynchrony: it improves clinical 
symptoms, reduces hospitalizations and lowers mortality in a considerable proportion 
of patients.3-6 In addition, HF patients with low LVEF are at increased risk for arrhythmic 
death. Prophylactic implantable cardioverter-defibrillator (ICD) implantation is indi-
cated for patients with ischemic or non-ischemic cardiomyopathy and LVEF ≤ 35%.7-9 
Theoretically, all patients who meet the indication criteria for CRT also qualify to have an 
ICD for primary prevention of sudden cardiac death. Consequently, ICDs combined with 
CRT (CRT-D) are part of the standard management of HF patients with reduced LVEF.10,11 
However, given the heterogeneity in mortality risk among HF patients and the fact that 
only a minority of patients will experience ventricular arrhythmias, appropriate risk 
prediction is of paramount importance in maximizing the survival benefit conferred by 
the CRT-D.12 Several models have been developed to predict mortality risk in HF patients 
such as the Seattle Heart Failure Model (SHFM) and the Heart Failure Survival Score 
(HFSS).13,14 Despite the fact that the SHFM takes the eventual use of device therapy, such 
as an ICD or CRT, into account, the model was not designed for HF patients who already 
had a device implanted. A risk estimation model to predict mortality in HF patients 
following CRT-D implantation does not exist. Therefore, the purpose of this study was 
to develop a risk estimation model to predict mortality in primary prevention CRT-D 
patients.
methods
study population
We used data from prospective ICD registries of the cardiology departments of Erasmus 
MC (Rotterdam, the Netherlands), the University Hospital of Basel (Basel, Switzerland), 
Ziekenhuis Oost-Limburg (Genk, Belgium), Medisch Centrum Alkmaar (Alkmaar, the 
Netherlands), and Medisch Spect Twente (Enschede, the Netherlands). From these 
registries, all patients (n = 1282) who received a first implantation of a CRT-D device for 
the primary prevention of sudden cardiac death between January 1st, 2000 and October 
31st, 2013 were identified.
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data collection, variable definitions and clinical endpoint
Potential candidate variables associated with mortality in heart failure were identified 
based on review of the literature, clinical relevance, and their routine availability. They 
included demographic characteristics, clinical presentation, laboratory data, and preex-
isting comorbid conditions.
Demographics, clinical data, and medical therapy prior to CRT-D implantation were 
obtained for all patients by searching the health records of the hospital. If multiple 
laboratory data were available, values from the date closest to the date of implantation 
were used; all laboratory values obtained up to 7 days prior to CRT-D implantation were 
accepted.
Diabetes mellitus was defined as HbA1c > 6.5% or the use of oral hypoglycemic agents 
or use of parenteral insulin; anemia as a serum hemoglobin concentration of < 12 g/
dL (female) or < 13 g/dL (male). The glomerular filtration rate (GFR) was estimated with 
the formula of Modified Diet in Renal Disease (MDRD).15 Renal function was stratified 
according to the KDIGO/KDOQ stages for chronic kidney disease (CKD): stage 1, i.e. ≥ 
90 ml/min/1.73m2; stage 2, i.e. 60-89 ml/min/1.73m2; stage 3, i.e. < 60 ml/min/1.73m2 
and stage 4, i.e. < 30 ml/min/1.73m2.16 Presence of CKD was defined as GFR < 60 ml/
min/1.73m2. Hyponatremia was defined as serum sodium level < 136 mmol/L and so-
dium levels of 136 - 137 mmol/L as low normal.
The clinical end-point for this study was all-cause mortality; patients who underwent 
cardiac transplantation were censored at the day of transplantation.
statistical analysis
For the purpose of this study, half of the patients were randomly selected by use of 
random integer assignment to form the derivation cohort, and the remainder formed 
the validation cohort. Summary baseline data are presented as median with 25th and 
75th percentiles, and categorical data are presented as percentages and counts. Data 
were compared by the Kruskal-Wallis H test and chi-square test as appropriate. Although 
most patients had a relatively complete data set, variables with > 5% of missing data 
were excluded from analysis (body mass index, diastolic and systolic blood pressure, and 
baseline heart rate). The method of multiple imputation was used to include variables 
with < 5% of missing data in model selection and regression analysis.
Candidate variables in the derivation cohort that were associated with mortality on 
univariate analysis (P ≤ 0.1) were included as covariates in a multiple logistic regression 
model. Backwards stepwise regression analysis was performed to determine the most 
predictive variables in the model equation, with a cutoff P value of 0.05 for retention in 
the model. A risk score was calculated for each individual patient as the value of the sum 
of products of the identified independent variables and their computed coefficients 
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(β1x1 + β2x2+ ... βnxn| where x1, x2, and xn are the values for the identified variables 
and β1, β2, and βn are the coefficients).
To assess the prognostic value of the risk score, the population was stratified into 
tertiles of the continuous risk score. Cumulative mortality rates were calculated accord-
ing to the Kaplan-Meier method and differences between groups compared with the 
log-rank test. The discriminative properties of the model were assessed by the Harrell C 
index for Cox models. In addition, the receiver operating characteristic area under the 
curve (ROC AUC) was assessed. Model discrimination was deemed poor if the C-statistic 
and ROC AUC was between 0.50 and 0.70, modest between 0.70 and 0.80, and good if > 
0.80. Calibration of the model was assessed by the Hosmer-Lemeshow goodness-of-fit 
test. The model was validated externally by assessing model performance in the valida-
tion cohort.
Statistical analysis was performed using STATA version 11 SE for Windows (StataCorp, 
College Station, TX) and SPSS version 21 (IBM Corp., Somers, NY). Statistical significance 
was defined as P < 0.05 (two-tailed).
resuLts
description of the derivation and validation cohorts
The derivation cohort consisted of 639 patients and the validation cohort of 643 pa-
tients (N = 1282 patients). Demographics and clinical characteristics of both cohorts 
are presented in Table 1. The derivation and validation cohort were similar with respect 
to age, gender, etiology of heart failure, comorbid conditions, laboratory values, and 
medical treatment. The majority of CRT-D recipients were men (76%) with a median age 
of 66 years. Ischemic etiology of heart failure was present in 50% of the patients.
The mortality rate in the overall cohort was 5.7% and 16.5%, at 1 and 3 years, respec-
tively. In the derivation cohort (n = 639), 1- and 3-year mortality was 5.0% and 15.9%. In 
the validation cohort (n = 643), 1- and 3-year mortality was 6.4% and 17.0%. The mortal-
ity rates were not different between the derivation and the validation cohort (P = 0.64).
Predictors of mortality
Univariate logistic regression analysis was performed to identify variables associated 
with mortality. We found that increased age, the presence of myocardial infarction, 
diabetes mellitus, COPD, CKD, hyponatremia and anemia were all associated with a 
higher risk of mortality. In addition, LVEF < 25% was also associated with a higher risk 
of mortality. Subsequently, a backward stepwise regression analysis was performed to 
select the most predictive variables for mortality. Model predictors of 3-year mortality 
included presence of myocardial infarction, COPD, CKD, hyponatremia, anemia, and 
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LVEF < 25% (Table 2). Age either as continuous variable or as binary variable with differ-
ent age cutoffs did not reach statistical significance in multivariate analysis.
Risk scores were derived for each individual patient using the obtained β-coefficients.
Risk score = 0.690 * (MI) + 0.645 * (LVEF25) + 0.632 * (COPD) + 0.890 * (CKD) + 0.712 * 
(hyponatremia) + 0.495 * (anemia)
table 1 - clinical characteristics of the derivation and validation cohorts
derivation cohort
(n=639)
Validation cohort
(n=643)
P value
demographics
Age, y 67 (58 - 73) 66 (59 - 72) 0.95
Male gender 483 (76%) 469 (73%) 0.31
clinical characteristics
NYHA class III-IV 372 (58%) 374 (58%) 0.91
Ejection fraction, % 24 (20 – 30) 25 (20 – 30) 0.40
Ischemic etiology 313 (49%) 326 (51%) 0.64
QRS duration, ms 160 (140 - 180) 160 (140 - 177) 0.07
comorbid condition
Atrial fibrillation 128 (20%) 139 (22%) 0.54
Diabetes mellitus 163 (26%) 169 (26%) 0.75
Cerebrovascular disease 54 (8%) 72 (11%) 0.11
Chronic obstructive pulmonary disease 93 (15%) 83 (13%) 0.42
Renal failure 254 (40%) 254 (40%) 0.91
Laboratory values
Hemoglobin, g/dL 13.7 (12.4 - 14.7) 13.9 (12.7 - 14.9) 0.05
Serum sodium, mmol/L 140 (137 - 142) 140 (137 - 142) 0.79
Serum BUN, mg/dL 8.3 (6.4 - 11.7) 8.1 (6.1 - 10.9) 0.16
Serum creatinine, mg/dL 1.1 (0.9 - 1.4) 1.1 (0.9 - 1.4) 0.23
medication
ACE inhibitor 481 (75%) 476 (74%) 0.65
Angiotensin receptor blocker 152 (24%) 160 (25%) 0.65
Amiodarone 82 (13%) 81 (13%) 0.93
Betablocker 521 (82%) 528 (82%) 0.83
Digoxin 104 (16%) 127 (20%) 0.11
Diuretic 513 (80%) 513 (80%) 0.82
Aldosteron antagonist 309 (48%) 284 (44%) 0.15
Allopurinol 48 (8%) 55 (9%) 0.54
Statin 350 (55%) 390 (61%) 0.04
Continuous data are presented as median (interquartile range). Categorical data are presented as n(%).
ACE = angiotensin converting enzyme; BUN = blood urea nitrogen; NYHA = New York Heart Association
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where: LVEF25 = LVEF ≤ 25%, 1 if present, otherwise 0; CKD = estimated GFR < 60 
ml/min/1.73m2, 1 if present, otherwise 0; Hyponatremia = serum level of sodium < 138 
mmol/L, 1 if present, otherwise 0; Anemia = serum level of hemoglobin < 12 g/dL, 1 if 
present, otherwise 0; MI, COPD = 1 if present, otherwise 0.
Subsequently, the derivation cohort was stratified by ascending tertiles of the derived 
risk score (low to high risk). Mortality rates by tertiles of risk are presented in Figure 
1. At 3-years follow-up, mortality rates were 4.6% in the low-risk group, 11.0% in the 
intermediate-risk group, and 29.1% in the high-risk group. Model discrimination as as-
sessed by the c-statistic was modest (c-index of 0.74 at 3-years follow-up). In addition, 
the calculated area under the ROC curve was 0.74 (95% CI, 0.68 to 0.79). Calibration of 
the model was assessed by the Hosmer-Lemeshow test. There was no evidence of lack 
of fit (chi-square = 0.95; P = 0.33).
table 2 - multivariable analysis of predictors of all-cause mortality
Predictor or (95% ci) P-value
Myocardial infarction 1.99 (1.24 - 3.22) 0.005
Ejection fraction 25% 1.91 (1.12 - 3.25) 0.02
Chronic obstructive pulmonary disease 1.88 (1.05 - 3.39) 0.04
Renal failure 2.44 (1.48 - 3.99) < 0.001
Hyponatremia 2.04 (1.25 - 3.33) 0.004
Anemia 1.64 (1.00 - 2.71) 0.05
figure 1 - mortality rates in the derivation cohort stratified by risk group
Dotted line = low risk; dashed line = intermediate risk; solid line = high risk.
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model validation
When the 3-year model was applied in the validation cohort (N = 643 patients), the 
discriminative ability of the model was maintained with an area under the ROC curve of 
0.73 (95% CI, 0.68 to 0.79). When comparing the areas under the ROC curve, no difference 
between the derivation and validation cohort was observed (Figure 2). The predicted 
and observed mortality rates were in close agreement among the risk groups (Figure 3). 
Given the good performance of the tentative model in both cohorts, data were merged 
to develop a final model on the entire cohort of 1282 patients. In Table 3, the mortality 
risk for the risk groups is presented.
figure 2 - roc-curves for the derivation and validation cohort
Solid line = derivation cohort; dashed line = validation cohort.
figure 3 - the 3-year mortality rates for the derivation and validation cohort stratified by risk group
table 3 - mortality risk sorted by risk group
risk groups 1-year mortality, % 3-year mortality, % or (95% ci) P-value
Low risk 1.4% 4.6% 1.00
Intermediate risk 3.4% 12.7% 3.28 (1.43 – 7.50) 0.005
High risk 10.3% 30.2% 9.87 (4.58 – 21.30) < 0.001
CI = confidence interval; OR = odds ratio.
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discussioN
The present international, multicenter, retrospective cohort study of 1282 HF patients 
demonstrates the feasibility of using a risk score to predict early mortality in a real-world 
population of CRT-D recipients. The risk score incorporates myocardial infarction, LVEF 
≤ 25%, COPD, CKD, hyponatremia, and anemia. These variables are readily available and 
individually associated with a poor outcome.
In HF patients with reduced LVEF, NYHA class ≥ II, and prolonged QRS duration, CRT 
improves clinical symptoms, reduces hospitalizations and lowers mortality in a consid-
erable proportion of patients.5,17 Patients eligible for CRT also qualify for defibrillator 
therapy as primary prevention of sudden cardiac death. Consequently, implantation of 
a CRT-D is part of the standard management of HF patients with reduced LVEF. However, 
the benefit of defibrillator therapy is not uniform and it remains to be determined which 
patients benefit and whether patients do not benefit from defibrillator therapy.
Better identification of patients who get the highest benefit of the additional defibril-
lator therapy is desirable to reduce unnecessary implantations and possible complica-
tions. Several previous studies have developed risk scores to estimate mortality in ICD 
recipients.18-22 Recently, a systematic review and meta-analysis determined older age, 
poor baseline renal function, history of COPD, diabetes mellitus, peripheral vascular dis-
ease, decreased LVEF, and ICD shocks during follow-up as strong predictors of mortality 
in ICD patients.23 Some of these predictors were also identified in our study, e.g. poor 
baseline renal function, COPD and decreased LVEF.
In a sub-analysis of the MADIT-II Trial, a risk score consisting of 5 clinical risk factors 
(NYHA class > II, atrial fibrillation, QRS duration > 120 ms, age > 70 years, and urea > 26 
mg/dL) was developed to differentiate between patients who would benefit from the 
ICD vs. those who would not.19 The MADIT-II risk score has recently been evaluated in 
cohorts of CRT patients showing poor to modest discrimination (C-statistic of 0.61 and 
0.72).24,25 Of the 5 risk factors in the MADIT-II score, only poor baseline renal function 
was a factor in our risk score. Risk factors as QRS width > 120 ms and NYHA > II mostly 
indicate CRT use.
The results of the present study are in line with those of several previous studies, 
indicating that renal dysfunction poses a strong and independent risk factor for overall 
mortality despite CRT-D implantation and optimized medical treatment of congestive 
heart failure. Besides renal dysfunction, we identified other clinical risk factors such as 
hyponatremia and anemia. Hyponatremia is a strong determinant of long-term mor-
tality in HF patients, irrespective of LVEF.26 Sharma et al. investigated the prognostic 
implication of hyponatremia in HF patients receiving CRT.27 Low baseline serum levels 
of sodium were associated with poor prognosis. The results of our study confirm the 
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association between low serum levels of sodium and a higher mortality risk even in a 
multivariate analysis.
The impact of baseline anemia on all-cause mortality in HF patients with reduced LVEF 
has been evaluated in the HF-ACTION trial.28 Over a median follow-up of 30 months, ane-
mia was associated with increased rates of death, hospitalizations, and HF exacerbation. 
Venkateswaran et al. examined the prognostic implication of anemia in CRT patients.29 
Baseline anemia and early post-implantation decline of hemoglobin were associated 
with a worse 2-year prognosis. In our study, baseline anemia was independently associ-
ated with higher mortality.
Taken together, our results confirm that medically complex HF patients, those with low 
LVEF, anemia, hyponatremia, and comorbidities as COPD and CKD, have an increased risk 
of mortality. This finding may be explained by an increase in HF and non-arrhythmic 
mortality as the presence of these clinical variables suggests a more advanced HF status. 
The decision whether to add ICD therapy is at the discretion of the physician. In this 
context, Levy et al. provided compelling evidence of the heterogeneity of risk among 
primary prevention ICD patients by applying the SHFM to the SCD-HeFT study cohort.12 
The highest risk group had an increased mortality with no benefit of ICD therapy despite 
the greatest incidence of appropriate ICD shocks.
Limitations
The current study has several limitations and these should be viewed in its method-
ological context. First, the design was a retrospective cohort study with prospectively 
collected data which cannot be compared with that of a randomized clinical trial. In 
addition, the risk score was not used to decide on implantation of a CRT-D. Second, the 
study cohort included patients over a 13-year period, during which guidelines for the 
implantation of defibrillators and treatment of HF changed. In the same period, the pro-
gramming of devices with respect to detection and treatment of ventricular arrhythmias 
changed.
conclusion
A risk score based on routine, readily available clinical variables can reliably identify 
patients at high risk for early mortality within 3 years after CRT-D implantation.
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Health care can be divided into preventive, curative, rehabilitative and supportive medi-
cine. Preventive medicine is regarded as the most effective form of medical practise, 
since good preventive medicine avoids the necessity of curative, rehabilitative and sup-
portive medicine. Preventive medicine does not only aim at preventing diseases from 
happening (i.e., primary prevention), but also at reducing the impact of a disease that 
has already occurred and softening the impact of an ongoing illness (i.e., secondary- 
and tertiary prevention, respectively). Major improvements in cardiovascular medical 
care, such as percutaneous coronary interventions (PCIs) and implantable cardioverter-
defibrillators (ICDs), have significantly reduced mortality, but this improvement in sur-
vival has also led to an increase in the number of patients suffering from chronic heart 
disease. To further improve secondary prevention in these patients, novel methods for 
risk stratification are urgently needed.
The aim of this thesis was to identify characteristics associated with adverse clinical 
outcome, and to present novel prediction models that may aid in risk stratification of 
patients at different stages of cardiovascular disease. First, we focused on patients with 
coronary artery disease, with or without left ventricular dysfunction. Specifically, we 
examined patients undergoing PCI, and identified characteristics associated with poor 
outcome after PCI (Part 1). Secondly, we focused on patients with established (chronic) 
heart failure ((C)HF), and investigated what strategy or which combination of biomarkers 
should be used for risk assessment (Part 2). Finally, we examined patients with severely 
reduced cardiac function, that require prevention of sudden cardiac death by means 
of an ICD with our without cardiac resynchronization therapy (CRT); here, we aimed to 
reveal characteristics associated with response and poor clinical outcome (Part 3).
Part i the influence of patient baseline and procedural characteristics on 
outcome after percutaneous coronary interventions
In chapter 2, we created an easy to use 5-year mortality risk score based on nine simple 
clinical and angiographic baseline variables. The IDEA-BIO study reveals that age, BMI, 
diabetes mellitus, renal insufficiency, prior myocardial infarction, indication for PCI, 
culprit left main, number of diseased vessels and cardiogenic shock are key predictors 
of mortality in PCI patients. Previous studies that have created mortality risk scores 
and prediction tools for patients who have undergone PCI have focused on short term 
outcome (i.e., 30 days). Our study is the first to examine long-term follow-up. Combined 
with the large sample size, this is an important strength of our study. By providing a tool 
for long-term risk stratification, we enable selection of patients who might benefit from 
more expensive PCI treatment options, such as biodegradable scaffolds (provided that 
long-term benefits of biodegradable scaffolds compared to newer generation drug-
eluting stents (DES) will be demonstrated by current studies).
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The benefit of newer generation DES, releasing everolimus (i.e. everolimus eluting 
stents (EES)) compared to early generation DES (i.e. sirolimus eluting stents (SES) and 
paclitaxel eluting stents (PES)), has been shown by several large trials in patients un-
dergoing PCI. In general, some patient categories are more prone to stent thrombosis 
(ST) than others; this includes patients with a reduced left ventricular ejection fraction 
(LVEF). chapter 3 showed that newer generation EES are associated with a lower risk 
of ST compared to early generation DES, independently of LVEF, even though ST rates 
were higher in patients with a moderate-severely impaired LVEF. This better outcome 
persisted even after 4 years of follow-up. The long-term safety and benefits of newer 
generation EES in patients with a reduced cardiac function suggests that EES should be 
the preferred stent when performing a PCI in patients with established systolic dysfunc-
tion.
In chapter 4, we examined prognosis after out-of-hospital cardiac arrest (OHCA). 
We especially focused on factors related to the occurrence of OHCA in ST-elevation 
myocardial infarction (STEMI), since these are still poorly understood. The multicenter 
registry used for this chapter displayed an association between left proximal coronary 
lesions and high risk of OHCA. Right coronary lesions resulted in the lowest risk of OHCA. 
Furthermore, culprit location was associated with cardiogenic shock and sub-optimal 
reperfusion after PCI, both of which were driving factors of prognosis after OHCA. Fi-
nally, this study showed that a strict policy consisting of a combined strategy of early 
start of basic life support, early invasive management with primary PCI and therapeutic 
hypothermia in patients suffering OHCA due to STEMI, resulted in a relatively large group 
of patients (77%) that survived one year of follow-up and had reasonable neurological 
outcome at discharge.
Part ii Novel methods and markers for risk assessment of patients with heart 
failure
Treatment of (C)HF is generally aimed at stabilizing or at decelerating disease progres-
sion. Currently, adjustment of therapy is largely based on clinical judgement and thus 
is usually only performed when symptoms or signs are worsening. Considerable clinical 
skills are required to recognize opportunities to titrate therapy and to implement inter-
ventional changes in a timely manner, which may lead to treatment delay in high-risk 
patients. Blood biomarkers may reflect subtle pathophysiological and hemodynamical 
cardiovascular changes, and may herewith predict an adverse disease course before it 
becomes clinically apparent or before symptoms are reported.
The Serial Biomarker meaSurements and new echocardiographic techniques in 
chronic Heart Failure patients result in Tailored prediction of prognosis (Bio-SHiFT) 
study was a prospective, observational study of stable outpatients with CHF, conducted 
in Erasmus MC, Rotterdam, The Netherlands and Noordwest Ziekenhuisgroep, Alkmaar, 
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The Netherlands. Patients were recruited during their regular outpatient visits and were 
in clinically stable condition. Patients were eligible if CHF (including HF with preserved 
ejection fraction) was diagnosed ≥3 months ago according to the guidelines of the 
European Society of Cardiology. At baseline and each follow-up visit, a short medical 
evaluation was performed and blood and urine samples were collected. Study follow-up 
visits were scheduled every 3 months, to a maximum follow-up duration of 30 months.
In chapter 5, we used the Bio-SHiFT data and showed that serial assessments of
N-terminal pro-brain natriuretic peptide (NT-proBNP), C-reactive protein (CRP) and 
New York Heart Association (NYHA) Functional Classification class were all indepen-
dently associated with adverse clinical outcome. Repeatedly measured NT-proBNP and 
CRP both added individually to serial NYHA-class assessments in terms of discriminative 
ability. These findings underscore the incremental value of biomarkers to NYHA class for 
monitoring stable CHF outpatients.
chapter 6 demonstrated that the dynamic, temporal patterns of serially-measured 
NT-proBNP and CRP levels are strong and independent predictors of adverse clinical 
events in CHF patients. On top of that, instantaneous rate of change in level of these 
biomarkers, as well as their long-term elevation, were also associated with adverse 
events. While the temporal pattern of high-sensitive troponin T (HsTNT) significantly 
predicted adverse events, its predictive capability was lost when combined with tem-
poral NT-proBNP and CRP patterns. These results suggest that individual patterns of 
biomarker change, as well as combinations of multiple biomarkers, should be taken into 
consideration for prognostication in patients with stable CHF.
Despite these findings, the predictive capabilities of the aforementioned biomarkers 
for worsening of CHF still leaves room for improvement. MicroRNAs (miRs) are upcoming 
novel biomarkers that seem promising for early diagnosis and treatment of HF. MiRs 
are non-coding, ~22 nucleotide long RNA sequences, which target messenger RNAs for 
cleavage or translational repression and thereby influence a great variety of biological 
processes. The stability of miRs in plasma, and consequently their reliable assessment 
in easily accessible samples, potentially makes them attractive biomarkers for a wide 
range of diseases, such as cardiovascular diseases. In chapter 7, we used the data of the 
Bio-SHiFT study and investigated the association of frequent repeated measurements 
of multiple miRs that were previously linked to HF (miR-1254, miR-22-3p, miR-423-5p, 
miR-486-5p and miR-320a) or have been shown to be cardiac-enriched (miR-345-5p, 
miR-378a-3p), with adverse clinical events in CHF patients. We discovered an inverse 
and independent association between temporal miR-22-3p patterns and adverse out-
come. The association was independent of clinical characteristics as well as temporal 
NT-proBNP, HsTNT and CRP patterns. The instantaneous rate of change in miR-22-3p 
level (i.e., the slope of the temporal pattern) was also inversely associated with adverse 
outcome. Moreover, we found inverse associations of temporal patterns of miR-22-3p 
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with temporal patterns of HsTNT and CRP. Therefore, the use of individual patterns of 
change of circulating miR-22-3p may be beneficial for CHF prognostication. An addi-
tional finding of this study was the significant, inverse association between ischemic 
cardiomyopathy (ICM) and miR1254, miR486-5p and miR320a.
chapter 8 showed the origination of a number of miRs produced by pig myocardium, 
including miR-1306-5p which had not yet been identified as a miR related to the heart, 
using direct RNA sequencing of plasma from instrumented pigs. Subsequently we 
showed, in a human, prospective acute HF cohort (TRIUMPH), that repeatedly-assessed 
circulating miR-1306-5p was associated with adverse clinical outcome, and provides 
prognostic information beyond NT-proBNP. These results imply that measuring miR-
1306-5p could aid in risk stratification of patients with HF. Herewith, patients may be 
identified that could benefit from closer follow-up and from more aggressive treatment.
Part iii Novel insights in characteristics associated with favourable outcome in 
defibrillation therapy and response to cardiac resynchronization therapy
The use of ICDs and CRT has had major impact on survival of patients with reduced 
cardiac function (i.e. LVEF <35%). CRT has reduced the number of HF hospitalizations 
and has been shown to induce cardiac reversed remodeling in patients suffering from 
CHF and wide QRS-complexes. But there are still major unidentified characteristics that 
favor or disfavor the response to these devices. Some patients respond very well to CRT 
and reach a LVEF of ≥35% after implantation. In chapter 9, we refered to these patients 
as functional responders, and we demonstrated that such functional responders have 
good prognosis. In fact we show that during a median follow-up of 3 years, backup from 
defibrillation therapy was not used in functional responders. Incidence of inappropriate 
shocks was similar among functional responders and functional non-responders. Defi-
brillator-shocks, whether appropriate or not, have adverse consequences for patients 
and lead to more frequent hospitalization and thereby higher costs. Altogether, our 
findings thus raise the hypothesis that functional responders may be assigned to CRT-P 
when a device change is needed, or that ICD therapy may be switched off to prevent 
unnecessary inappropriate shocks without compromising clinical outcome.
Another major determinant, not only of mortality, but also of appropriate and inap-
propriate shocks in CHF patients treated with CRT-D, is a history of atrial fibrillation (AF), 
as described in chapter 10. The retrospective, multi-centre, observational, follow-up 
study, on 550 real-life CHF patients treated with CRT-D, described in this chapter, shows 
that a total of forty-six percent of all patients receiving inappropriate shocks appeared 
to have a history of AF at baseline. These results suggest that benefit may be derived 
from an optimal medicinal policy to keep patients in sinus rhythm, and prevent AF; and 
possibly a His bundle ablation may be considered. Furthermore, mortality and occur-
rence of both appropriate and inappropriate shocks in a population of ICD patients with 
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an impaired left ventricular function due to coronary artery disease (CAD) vs. dilated 
cardiomyopathy patients did not seem to differ, as reported in chapter 11. The popula-
tion described in this chapter consisted of mainly ICD-only patients and only 33% CRT-D 
patients. Conversely, chapter 12 showed that prior myocardial infarction did seem to be 
associated with (3-year) mortality in a population consisting of all CRT-D patients. Other 
risk factors associated with mortality were LVEF ≤25%, COPD, chronic kidney disease, 
hyponatremia and anemia. The results of these studies could be used for prediction of 
prognosis in patients with CHF and could be used to identify patients in need of closer 
follow-up.
conclusions
- Long-term (i.e. 5-year) mortality after PCI can be adequately predicted using a 5-year 
mortality risk score based on nine simple clinical and angiographic baseline vari-
ables.
- Newer generation EES are associated with a lower risk of ST compared to early gen-
eration DES, independently of LVEF, even though ST rates are higher in patients with 
a moderately-to-severely impaired LVEF.
- A strict policy consisting of a combined strategy of early start of basic life support, 
early invasive management with primary PCI and therapeutic hypothermia in pa-
tients suffering OHCA due to STEMI, results in a relatively large group of patients 
(77%) that survive during one-year follow-up with reasonable neurological outcome 
at discharge. Left proximal coronary lesions carry higher risk for OHCA after STEMI 
compared to right coronary lesions.
- Repeatedly measured NT-proBNP and CRP both add individually to serial NYHA-class 
assessments for monitoring CHF outpatients in terms of discriminative ability, which 
underscores the value of biomarkers to NYHA class measurements only.
- The dynamic, temporal patterns of serially-measured NT-proBNP and CRP levels are 
strong and independent predictors of adverse clinical events in CHF patients. On top 
of evolution of biomarker level, instantaneous rate of change in level of NT-proBNP 
and CRP and long-term elevation of NT-proBNP are associated with adverse outcome.
- MiR-1306-5p is related to the heart and is associated with adverse clinical outcome 
in patients with acute HF. In patients with stable CHF, the temporal pattern of circu-
lating miR-22-3p is a strong and independent predictor of prognosis.
- Functional response to CRT (patients who reach a LVEF of ≥35% after implantation) 
is associated with a good prognosis, and functional responders do not need backup 
from defibrillation therapy.
- AF is associated with adverse events in CRT-D patients. Furthermore, myocardial 
infarction, LVEF ≤25%, COPD, chronic kidney disease, hyponatremia and anemia pre-
dict mortality in CRT-D patients.
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- CAD is associated with poor survival in CRT-D patients, but we did not find an as-
sociation between mortality and CAD in a population of mainly ICD-only patients, 
without CRT.
future directions
This thesis describes additional insights into patient characteristics that facilitate prog-
nostication in patients with cardiovascular diseases. Most importantly, it shows that the 
individual patterns of change of several circulating biomarkers carry incremental value 
for prognostication. As such, additional research on the use of blood biomarkers for 
prognostication, as well as for tailored adjustment of treatment, is warranted. The results 
of the ongoing Bio-SHiFT study are expected to provide information on individual pat-
terns of change of a wide range of novel biomarker levels and thus carry potential to 
further improve individual risk prediction. Future studies beyond the Bio-SHiFT study 
should examine the role of tailored adjustment of treatment using these biomarker pat-
terns and may thereby contribute to personalized medicine.
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sAmeNVAttiNG eN coNcLusies
Gezondheidszorg kan worden onderverdeel in preventieve, genezingsgerichte, 
revalidatie-gerichte en ondersteunende geneeskunde. Preventieve geneeskunde wordt 
beschouwd als de meest effectieve vorm van geneeskunde, omdat preventieve genees-
kunde de noodzaak tot genezingsgerichte, revalidatie-gerichte en ondersteunende 
geneeskunde kan voorkomen. Preventieve geneeskunde richt zich niet alleen maar op 
het voorkomen van ziektes (oftewel primaire preventie), maar ook op het verminde-
ren van de kans op recidieven en het verlagen van de morbiditeit van een chronische 
ziekte (secundaire en tertiaire preventie respectievelijk). Belangrijke verbeteringen in 
de cardiovasculaire gezondheidszorg, zoals percutane coronaire interventies (PCI’s) en 
implanteerbare cardioverter defibrillators (ICD’s), hebben de mortaliteit fors verlaagd, 
maar er wel voor gezorgd dat er een toename is in het aantal patiënten met een chroni-
sche ziekte. Om de secundaire preventie in deze patiëntengroep verder te verbeteren, 
zijn dringend nieuwe methoden voor risicostratificatie nodig.
Het doel van deze dissertatie was het identificeren van factoren geassocieerd met 
een slechte klinische uitkomst en om nieuwe voorspelmodellen te creëren die kunnen 
helpen bij het inschatten van de risico’s van patiënten in verschillende fasen van cardio-
vasculaire ziekte. Allereerst hebben wij ons gericht op patiënten met coronarialijden, 
al dan niet met een verminderde linker kamer functie. Wij hebben specifiek gekeken 
naar patiënten die een PCI ondergingen en verschillende factoren beschreven die 
geassocieerd zijn met een slechte klinische uitkomst na PCI (deel 1). Daarna hebben 
wij ons gericht op patiënten met (chronisch) hartfalen ((C)HF) en hebben gezocht naar 
de beste strategie en combinatie van biomarkers die zal moeten worden gebruikt voor 
het bepalen van prognose (deel 2). Tot slot hebben wij patiënten onderzocht met een 
ernstig verminderde linker kamerfunctie met noodzaak tot bescherming tegen plotse 
hartdood middels een ICD, al dan niet met cardiale resynchronisatie therapie (CRT). Ook 
binnen deze patiëntengroep hebben wij ons gericht op karakteristieken geassocieerd 
met goede reactie op therapie en klinische uitkomst (deel 3).
deel i de invloed van patiënt karakteristieken en procedurele factoren 
geassocieerd met klinische uitkomst na percutane coronaire interventies
In hoofdstuk 2 hebben wij m.b.v. 9 simpele klinische en angiografische karakteristieken 
een risicomodel gemaakt voor het voorspellen van 5-jaars mortaliteit na PCI. De IDEA-
BIO studie liet zien dat leeftijd, BMI, diabetes mellitus, nierfunctiestoornissen, eerdere 
hartinfarcten, de indicatie voor PCI, culprit hoofdstam, het aantal aangedane coronairen 
en cardiogene shock voorspellers zijn van 5-jaars mortaliteit na PCI. Eerdere studies 
hebben risicomodellen gemaakt voor post-PCI patiënten, echter hadden de meeste van 
deze studies zich gericht op korte termijn uitkomst (30 dagen na PCI). Dit was de eerste 
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studie waarin lange termijn uitkomst is bekeken. Daarbij is de kracht van deze studie 
de grote populatie die is onderzocht. Mogelijk maakt dit lange termijn risicomodel het 
mogelijk om patiënten te selecteren die kunnen profiteren van duurdere interventies, 
zoals biologisch afbreekbare stents (mits betere overleving door biologisch afbreekbare 
stents t.o.v. nieuwe generatie ‘drug-eluting stents’ (DES) op lange termijn kan worden 
aangetoond in huidige studies).
Het voordeel van nieuwe generatie DES, die everolimus bevatten (oftewel ‘everolimus-
eluting stents’ (EES)) t.o.v. oude generatie DES (oftewel ‘sirolimus eluting stents’ (SES) en 
‘paclitaxel eluting stents’ (PES)) is reeds in grote studies aangetoond. Sommige patiën-
tgroepen zijn gevoeliger voor stent trombose (ST) dan anderen. Zo hebben patiënten 
met een verminderde linker ventrikel ejectie fractie (LVEF) een verhoogd risico op ST. In 
hoofdstuk 3 lieten we zien dat nieuwe generatie EES geassocieerd zijn met een lager 
risico op ST t.o.v. oude generatie DES, onafhankelijk van de LVEF. Dit lagere ST risico zette 
zich voort tot 4 jaar na follow-up. De lange termijn veiligheid en voordelen van nieuwe 
generatie EES bij patiënten met een verminderde LVEF suggereert dat EES de stent van 
keuze is wanneer een PCI moet worden uitgevoerd bij patiënten met een verminderde 
LVEF.
In hoofdstuk 4 hebben we de prognose onderzocht van patiënten die een circulatie 
stilstand buiten het ziekenhuis, oftewel een ‘out-of-hospital cardiac arrest’ (OHCA), 
doormaakten. We hebben ons gericht op factoren gerelateerd aan het optreden van 
OHCA bij patiënten met ST-elevatie myocardinfarcten. De multicenter registratie die wij 
hebben gebruikt in dit hoofdstuk, liet een associatie zien tussen laesies in de proximale 
linker coronair en een verhoogd risico op OHCA. Laesies in de rechter coronair waren 
geassocieerd met het laagste risico op OHCA. Daarbij was de locatie van de culprit geas-
socieerd met cardiogene shock en suboptimale reperfusie na PCI; beiden belangrijke 
factoren geassocieerd met prognose na OHCA. Tot slot liet deze studie zien dat een 
strikt beleid van vroeg starten met basic life support, vroeg invasief handelen middels 
primaire PCI en therapeutische hypothermie resulteerde in een relatief grote patiënt 
groep (77%) die langer dan 1 jaar overleefden met een redelijke neurologische uitkomst.
deel ii Nieuwe methoden en markers voor risicostratificatie van patiënten met 
hartfalen.
De behandeling van (C)HF is voornamelijk gericht op het stabiliseren en vertragen van 
ziekteprogressie. Op dit moment is het bijstellen van therapie grotendeels gebaseerd op 
klinische beoordeling, waardoor het bijstellen van therapie normaal gesproken alleen 
gebeurd als tekenen of symptomen verslechteren. Er zijn aanzienlijke vaardigheden 
vereist voor de juiste timing voor het bijstellen van therapie, wat zou kunnen lijden tot 
vertraagde therapie optimalisatie bij hoog risico patiënten. Bloed biomarkers kunnen 
subtiele pathofysiologische en hemodynamische cardiovasculaire veranderingen laten 
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zien en mogelijk ziekte verslechtering voorspellen voordat het zich klinisch uit. De ´Se-
rial Biomarker meaSurements and new echocardiographic techniques in chronic Heart 
Failure patients result in Tailored prediction of prognosis´ (Bio-SHiFT) studie was een 
prospectieve, observationele studie, opgezet in het Erasmus MC, Rotterdam, Nederland 
en Noordwest Ziekenhuisgroep, Alkmaar, Nederland, naar stabiele CHF patiënten, die 
de polikliniek bezochten. Patiënten werden benaderd tijdens regulaire polikliniek be-
zoeken in stabiele toestanden geschikt bevonden indien zij bekend waren met CHF (al 
dan niet met behouden kamerfunctie), gediagnosticeerd ≥3 maanden geleden, volgens 
de richtlijnen van de ‘European Society of Cardiology’. Bij start en bij elk follow-up mo-
ment werd een korte medische evaluatie verricht en werden bloed en urine monsters 
verzameld. Studie follow-up werd elke 3 maanden verricht, gedurende maximaal 30 
maanden.
In hoofdstuk 5 werd de data van de Bio-SHiFT studie gebruikt om aan te tonen dat 
seriële metingen van N-terminal pro-brain natriuretic peptide (NT-proBNP), C-reactive 
protein (CRP) en New York Heart Association (NYHA) functionele klasse onafhankelijk 
geassocieerd waren met slechte klinische uitkomst. Herhaalde NT-proBNP en CRP 
metingen verbeterde de discriminatie t.o.v. een model met alleen seriële NYHA-klasse 
metingen, hetgeen de waarde van seriële biomarker metingen onderstreept.
hoofdstuk 6 liet zien dat de dynamische, temporele patronen van serieel gemeten 
NT-proBNP en CRP levels sterke en onafhankelijke voorspellers zijn van slechte klinische 
uitkomst bij CHF patiënten. Daarbij zijn directe veranderingen van het level van deze 
biomarkers en langdurige verhoging ook geassocieerd met slechte klinische uitkomst. 
Het temporele patroon van high-sensitive troponin T (HsTNT) was ook significant geas-
socieerd met slechte klinische uitkomst, maar niet onafhankelijk van de temporele pa-
tronen van NT-proBNP en CRP. Dit resultaat suggereert dat het gebruik van individuele 
patronen van verandering van biomarkers en de combinatie van verschillende biomar-
kers zal moeten worden overwogen bij het bepalen van de prognose van patiënten met 
stabiel CHF.
Ondanks de genoemde bevindingen is er nog steeds veel ruimte voor verbetering. 
MicroRNA´s (miRs) zijn biomarkers in opkomst en voorgaande studies hebben veelbe-
lovende resultaten laten zien bij het vroeg diagnosticeren en behandelen van HF. MiRs 
zijn niet coderende, ~22 nucleotiden lange RNA sequenties, die een rol spelen bij het 
splijten of bij translationele onderdrukking van messenger RNA en beïnvloeden daarom 
vele biologische processen. De stabiliteit van miRs in plasma en daarbij hun betrouw-
bare beoordeling en makkelijke bereikbaarheid, maakt miRs aantrekkelijke biomarkers 
voor vele ziektebeelden, waaronder cardiovasculaire ziektes. In hoofdstuk 7 hebben 
we Bio-SHiFT data gebruikt om de associatie te onderzoeken tussen slechte klinische 
uitkomst van CHF patiënten en frequente, herhaalde metingen van meerdere miRs die 
eerder aan HF gerelateerd werden (miR-1254, miR-22-3p, miR-423-5p, miR-486-5p en 
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miR-320a) of myocard verrijkt zijn (miR-345-5p, miR-378a-3p). Hierbij ontdekten we een 
omgekeerde en onafhankelijke relatie tussen temporele miR-22-3p patronen en slechte 
klinische uitkomst. Deze associatie was onafhankelijk van klinische karakteristieken en 
NT-proBNP, HsTNT en CRP patronen. De acute verandering van miR-22-3p level (oftewel 
de helling van het temporele patroon) was ook omgekeerd geassocieerd met slechte 
klinische uitkomst. Verder vonden we dat het temporele patroon van miR-22-3p omge-
keerd evenredig was aan de temporele patronen van HsTNT en CRP. De uitkomst sug-
gereert dat de individuele patronen van miR-22-3p zou kunnen worden gebruikt voor 
het bepalen van de prognose van CHF patiënten. Een bijkomstige bevinding in deze 
studie was de significant omgekeerde relatie tussen een ischemische cardiomyopathie 
(ICM) en miR1254, miR486-5p en miR320a.
In hoofdstuk 8 lieten we zien hoe we een aantal miRs ontdekten die geproduceerd 
werden in myocard van varkens. Er werd directe RNA sequencing van plasma van 
behandelde varkens verricht, waarbij o.a. miR-1306-5p werd gevonden, welke nog 
niet eerder geassocieerd werd met myocard. Vervolgens hebben we in een prospectief 
cohort bestaande uit acuut HF patiënten (TRIUMPH) aangetoond dat herhaald gemeten 
circulerend miR-1306-5p geassocieerd was met slechte klinische uitkomst en prognosti-
sche informatie bevat boven NT-proBNP. Deze resultaten impliceren dat het meten van 
miR-1306-5p kan helpen bij het stratificeren van het risico van HF patiënten. Daarbij 
zou miR-1306-5p mogelijk kunnen helpen bij het identificeren van patiënten die baat 
kunnen hebben bij nauwere follow-up en agressievere behandelopties.
deel iii Nieuwe inzichten in karakteristieken geassocieerd met gunstige 
uitkomst bij defibrillatie therapie en reactie op cardiale resynchronisatie 
therapie
Het gebruik van ICD’s en CRT heeft een grote invloed gehad op de overleving van 
patiënten met een verminderde kamerfunctie (oftewel een LVEF <35%). CRT heeft het 
aantal ziekenhuis opnames voor HF verminderd en kan herstel van het hart (reversed 
remodeling) induceren bij patiënten met CHF en verbrede QRS complexen. Vele ka-
rakteristieken geassocieerd met een betere of slechtere respons op CRT moeten nog 
gevonden worden. Sommige patiënten reageren erg goed op CRT en bereiken een LVEF 
≥35% na implantatie. In hoofdstuk 9 noemen we deze patiënten functionele reactie 
patiënten en laten zien dat functionele reactie geassocieerd is met een goede prognose. 
Gedurende een mediane follow-up van 3 jaar hadden functionele reactie patiënten 
geen schok therapie van hun geïmplanteerde cardioverter-defibrillator nodig. De 
incidentie van onterechte schokken was gelijk tussen functionele en niet-functionele 
reactie patiënten. Zulke schokken, terecht of onterecht, hebben nadelige gevolgen voor 
patiënten en lijden tot frequentere ziekenhuis opnames en daarbij ook hogere kosten. 
Concluderend suggereren onze bevindingen dat bij functionele reactie patiënten in 
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geval van noodzaak tot vervanging (bijv. bij het leeg raken van de batterij) het CRT met 
defibrillator (CRT-D) apparaat kan worden vervangen door een CRT zonder defibrillator 
apparaat.
Een andere belangrijke determinant bij CHF patiënten behandeld met CRT-D, niet 
alleen voor sterfte, maar ook voor terechte en onterechte schokken, is het hebben 
van atrium fibrilleren (AF), zoals beschreven in hoofdstuk 10. Het retrospectieve, 
multicenter, observationele studie, verricht op 550 echte patiënten (dus geen studie 
patiënten) onderzoek beschreven in dit hoofdstuk laat zien dat 47% van alle patiënten 
die onterechte schokken kregen, bekend waren met AF. Deze resultaten suggereren dat 
het bij CRT-D patiënten belangrijk is om ze in sinusritme te houden en AF te voorkomen, 
mogelijk zelfs door middel van His bundel ablatie.
Mortaliteit en het optreden van (on)terechte schokken in een populatie ICD patiënten 
met een verminderde LVEF door coronarialijden (oftewel coronary artery disease (CAD)) 
tegenover patiënten met een dilaterende cardiomyopathie, leek niet te verschillen, 
zoals te lezen in hoofdstuk 11. De populatie waarop het onderzoek beschreven in dit 
hoofdstuk is verricht, bestond voornamelijk uit patiënten met alleen een ICD en slechts 
33% CRT-D patiënten. Omgekeerd laten we in hoofdstuk 12 zien dat eerdere hartinfarc-
ten geassocieerd waren met (3-jaars) mortaliteit in een populatie bestaande uit alleen 
maar CRT-D patiënten. Andere risicofactoren geassocieerd met mortaliteit van CRT-D 
patiënten waren LVEF ≤25%, COPD, chronisch nierfalen, hyponatriëmie en anemie. Het 
resultaat van deze studie kan worden gebruikt bij het voorspellen van de prognose van 
CHF patiënten die behandeld worden met CRT-D, die mogelijk nauwere follow-up nodig 
hebben.
conclusies
- Lange termijn (5-jaars) sterfte na PCI kan adequaat voorspeld worden middels 
5-jaars sterfte risicomodel gebaseerd op 9 eenvoudige klinische en angiografische 
variabelen.
- Nieuwe generatie EES zijn geassocieerd met een lager risico op ST in vergelijking 
met oude generatie DES, onafhankelijk van LVEF, ondanks dat ST vaker voorkomt bij 
patiënten met een matig tot ernstig verminderde LVEF.
- Een strikt beleid, bestaande uit de combinatie van vroeg starten met reanimeren, 
vroeg invasief handelen middels primaire PCI en therapeutische hypothermie bij 
patiënten die een circulatie stilstand buiten het ziekenhuis doormaakten, resulteert 
in een relatief grote groep (77%) patiënten die na het voorval nog in leven waren na 
1 jaar en die een redelijke neurologische uitkomst hadden bij ontslag. Laesies proxi-
maal in de linker coronair zijn geassocieerd met een groter risico op een circulatie 
stilstand buiten het ziekenhuis in vergelijking met laesies in de rechter coronair.
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- Herhaaldelijk gemeten NT-proBNP en CRP dragen beiden individueel en onafhan-
kelijk van elkaar bij aan seriële NYHA klasse metingen bij het monitoren van CHF 
patiënten door het verbeteren van discriminatie. Dit benadrukt de waarde van 
biomarkers boven het alleen scoren van de NYHA klasse.
- De dynamische, temporele patronen van serieel gemeten NT-proBNP en CRP levels 
zijn sterke en onafhankelijke voorspellers van slechte klinische uitkomst van CHF pa-
tiënten. Naast de voortgang van biomarker levels zijn directe veranderingen van het 
level van deze biomarkers en langdurige verhoging ook geassocieerd met slechte 
klinische uitkomst.
- MiR-1306-5p is geassocieerd met het hart en met slechte klinische uitkomst van 
acuut HF patiënten. Bij patiënten met stabiel CHF is het temporele patroon van 
circulerend miR-22-3p een sterke en onafhankelijke voorspeller van prognose.
- Functionele reactie op CRT (patiënten die een LVEF ≥35% bereiken na implantatie) 
is geassocieerd met een goede prognose en bij deze patiënten is er geen noodzaak 
voor defibrillatie therapie.
- AF is geassocieerd met slechte klinische uitkomst bij CRT-D patiënten. Daarnaast 
voorspellen een verleden van myocard infarct, LVEF ≤25%, COPD, chronisch nierfa-
len, hyponatriëmie en anemie mortaliteit bij CRT-D patiënten.
- CAD is geassocieerd met slechte overleving in CRT-D patiënten, maar wij vonden 
geen associatie tussen sterfte en CAD in een populatie bestaande uit voornamelijk 
ICD patiënten zonder CRT.
toekomstige richtingen
Deze dissertatie beschrijft bijdragende inzichten in patiënt karakteristieken die het 
voorspellen van prognose van patiënten met cardiovasculaire ziekten vergemakkelijkt. 
Een grote rol is weggelegd voor individuele, veranderende patronen van verschillende 
circulerende biomarkers, die een grote bijdrage leveren aan het voorspellen van prog-
nose. Om deze reden is het belangrijk dat er meer onderzoek volgt naar het gebruik van 
biomarkers als voorspellers van prognose, maar ook voor het titreren van therapie. De 
resultaten van de Bio-SHiFT studie zullen ons naar alle waarschijnlijkheid meer informa-
tie en inzicht in veranderende individuele patronen van het level van een groot aantal 
nieuwe biomarkers verschaffen. Daarmee zal deze studie bijdragen aan verdere verbete-
ring van individuele risicostratificatie. Toekomstige studies na de Bio-SHiFT studie zullen 
de rol van het gebruik van deze nieuwe biomarkers bij het titreren van therapie moeten 
onderzoeken en op die manier mogelijk bijdragen aan persoonlijke geneeskunde.
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